{ "version": "2.2", "instance": { "iva-20240630x6k.htm iva-20240630xex99d1.htm": { "nsprefix": "iva", "nsuri": "http://www.inventivapharma.com/20240630", "dts": { "schema": { "local": [ "iva-20240630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "calculationLink": { "local": [ "iva-20240630_cal.xml" ] }, "definitionLink": { "local": [ "iva-20240630_def.xml" ] }, "labelLink": { "local": [ "iva-20240630_lab.xml" ] }, "presentationLink": { "local": [ "iva-20240630_pre.xml" ] }, "inline": { "local": [ "iva-20240630x6k.htm", "iva-20240630xex99d1.htm" ] } }, "keyStandard": 187, "keyCustom": 179, "axisStandard": 23, "axisCustom": 1, "memberStandard": 32, "memberCustom": 83, "hidden": { "total": 11, "http://xbrl.sec.gov/dei/2023": 6, "http://www.inventivapharma.com/20240630": 1, "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full": 4 }, "contextCount": 318, "entityCount": 1, "segmentCount": 120, "elementCount": 590, "unitCount": 18, "baseTaxonomies": { "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full": 772, "http://xbrl.sec.gov/dei/2023": 8 }, "report": { "R1": { "role": "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation", "longName": "00090 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630x6k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630x6k.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition", "longName": "00100 - Statement - Unaudited interim condensed consolidated statement of financial position", "shortName": "Unaudited interim condensed consolidated statement of financial position", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ", "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ", "name": "ifrs-full:DeferredTaxAssets", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "unique": true } }, "R3": { "role": "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss", "longName": "00200 - Statement - Unaudited interim condensed consolidated statement of income (loss)", "shortName": "Unaudited interim condensed consolidated statement of income (loss)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA", "name": "ifrs-full:Revenue", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA", "name": "ifrs-full:SalesAndMarketingExpense", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "unique": true } }, "R4": { "role": "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss", "longName": "00300 - Statement - Unaudited interim condensed consolidated statement of comprehensive (income) loss", "shortName": "Unaudited interim condensed consolidated statement of comprehensive (income) loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA", "name": "ifrs-full:ProfitLoss", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA", "name": "ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "unique": true } }, "R5": { "role": "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity", "longName": "00400 - Statement - Unaudited interim condensed consolidated statement of changes in shareholders' equity", "shortName": "Unaudited interim condensed consolidated statement of changes in shareholders' equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_0VRJS0P300WTp8zcUcUTug", "name": "ifrs-full:Equity", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember_XLIDsKCJTEm0UB5CIk-Tiw", "name": "ifrs-full:ProfitLoss", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "unique": true } }, "R6": { "role": "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows", "longName": "00500 - Statement - Unaudited interim condensed consolidated statement of cash flows", "shortName": "Unaudited interim condensed consolidated statement of cash flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA", "name": "ifrs-full:ProfitLoss", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA", "name": "iva:AdjustmentsForDepreciationAmortisationAndProvisions", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "unique": true } }, "R7": { "role": "http://www.inventivapharma.com/role/DisclosureCompanyInformation", "longName": "10101 - Disclosure - Company information", "shortName": "Company information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA", "name": "iva:CompanyInformationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA", "name": "iva:CompanyInformationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfCompliance", "longName": "10201 - Disclosure - Basis of preparation and statement of compliance", "shortName": "Basis of preparation and statement of compliance", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA", "name": "ifrs-full:StatementOfIFRSCompliance", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA", "name": "ifrs-full:StatementOfIFRSCompliance", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.inventivapharma.com/role/DisclosureAccountingPrinciples", "longName": "10301 - Disclosure - Accounting Principles", "shortName": "Accounting Principles", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA", "name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA", "name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPosition", "longName": "10401 - Disclosure - Notes to the interim condensed consolidated statement of financial position", "shortName": "Notes to the interim condensed consolidated statement of financial position", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA", "name": "iva:DisclosureOfNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA", "name": "iva:DisclosureOfNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLoss", "longName": "10501 - Disclosure - Notes to the interim condensed consolidated statement of (income) loss", "shortName": "Notes to the interim condensed consolidated statement of (income) loss", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA", "name": "iva:DisclosureOfComponentsOfIncomeStatementTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA", "name": "iva:DisclosureOfComponentsOfIncomeStatementTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformation", "longName": "10601 - Disclosure - Other financial information", "shortName": "Other financial information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA", "name": "iva:DisclosureOfOtherFinancialInformationTextblock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA", "name": "iva:DisclosureOfOtherFinancialInformationTextblock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies", "longName": "20302 - Disclosure - Accounting Principles (Policies)", "shortName": "Accounting Principles (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "13", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA", "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA", "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceTables", "longName": "30203 - Disclosure - Basis of preparation and statement of compliance (Tables)", "shortName": "Basis of preparation and statement of compliance (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "14", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA", "name": "ifrs-full:DisclosureOfInterestsInSubsidiariesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA", "name": "ifrs-full:DisclosureOfInterestsInSubsidiariesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesTables", "longName": "30303 - Disclosure - Accounting Principles (Tables)", "shortName": "Accounting Principles (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "15", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA", "name": "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory", "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA", "name": "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory", "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables", "longName": "30403 - Disclosure - Notes to the interim condensed consolidated statement of financial position (Tables)", "shortName": "Notes to the interim condensed consolidated statement of financial position (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "16", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA", "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "iva:DisclosureOfNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA", "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "iva:DisclosureOfNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossTables", "longName": "30503 - Disclosure - Notes to the interim condensed consolidated statement of (income) loss (Tables)", "shortName": "Notes to the interim condensed consolidated statement of (income) loss (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "17", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA", "name": "iva:RevenueAndOtherIncomeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "iva:DisclosureOfComponentsOfIncomeStatementTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA", "name": "iva:RevenueAndOtherIncomeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "iva:DisclosureOfComponentsOfIncomeStatementTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationTables", "longName": "30603 - Disclosure - Other financial information (Tables)", "shortName": "Other financial information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "18", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA", "name": "ifrs-full:DisclosureOfContingentLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "iva:DisclosureOfOtherFinancialInformationTextblock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA", "name": "ifrs-full:DisclosureOfContingentLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "iva:DisclosureOfOtherFinancialInformationTextblock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "longName": "40101 - Disclosure - Company information - (Details)", "shortName": "Company information - (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "19", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA", "name": "ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_1_4_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_V_UnvG7OVU6Postqxl9qTw", "name": "iva:IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "unitRef": "Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "unique": true } }, "R20": { "role": "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details", "longName": "40102 - Disclosure - Company information - Significant events in the first half of 2024 (Details)", "shortName": "Company information - Significant events in the first half of 2024 (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "20", "firstAnchor": { "contextRef": "As_Of_1_18_2024_u8VUV2GPAUmg3FPfMqwLIg", "name": "ifrs-full:NotionalAmount", "unitRef": "Unit_Standard_USD_X6E05lIDQEullbfuSGuJCw", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankMember_TxixfQbZCE2_vJzh9SnQSQ", "name": "iva:PercentageOfShareCapitalHeldByCounterpartyIfAllOutstandingWarrantsAreExercised", "unitRef": "Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "unique": true } }, "R21": { "role": "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails", "longName": "40201 - Disclosure - Basis of preparation and statement of compliance - Significant Investments In Subsidiaries (Details)", "shortName": "Basis of preparation and statement of compliance - Significant Investments In Subsidiaries (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "21", "firstAnchor": { "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ", "name": "iva:NumberOfEntitiesBeingConsolidated", "unitRef": "Unit_Standard_entity_-MmOzsDakEmzabilM8ZRiQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ifrs-full:DisclosureOfInterestsInSubsidiariesExplanatory", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ", "name": "iva:NumberOfEntitiesBeingConsolidated", "unitRef": "Unit_Standard_entity_-MmOzsDakEmzabilM8ZRiQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ifrs-full:DisclosureOfInterestsInSubsidiariesExplanatory", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceForeignExchangeRatesDetails", "longName": "40202 - Disclosure - Basis of preparation and statement of compliance - Foreign Exchange Rates (Details)", "shortName": "Basis of preparation and statement of compliance - Foreign Exchange Rates (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "22", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA", "name": "ifrs-full:AverageForeignExchangeRate", "unitRef": "Unit_Divide_EUR_USD_sLQkfMeGDkaNmYTZmSqm9Q", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA", "name": "ifrs-full:AverageForeignExchangeRate", "unitRef": "Unit_Divide_EUR_USD_sLQkfMeGDkaNmYTZmSqm9Q", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "longName": "40301 - Disclosure - Accounting Principles - Fair value measurement (Details)", "shortName": "Accounting Principles - Fair value measurement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "23", "firstAnchor": { "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ", "name": "ifrs-full:FinancialLiabilities", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_iiyUwIL1okucU3luLH42uQ", "name": "ifrs-full:FinancialLiabilities", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ix:continuation", "ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory", "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "unique": true } }, "R24": { "role": "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "longName": "40302 - Disclosure - Accounting principles - Going concern (Details)", "shortName": "Accounting principles - Going concern (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "24", "firstAnchor": { "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ", "name": "ifrs-full:CashAndCashEquivalents", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true }, "uniqueAnchor": null }, "R25": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionIntangibleAssetsDetails", "longName": "40401 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Intangible assets (Details)", "shortName": "Notes to the interim condensed consolidated statement of financial position - Intangible assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ", "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_na6RZmuG5U2D4vmO3x7mnw", "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "iva:DisclosureOfNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "unique": true } }, "R26": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionPropertyPlantAndEquipmentDetails", "longName": "40402 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Property, plant, and equipment (Details)", "shortName": "Notes to the interim condensed consolidated statement of financial position - Property, plant, and equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ", "name": "ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_OjiU0SQcREq22dnbIpV6fg", "name": "ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "iva:DisclosureOfNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "unique": true } }, "R27": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionPropertyPlantAndEquipmentAdditionalInformationDetails", "longName": "40403 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Property, plant, and equipment - Additional Information (Details)", "shortName": "Notes to the interim condensed consolidated statement of financial position - Property, plant, and equipment - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA", "name": "ifrs-full:ChangesInPropertyPlantAndEquipment", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "iva:DisclosureOfNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA", "name": "ifrs-full:ChangesInPropertyPlantAndEquipment", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "iva:DisclosureOfNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodAdditionalInformationDetails", "longName": "40404 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Investments accounted for using the equity method - Additional Information (Details)", "shortName": "Notes to the interim condensed consolidated statement of financial position - Investments accounted for using the equity method - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "Duration_10_11_2023_To_10_11_2023_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_0ACGkUM49U6-A_OhxFep5w", "name": "iva:NumberOfSharesAcquiredInAssociate", "unitRef": "Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "iva:DisclosureOfNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_10_11_2023_To_10_11_2023_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_0ACGkUM49U6-A_OhxFep5w", "name": "iva:NumberOfSharesAcquiredInAssociate", "unitRef": "Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "iva:DisclosureOfNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "longName": "40405 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Investments accounted for using the equity method - investment in Hepalys accounted for using equity method of accounting (Details)", "shortName": "Notes to the interim condensed consolidated statement of financial position - Investments accounted for using the equity method - investment in Hepalys accounted for using equity method of accounting (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ", "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_HepalysPharmaIncMember_Nnjp7bngW0Ga6BDie0V6fw", "name": "iva:EntitySShareOfNetAssetsInInvestmentsAccountedForUsingEquityMethod", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfReconciliationOfSummarisedFinancialInformationOfAssociateAccountedForUsingEquityMethodToCarryingAmountOfInterestInAssociateExplanatory", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "unique": true } }, "R30": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherNonCurrentAssetsDetails", "longName": "40406 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Other non-current assets (Details)", "shortName": "Notes to the interim condensed consolidated statement of financial position - Other non-current assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ", "name": "iva:NonCurrentLongTermDepositsFromCustomers", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfOtherNoncurrentAssetsTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ", "name": "iva:NonCurrentLongTermDepositsFromCustomers", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfOtherNoncurrentAssetsTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherNonCurrentAssetsLongTermDepositAccountsDetails", "longName": "40407 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Other non-current assets - Long-term deposit accounts (Details)", "shortName": "Notes to the interim condensed consolidated statement of financial position - Other non-current assets - Long-term deposit accounts (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA", "name": "iva:IncreaseDecreaseInLongTermDepositAccounts", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA", "name": "iva:IncreaseDecreaseInLongTermDepositAccounts", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInventoriesDetails", "longName": "40408 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Inventories (Details)", "shortName": "Notes to the interim condensed consolidated statement of financial position - Inventories (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ", "name": "ifrs-full:Inventories", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_SNcEwTle60O3eQH3YNWEsw", "name": "ifrs-full:Inventories", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:IfrsScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "unique": true } }, "R33": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsTradeReceivablesDetails", "longName": "40409 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Trade receivables, tax receivables and other current assets - Trade Receivables (Details)", "shortName": "Notes to the interim condensed consolidated statement of financial position - Trade receivables, tax receivables and other current assets - Trade Receivables (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ", "name": "ifrs-full:TradeAndOtherCurrentReceivables", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanThreeMonthsMember_2nR6xWsu-0CvgK_C4H2nmQ", "name": "ifrs-full:TradeAndOtherCurrentReceivables", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfTradeReceivablesTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "unique": true } }, "R34": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails", "longName": "40410 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Trade receivables, tax receivables and other current assets- Other Current Assets and Receivables (Details)", "shortName": "Notes to the interim condensed consolidated statement of financial position - Trade receivables, tax receivables and other current assets- Other Current Assets and Receivables (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ", "name": "iva:CirAndOtherResearchTaxCreditsReceivable", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ", "name": "iva:OtherCurrentTaxReceivables", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "unique": true } }, "R35": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsAdditionalInformationDetails", "longName": "40411 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Trade receivables, tax receivables and other current assets - Additional Information (Details)", "shortName": "Notes to the interim condensed consolidated statement of financial position - Trade receivables, tax receivables and other current assets - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA", "name": "iva:IncreaseDecreaseInShortTermDepositAccounts", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA", "name": "iva:IncreaseDecreaseInShortTermDepositAccounts", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionCashAndCashEquivalentsDetails", "longName": "40412 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Cash and cash equivalents (Details)", "shortName": "Notes to the interim condensed consolidated statement of financial position - Cash and cash equivalents (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ", "name": "ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfCashAndCashEquivalentsTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ", "name": "ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfCashAndCashEquivalentsTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityShareCapitalDetails", "longName": "40413 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Shareholders' equity - Share capital (Details)", "shortName": "Notes to the interim condensed consolidated statement of financial position - Shareholders' equity - Share capital (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ", "name": "ifrs-full:IssuedCapital", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true }, "uniqueAnchor": null }, "R38": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityChangesInShareCapitalDetails", "longName": "40414 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Shareholders' equity - Changes in share capital (Details)", "shortName": "Notes to the interim condensed consolidated statement of financial position - Shareholders' equity - Changes in share capital (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ", "name": "ifrs-full:Equity", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_3_25_2024_To_3_25_2024_avq7MDuDZ0qTbuTPxd88pQ", "name": "ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding", "unitRef": "Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "unique": true } }, "R39": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityLiquidityAgreementDetails", "longName": "40415 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Shareholders' equity - Liquidity agreement (Details)", "shortName": "Notes to the interim condensed consolidated statement of financial position - Shareholders' equity - Liquidity agreement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_1_1_2024__TV_WDfEOkuUvGKOfMbQLg", "name": "iva:LiquidityAgreementTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_1_1_2024__TV_WDfEOkuUvGKOfMbQLg", "name": "iva:LiquidityAgreementTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityOptionsAndShareWarrantsBsaAndBspceDetails", "longName": "40416 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Shareholders' equity - Options and share warrants (BSA and BSPCE) (Details)", "shortName": "Notes to the interim condensed consolidated statement of financial position - Shareholders' equity - Options and share warrants (BSA and BSPCE) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "As_Of_12_31_2017_ifrs-full_CategoriesOfRelatedPartiesAxis_iva_DirectorsMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BsaShareWarrantsMember_tc0AHGj00kS5B7lAXTpurw", "name": "iva:WarrantsSubscriptionPrice", "unitRef": "Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2017_ifrs-full_CategoriesOfRelatedPartiesAxis_iva_DirectorsMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BsaShareWarrantsMember_tc0AHGj00kS5B7lAXTpurw", "name": "iva:WarrantsSubscriptionPrice", "unitRef": "Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails", "longName": "40417 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Shareholders' equity - Movements in BSPCE and BSA share warrants (in number of shares issuable upon exercise) (Details)", "shortName": "Notes to the interim condensed consolidated statement of financial position - Shareholders' equity - Movements in BSPCE and BSA share warrants (in number of shares issuable upon exercise) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "Duration_3_25_2024_To_3_25_2024_avq7MDuDZ0qTbuTPxd88pQ", "name": "ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted", "unitRef": "Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BspceAndBsaShareWarrantsMember_AXg3-r_gg0WamRv2dUykVQ", "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "unitRef": "Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "unique": true } }, "R42": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFreeShareAwardsAndPerformanceUnitsDetails", "longName": "40418 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Free share awards and Performance units (Details)", "shortName": "Notes to the interim condensed consolidated statement of financial position - Free share awards and Performance units (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA", "name": "iva:NumberOfAwardPlansAttributed", "unitRef": "Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA", "name": "iva:NumberOfAwardPlansAttributed", "unitRef": "Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFinancialDebtDetails", "longName": "40419 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Financial debt - Financial debt (Details)", "shortName": "Notes to the interim condensed consolidated statement of financial position - Financial debt - Financial debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ", "name": "ifrs-full:LoansReceived", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true }, "uniqueAnchor": null }, "R44": { "role": "http://www.inventivapharma.com/role/DisclosureDisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtMovementsInPeriodBreakDownDetails", "longName": "40420 - Disclosure - Disclosure - Notes to the interim condensed consolidated statement of financial position - Financial debt - Movements in the period break down (Details)", "shortName": "Disclosure - Notes to the interim condensed consolidated statement of financial position - Financial debt - Movements in the period break down (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "As_Of_12_31_2022__ShBeryiXEKxoX7Xx7OS6A", "name": "ifrs-full:Borrowings", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "iva:DisclosureOfChangesInBorrowingsTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA", "name": "iva:IncreaseInBorrowingsThroughSubscriptionOfDerivativesInstruments", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfChangesInBorrowingsTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "unique": true } }, "R45": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "longName": "40421 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Financial debt - French state-guaranteed loan (\"PGE\") and equity recovery loans (\"PPR\") (Details)", "shortName": "Notes to the interim condensed consolidated statement of financial position - Financial debt - French state-guaranteed loan (\"PGE\") and equity recovery loans (\"PPR\") (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA", "name": "ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_6_1_2022_To_6_30_2022_ifrs-full_BorrowingsByNameAxis_iva_LoanAgreementsWithSyndicateOfFrenchBanksUnderStimulusEconomicPlanMember_rVGAMd543kWMTqS80gXZVA", "name": "iva:NumberOfLoanAgreements", "unitRef": "Unit_Standard_loan_rE4-q-dHoUqS2Tn_Pp9_NQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "unique": true } }, "R46": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "longName": "40422 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Financial debt - Credit facility agreement with the European Investment Bank (Details)", "shortName": "Notes to the interim condensed consolidated statement of financial position - Financial debt - Credit facility agreement with the European Investment Bank (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "As_Of_1_18_2024_u8VUV2GPAUmg3FPfMqwLIg", "name": "ifrs-full:NotionalAmount", "unitRef": "Unit_Standard_USD_X6E05lIDQEullbfuSGuJCw", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_5_16_2022_To_5_16_2022_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankMember_iCBdyRK5rUeePAFm5LecHg", "name": "iva:NumberOfEqualTranches", "unitRef": "Unit_Standard_tranche_EQcocZ7SkkmFtux0nXQhjQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "unique": true } }, "R47": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails", "longName": "40423 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Financial debt - Derivatives (Details)", "shortName": "Notes to the interim condensed consolidated statement of financial position - Financial debt - Derivatives (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "Duration_3_25_2024_To_3_25_2024_avq7MDuDZ0qTbuTPxd88pQ", "name": "ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted", "unitRef": "Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_11_28_2022_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_lpf5jlqhR0GVIbvPIhKnYw", "name": "iva:IfrsClassOfWarrantOrRightOutstanding", "unitRef": "Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfValuationApproachForBsaShareBasedPaymentArrangementTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "unique": true } }, "R48": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtLeaseLiabilitiesDetails", "longName": "40424 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Financial debt - Lease liabilities (Details)", "shortName": "Notes to the interim condensed consolidated statement of financial position - Financial debt - Lease liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ", "name": "ifrs-full:LeaseLiabilities", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_kzwvvp3aW0urQssQBeD-RA", "name": "iva:IncreaseDecreaseInLeaseLiabilities", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "unique": true } }, "R49": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails", "longName": "40425 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Maturity of long-term debt and of short-term borrowings and debt (Details)", "shortName": "Notes to the interim condensed consolidated statement of financial position - Maturity of long-term debt and of short-term borrowings and debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ", "name": "ifrs-full:LoansReceived", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_o2Fe8k_JVUOuzAwFE3EH9g", "name": "ifrs-full:LoansReceived", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:MaturityAnalysisForNonderivativeFinancialLiabilities", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "unique": true } }, "R50": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtRoyaltyCertificatesLiabilitiesDetails", "longName": "40426 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Financial debt - Royalty Certificates liabilities (Details)", "shortName": "Notes to the interim condensed consolidated statement of financial position - Financial debt - Royalty Certificates liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ", "name": "ifrs-full:FinancialLiabilities", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_RoyaltyCertificatesLiabilitiesMember_mEPm5drgy0O0deuPued1-Q", "name": "iva:RoyaltyCertificatesEffectiveInterestRate", "unitRef": "Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "unique": true } }, "R51": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsForRetirementBenefitObligationsNetProvisionDetails", "longName": "40427 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Provisions for retirement benefit obligations - Net provision (Details)", "shortName": "Notes to the interim condensed consolidated statement of financial position - Provisions for retirement benefit obligations - Net provision (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ", "name": "ifrs-full:OtherProvisions", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ", "name": "ifrs-full:OtherProvisions", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsForRetirementBenefitObligationsChangesInNetProvisionDetails", "longName": "40428 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Provisions for retirement benefit obligations - Changes in the net provision (Details)", "shortName": "Notes to the interim condensed consolidated statement of financial position - Provisions for retirement benefit obligations - Changes in the net provision (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ", "name": "ifrs-full:LiabilityAssetOfDefinedBenefitPlans", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "iva:DisclosureOfProvisionRecordedInRespectOfDefinedBenefitSchemesAtEndOfEachReportingPeriodExplanatory", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA", "name": "ifrs-full:IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfChangesInProvisionRecordedInRespectOfDefinedBenefitSchemesExplanatory", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "unique": true } }, "R53": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsForRetirementBenefitObligationsBreakdownOfExpenseRecognizedForYearDetails", "longName": "40429 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Provisions for retirement benefit obligations - Breakdown of expense recognized for the year (Details)", "shortName": "Notes to the interim condensed consolidated statement of financial position - Provisions for retirement benefit obligations - Breakdown of expense recognized for the year (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA", "name": "ifrs-full:CurrentServiceCostDefinedBenefitPlans", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfExpensesRecognizedInStatementOfIncomeLossForRetirementBenefitObligationsExplanatory", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA", "name": "ifrs-full:CurrentServiceCostDefinedBenefitPlans", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfExpensesRecognizedInStatementOfIncomeLossForRetirementBenefitObligationsExplanatory", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesDetails", "longName": "40430 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Other current and non-current liabilities (Details)", "shortName": "Notes to the interim condensed consolidated statement of financial position - Other current and non-current liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ", "name": "iva:EmployeeRelatedPayables", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfOtherCurrentLiabilitiesExplanatory", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ", "name": "iva:EmployeeRelatedPayables", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfOtherCurrentLiabilitiesExplanatory", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesAdditionalInformationDetails", "longName": "40431 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Other current and non-current liabilities - Additional information (Details)", "shortName": "Notes to the interim condensed consolidated statement of financial position - Other current and non-current liabilities - Additional information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ", "name": "ifrs-full:OtherNoncurrentLiabilities", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LicensingAndCollaborationAgreementWithCttqMember_ZxMBck8Vv06CkTltj3JJkg", "name": "ifrs-full:OtherNoncurrentLiabilities", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "unique": true } }, "R56": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesShortTermContractLiabilitiesAndOtherCurrentLiabilitiesDetails", "longName": "40432 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Trade payables, short-term contract liabilities and other current liabilities (Details)", "shortName": "Notes to the interim condensed consolidated statement of financial position - Trade payables, short-term contract liabilities and other current liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ", "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ", "name": "iva:TradePayablesAndOtherCurrentLiabilities", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "iva:DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "unique": true } }, "R57": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesBreakDownDetails", "longName": "40433 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Trade payables break down (Details)", "shortName": "Notes to the interim condensed consolidated statement of financial position - Trade payables break down (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ", "name": "ifrs-full:TradeAndOtherCurrentPayables", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ", "name": "ifrs-full:TradeAndOtherCurrentPayables", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails", "longName": "40434 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Financial assets and liabilities (Details)", "shortName": "Notes to the interim condensed consolidated statement of financial position - Financial assets and liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ", "name": "ifrs-full:FinancialAssets", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ", "name": "ifrs-full:FinancialAssets", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossRevenuesAndOtherIncomeDetails", "longName": "40501 - Disclosure - Notes to the interim condensed consolidated statement of (income) loss - Revenues and other income (Details)", "shortName": "Notes to the interim condensed consolidated statement of (income) loss - Revenues and other income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA", "name": "ifrs-full:RevenueFromContractsWithCustomers", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:RevenueAndOtherIncomeTableTextBlock", "iva:DisclosureOfComponentsOfIncomeStatementTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA", "name": "ifrs-full:RevenueFromContractsWithCustomers", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:RevenueAndOtherIncomeTableTextBlock", "iva:DisclosureOfComponentsOfIncomeStatementTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossNarrativesDetails", "longName": "40502 - Disclosure - Notes to the interim condensed consolidated statement of (income) loss - Narratives (Details)", "shortName": "Notes to the interim condensed consolidated statement of (income) loss - Narratives (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ", "name": "iva:CurrentTaxCreditResearchCurrentYear", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "iva:DisclosureOfComponentsOfIncomeStatementTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_dei_LegalEntityAxis_iva_InventivaIncMember_yX8YJNqJxEeoquiF4wd66g", "name": "iva:CirAndOtherResearchTaxCreditsReceivable", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "iva:DisclosureOfComponentsOfIncomeStatementTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "unique": true } }, "R61": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails", "longName": "40503 - Disclosure - Notes to the interim condensed consolidated statement of (income) loss - Operating expenses (Details)", "shortName": "Notes to the interim condensed consolidated statement of (income) loss - Operating expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA", "name": "iva:Disposables", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:ResearchAndDevelopmentMarketingTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA", "name": "iva:Disposables", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:ResearchAndDevelopmentMarketingTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true } }, "R62": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesPersonnelCostsAndHeadcountDetails", "longName": "40504 - Disclosure - Notes to the interim condensed consolidated statement of (income) loss - Operating expenses - Personnel costs and headcount (Details)", "shortName": "Notes to the interim condensed consolidated statement of (income) loss - Operating expenses - Personnel costs and headcount (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ", "name": "ifrs-full:NumberOfEmployees", "unitRef": "Unit_Standard_employee_t09Loy2TV0yh-O2RJe0wMQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ", "name": "ifrs-full:NumberOfEmployees", "unitRef": "Unit_Standard_employee_t09Loy2TV0yh-O2RJe0wMQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOtherOperatingIncomeAndExpensesDetails", "longName": "40505 - Disclosure - Notes to the interim condensed consolidated statement of (income) loss - Other operating income and expenses - (Details)", "shortName": "Notes to the interim condensed consolidated statement of (income) loss - Other operating income and expenses - (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA", "name": "ifrs-full:MiscellaneousOtherOperatingIncome", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfOtherOperatingIncomeExpenseTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA", "name": "ifrs-full:MiscellaneousOtherOperatingIncome", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfOtherOperatingIncomeExpenseTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true } }, "R64": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails", "longName": "40506 - Disclosure - Notes to the interim condensed consolidated statement of (income) loss - Financial income and expenses (Details)", "shortName": "Notes to the interim condensed consolidated statement of (income) loss - Financial income and expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA", "name": "ifrs-full:InterestIncomeOnCashAndCashEquivalents", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:FinancialIncomeAndExpensesTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA", "name": "ifrs-full:InterestIncomeOnCashAndCashEquivalents", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:FinancialIncomeAndExpensesTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true } }, "R65": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails", "longName": "40507 - Disclosure - Notes to the interim condensed consolidated statement of (income) loss - Share of net profit - Equity method (Details)", "shortName": "Notes to the interim condensed consolidated statement of (income) loss - Share of net profit - Equity method (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA", "name": "ifrs-full:ResearchAndDevelopmentExpense", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg", "name": "ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "unique": true } }, "R66": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossIncomeTaxDetails", "longName": "40508 - Disclosure - Notes to the interim condensed consolidated statement of (income) loss - Income tax (Details)", "shortName": "Notes to the interim condensed consolidated statement of (income) loss - Income tax (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_oxFIDH8XQUKPgIUFQceRfA", "name": "ifrs-full:TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods", "unitRef": "Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_oxFIDH8XQUKPgIUFQceRfA", "name": "ifrs-full:TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods", "unitRef": "Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true } }, "R67": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossBasicAndDilutedLossPerShareDetails", "longName": "40509 - Disclosure - Notes to the interim condensed consolidated statement of (income) loss - Basic and diluted loss per share (Details)", "shortName": "Notes to the interim condensed consolidated statement of (income) loss - Basic and diluted loss per share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA", "name": "ifrs-full:ProfitLoss", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true }, "uniqueAnchor": null }, "R68": { "role": "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails", "longName": "40601 - Disclosure - Other financial information (Details)", "shortName": "Other financial information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ", "name": "ifrs-full:ContractualCapitalCommitments", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfContingentLiabilitiesExplanatory", "iva:DisclosureOfOtherFinancialInformationTextblock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ", "name": "ifrs-full:ContractualCapitalCommitments", "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfContingentLiabilitiesExplanatory", "iva:DisclosureOfOtherFinancialInformationTextblock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true, "unique": true } }, "R69": { "role": "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails", "longName": "40602 - Disclosure - Other financial information - Events after the reporting date (Details)", "shortName": "Other financial information - Events after the reporting date (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ", "name": "ifrs-full:ParValuePerShare", "unitRef": "Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_WarrantAgreementWithEuropeanInvestmentBankMember_IGbGo6uT7EO_KIZuumIllA", "name": "iva:IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "unitRef": "Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20240630xex99d1.htm", "unique": true } } }, "tag": { "iva_AccountingPrinciplesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "AccountingPrinciplesAbstract", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Accounting Principles" } } }, "auth_ref": [] }, "ifrs-full_AccrualsClassifiedAsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AccrualsClassifiedAsCurrent", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesShortTermContractLiabilitiesAndOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Accruals classified as current", "terseLabel": "Accrued expenses" } }, "en": { "role": { "documentation": "The amount of accruals classified as current. [Refer: Accruals]" } } }, "auth_ref": [ "r220" ] }, "iva_AccrualsClassifiedAsCurrentRelatingToScientificProjects": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "AccrualsClassifiedAsCurrentRelatingToScientificProjects", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesShortTermContractLiabilitiesAndOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of accruals classified as current relating to scientific projects", "label": "Accruals classified as current relating to scientific projects", "terseLabel": "Accrued liabilities relating to scientific projects" } } }, "auth_ref": [] }, "iva_AccruedIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "AccruedIncomeMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for accrued income.", "label": "Current accrued income", "terseLabel": "Current accrued income" } } }, "auth_ref": [] }, "iva_AccruedPayrollAndOtherEmployeeRelatedTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "AccruedPayrollAndOtherEmployeeRelatedTaxes", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesDetails": { "parentTag": "ifrs-full_OtherCurrentLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount pertaining to accrued payroll and other employee related taxes.", "label": "Accrued payroll and other employeerelated taxes", "terseLabel": "Accrued payroll and other employeerelated taxes" } } }, "auth_ref": [] }, "ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AccumulatedDepreciationAmortisationAndImpairmentMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionIntangibleAssetsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionPropertyPlantAndEquipmentAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Accumulated depreciation, amortisation and impairment [member]", "terseLabel": "Amortization", "verboseLabel": "Depreciation and impairment" } }, "en": { "role": { "documentation": "This member stands for accumulated depreciation, amortisation and impairment. [Refer: Impairment loss; Depreciation and amortisation expense]" } } }, "auth_ref": [ "r46", "r49", "r71", "r76", "r79" ] }, "ifrs-full_AccumulatedImpairmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AccumulatedImpairmentMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInventoriesDetails" ], "lang": { "en-us": { "role": { "label": "Inventories write-down" } }, "en": { "role": { "documentation": "This member stands for accumulated impairment. [Refer: Impairment loss]" } } }, "auth_ref": [ "r137", "r143", "r200", "r227", "r233", "r234", "r235" ] }, "ifrs-full_AdditionsToRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdditionsToRightofuseAssets", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionPropertyPlantAndEquipmentAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Additions To Right of use Assets", "terseLabel": "Additions to right-of-use assets" } }, "en": { "role": { "documentation": "The amount of additions to right-of-use assets. [Refer: Right-of-use assets]" } } }, "auth_ref": [ "r124" ] }, "ifrs-full_AdjustedWeightedAverageShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustedWeightedAverageShares", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossBasicAndDilutedLossPerShareDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Adjusted weighted average number of ordinary shares outstanding", "terseLabel": "Weighted average number of shares outstanding used to calculate diluted loss per share" } }, "en": { "role": { "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } } }, "auth_ref": [ "r66" ] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInInventories", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for decrease (increase) in inventories", "terseLabel": "Decrease / (increase) in inventories" } }, "en": { "role": { "documentation": "Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]" } } }, "auth_ref": [ "r237" ] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for decrease (increase) in trade and other receivables", "terseLabel": "Decrease / (increase) in operating and other receivables" } }, "en": { "role": { "documentation": "Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]" } } }, "auth_ref": [ "r239" ] }, "iva_AdjustmentsForDepreciationAmortisationAndProvisions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "AdjustmentsForDepreciationAmortisationAndProvisions", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Adjustments for depreciation, amortisation expense and provisions to reconcile profit (loss) to net cash flow from (used in) operating activities.", "label": "Adjustments for Depreciation, Amortisation and Provisions", "terseLabel": "Depreciation, amortization and provisions" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForFairValueGainsLosses": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForFairValueGainsLosses", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for fair value losses (gains)", "terseLabel": "Fair value variation through profit and loss" } }, "en": { "role": { "documentation": "Adjustments for fair value losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r238" ] }, "ifrs-full_AdjustmentsForFinanceIncomeCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForFinanceIncomeCost", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for finance income (cost)", "negatedLabel": "Cost of debt" } }, "en": { "role": { "documentation": "Adjustments for net finance income or cost to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income (cost); Profit (loss)]" } } }, "auth_ref": [ "r239" ] }, "ifrs-full_AdjustmentsForIncomeTaxExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForIncomeTaxExpense", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for income tax expense", "terseLabel": "Deferred and current taxes" } }, "en": { "role": { "documentation": "Adjustments for income tax expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r86" ] }, "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for increase (decrease) in trade and other payables", "verboseLabel": "Increase / (decrease) in operating and other payables" } }, "en": { "role": { "documentation": "Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]" } } }, "auth_ref": [ "r239" ] }, "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForReconcileProfitLossAbstract", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile profit (loss) [abstract]", "terseLabel": "Elimination of non-cash or non-operating income and expenses" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForSharebasedPayments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForSharebasedPayments", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for share-based payments", "terseLabel": "Sharebased compensation expense" } }, "en": { "role": { "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r238" ] }, "iva_AdjustmentsForTaxCredits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "AdjustmentsForTaxCredits", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Adjustments for tax credit to reconcile profit (loss) to net cash flow from (used in) operating activities.", "label": "Adjustments For Tax Credits", "terseLabel": "Tax credits" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForUndistributedProfitsOfAssociates": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForUndistributedProfitsOfAssociates", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for undistributed profits of associates", "negatedLabel": "Share of net profit of associates and joint ventures accounted for using the equity method" } }, "en": { "role": { "documentation": "Adjustments for undistributed profits of associates to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Associates [member]; Profit (loss)]" } } }, "auth_ref": [ "r238" ] }, "ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForUnrealisedForeignExchangeLossesGains", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for unrealised foreign exchange losses (gains)", "terseLabel": "Exchange (gains) / losses" } }, "en": { "role": { "documentation": "Adjustments for unrealised foreign exchange losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r193", "r238" ] }, "iva_AdvancePaymentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "AdvancePaymentMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for advance payment.", "label": "Advance payment", "terseLabel": "Advance payment" } } }, "auth_ref": [] }, "iva_Aga2021Aga2021BisMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "Aga2021Aga2021BisMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFreeShareAwardsAndPerformanceUnitsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for AGA 2021 & AGA 2021 bis.", "label": "AGA 2021 & AGA 2021 bis [Member]", "terseLabel": "AGA 2021 & AGA 2021 bis" } } }, "auth_ref": [] }, "iva_AggregateAmountToBeReceivedEitherInExchangeForNewSharesOfCompanyOrThroughReceiptOfUpfrontOrMilestonePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "AggregateAmountToBeReceivedEitherInExchangeForNewSharesOfCompanyOrThroughReceiptOfUpfrontOrMilestonePayments", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details" ], "lang": { "en-us": { "role": { "documentation": "Aggregate amount to be received by the company, either in exchange for new shares of the Company or through the receipt of upfront or milestone payments, pursuant to the debt arrangement.", "label": "Aggregate Amount To Be Received Either In Exchange For New Shares Of The Company Or Through The Receipt Of Upfront Or Milestone Payments", "verboseLabel": "Aggregate amount to be received under the conditions precedent to the EIB Financing" } } }, "auth_ref": [] }, "iva_AggregateAmountToBeReceivedEitherInExchangeForNewSharesOrWarrantsOfCompany": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "AggregateAmountToBeReceivedEitherInExchangeForNewSharesOrWarrantsOfCompany", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Aggregate amount to be received by the company, either in exchange for new shares or warrants of the Company.", "label": "Aggregate Amount To Be Received Either In Exchange For New Shares or Warrants Of The Company", "terseLabel": "Aggregate amount to be received either in exchange for new shares or warrants" } } }, "auth_ref": [] }, "ifrs-full_AggregatedTimeBandsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AggregatedTimeBandsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesBreakDownDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Aggregated time bands [member]" } }, "en": { "role": { "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used." } } }, "auth_ref": [ "r22", "r121", "r125", "r126", "r127", "r128", "r129", "r130", "r139", "r183", "r202", "r207" ] }, "iva_AgreementsConcerningProvisionOfFacilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "AgreementsConcerningProvisionOfFacilities", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails": { "parentTag": "iva_ContractualCapitalCommitmentReceived", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of agreements concerning provision of facilities.", "label": "Agreements concerning the provision of facilities", "terseLabel": "Agreements concerning the provision of facilities" } } }, "auth_ref": [] }, "ifrs-full_AllLevelsOfFairValueHierarchyMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AllLevelsOfFairValueHierarchyMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails" ], "lang": { "en-us": { "role": { "label": "All levels of fair value hierarchy [member]" } }, "en": { "role": { "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used." } } }, "auth_ref": [ "r52", "r113" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "iva_AmountInvoicedToCounterpartyForInitialPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "AmountInvoicedToCounterpartyForInitialPayment", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "documentation": "This amount represents the information of invoiced to counterparty for initial payment.", "label": "Amount Invoiced To Counterparty For Initial Payment", "terseLabel": "Amount invoiced to counterparty for milestone payment" } } }, "auth_ref": [] }, "iva_AnnualRoyaltyPercentageOnFutureNetSalesOfLanifibranor": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "AnnualRoyaltyPercentageOnFutureNetSalesOfLanifibranor", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtRoyaltyCertificatesLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of annual royalty on future net sales of Lanifibranor.", "label": "Annual Royalty Percentage on Future Net Sales of Lanifibranor", "terseLabel": "Annual royalty percentage" } } }, "auth_ref": [] }, "ifrs-full_Assets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets" } }, "en": { "role": { "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } } }, "auth_ref": [ "r19", "r112", "r113", "r115", "r162", "r166" ] }, "ifrs-full_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AssetsAbstract", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Assets [abstract]", "terseLabel": "ASSETS" } } }, "auth_ref": [] }, "ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AttributionOfExpensesByNatureToTheirFunctionAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "label": "Attribution of expenses by nature to their function [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r212", "r215" ] }, "ifrs-full_AverageForeignExchangeRate": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AverageForeignExchangeRate", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceForeignExchangeRatesDetails" ], "lang": { "en-us": { "role": { "label": "Average foreign exchange rate", "terseLabel": "Average exchange rate for the period" } }, "en": { "role": { "documentation": "The average exchange rate used by the entity. Exchange rate is the ratio of exchange for two currencies." } } }, "auth_ref": [ "r215" ] }, "ifrs-full_BankOverdraftsClassifiedAsCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "BankOverdraftsClassifiedAsCashEquivalents", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionCashAndCashEquivalentsDetails": { "parentTag": "ifrs-full_CashAndCashEquivalents", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionCashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "label": "Bank overdrafts", "negatedLabel": "Bank overdrafts", "terseLabel": "Bank overdrafts inclusive of cash and cash equivalents" } }, "en": { "role": { "documentation": "The amount that has been withdrawn from an account in excess of existing cash balances. This is considered a short-term extension of credit by the bank. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r240" ] }, "ifrs-full_BasicEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "BasicEarningsLossPerShare", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossBasicAndDilutedLossPerShareDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Basic earnings (loss) per share", "terseLabel": "Basic loss per share" } }, "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)." } } }, "auth_ref": [ "r64", "r65" ] }, "iva_BonusShareAwardPlansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "BonusShareAwardPlansMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFreeShareAwardsAndPerformanceUnitsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for bonus share award plans.", "label": "Bonus Share Award Plans [Member]", "terseLabel": "Bonus share award plans" } } }, "auth_ref": [] }, "ifrs-full_BorrowingCostsIncurred": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "BorrowingCostsIncurred", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "label": "Borrowing costs incurred", "terseLabel": "Borrowing costs" } }, "en": { "role": { "documentation": "The amount of interest and other costs that an entity incurs in connection with the borrowing of funds." } } }, "auth_ref": [ "r215" ] }, "ifrs-full_Borrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Borrowings", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFinancialDebtDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureDisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtMovementsInPeriodBreakDownDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFinancialDebtDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtRoyaltyCertificatesLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails" ], "lang": { "en-us": { "role": { "label": "Borrowings", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "terseLabel": "Borrowings", "totalLabel": "Total debt" } }, "en": { "role": { "documentation": "The amount of outstanding funds that the entity is obligated to repay." } } }, "auth_ref": [ "r218" ] }, "iva_BorrowingsActualizationRate": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "BorrowingsActualizationRate", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "The actualization interest rate on borrowings.", "label": "Borrowings, Actualization Rate", "terseLabel": "Actualization rate" } } }, "auth_ref": [] }, "ifrs-full_BorrowingsByNameAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "BorrowingsByNameAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtRoyaltyCertificatesLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "label": "Borrowings by name [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r244" ] }, "ifrs-full_BorrowingsByNameMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "BorrowingsByNameMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtRoyaltyCertificatesLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "label": "Borrowings by name [member]" } }, "en": { "role": { "documentation": "This member stands for all borrowings when disaggregated by name. It also represents the standard value for the 'Borrowings by name' axis if no other member is used. [Refer: Borrowings]" } } }, "auth_ref": [ "r244" ] }, "iva_BorrowingsEffectiveInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "BorrowingsEffectiveInterestRate", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "The effective interest rate on borrowings.", "label": "Borrowings, effective interest rate" } } }, "auth_ref": [] }, "ifrs-full_BorrowingsInterestRate": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "BorrowingsInterestRate", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Borrowings, interest rate", "terseLabel": "Interest rate" } }, "en": { "role": { "documentation": "The interest rate on borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r244" ] }, "iva_BorrowingsMaximumExtensionTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "BorrowingsMaximumExtensionTerm", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "documentation": "Period up to which the maturity term of the borrowings can be extended.", "label": "Borrowings, Maximum Extension Term", "verboseLabel": "Extension of term of debt" } } }, "auth_ref": [] }, "ifrs-full_BottomOfRangeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "BottomOfRangeMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" ], "lang": { "en-us": { "role": { "label": "Minimum", "terseLabel": "Minimum" } }, "en": { "role": { "documentation": "This member stands for the bottom of a range." } } }, "auth_ref": [ "r117", "r129", "r133", "r196", "r197", "r244" ] }, "iva_Bsa2017PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "Bsa2017PlanMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for BSA - 2017 plan.", "label": "BSA - 2017 plan" } } }, "auth_ref": [] }, "iva_Bsa2018PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "Bsa2018PlanMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for BSA - 2018 plan.", "label": "BSA - 2018 plan" } } }, "auth_ref": [] }, "iva_Bsa2022Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "Bsa2022Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the BSA 2022 share-based payment plan", "label": "BSA 2022 [Member]", "terseLabel": "BSA 2022" } } }, "auth_ref": [] }, "iva_Bsa20231ShareWarrantPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "Bsa20231ShareWarrantPlanMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityOptionsAndShareWarrantsBsaAndBspceDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for BSA 2023-1 share warrants plan.", "label": "BSA 2023-1 Share Warrant Plan [Member]", "terseLabel": "BSA 2023 plan" } } }, "auth_ref": [] }, "iva_Bsa20232ShareWarrantPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "Bsa20232ShareWarrantPlanMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityOptionsAndShareWarrantsBsaAndBspceDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for BSA 2023-2 share warrants plan.", "label": "BSA 2023-2 Share Warrant Plan [Member]", "terseLabel": "BSA- 2 2023 plan" } } }, "auth_ref": [] }, "iva_Bsa2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "Bsa2024Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the BSA 2024 share-based payment plan", "label": "BSA 2024 [Member]" } } }, "auth_ref": [] }, "iva_BsaPlansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "BsaPlansMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for BSA plans.", "label": "BSA plans" } } }, "auth_ref": [] }, "iva_BsaShareWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "BsaShareWarrantsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityOptionsAndShareWarrantsBsaAndBspceDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for BSA share warrants.", "label": "BSA share warrants" } } }, "auth_ref": [] }, "iva_Bspce2021PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "Bspce2021PlanMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for BSPCE 2021 plan.", "label": "BSPCE 2021" } } }, "auth_ref": [] }, "iva_BspceAndBsaShareWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "BspceAndBsaShareWarrantsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables" ], "lang": { "en-us": { "role": { "documentation": "This member stands for BSPCE and BSA share warrants.", "label": "BSPCE and BSA Share Warrants", "verboseLabel": "BSPCE share warrants and BSA share warrants" } } }, "auth_ref": [] }, "iva_BspcePlansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "BspcePlansMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for BSPCE plans.", "label": "BSPCE plans" } } }, "auth_ref": [] }, "ifrs-full_CapitalReserve": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CapitalReserve", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails" ], "lang": { "en-us": { "role": { "label": "Capital reserve", "terseLabel": "Capital reserve" } }, "en": { "role": { "documentation": "A component of equity representing the capital reserves." } } }, "auth_ref": [ "r218" ] }, "iva_CapitalSurplusOthers": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "CapitalSurplusOthers", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails" ], "lang": { "en-us": { "role": { "documentation": "A component of equity representing the capital surplus-others.", "label": "Capital Surplus Others", "verboseLabel": "Capital surplus-others" } } }, "auth_ref": [] }, "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionIntangibleAssetsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInventoriesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionPropertyPlantAndEquipmentAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r46", "r47", "r71", "r72", "r75", "r76", "r77", "r78", "r79", "r137", "r143", "r144" ] }, "ifrs-full_CarryingAmountMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CarryingAmountMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionIntangibleAssetsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInventoriesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionPropertyPlantAndEquipmentAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Carrying amount [member]" } }, "en": { "role": { "documentation": "This member stands for the amount at which an asset is recognised in the statement of financial position (after deducting any accumulated depreciation or amortisation and accumulated impairment losses). It also represents the standard value for the 'Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount' axis if no other member is used. [Refer: Depreciation and amortisation expense; Impairment loss]" } } }, "auth_ref": [ "r47", "r72", "r75", "r77", "r78", "r137", "r143", "r144" ] }, "ifrs-full_Cash": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Cash", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionCashAndCashEquivalentsDetails": { "parentTag": "ifrs-full_CashAndCashEquivalents", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionCashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "label": "Cash", "terseLabel": "Cash at bank and at hand" } }, "en": { "role": { "documentation": "The amount of cash on hand and demand deposits. [Refer: Cash on hand]" } } }, "auth_ref": [ "r240" ] }, "ifrs-full_CashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashAndCashEquivalents", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 4.0 }, "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionCashAndCashEquivalentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionCashAndCashEquivalentsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Cash and cash equivalent", "periodEndLabel": "Net cash and cash equivalents at the end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period", "terseLabel": "Cash and cash equivalents", "totalLabel": "Cash and cash equivalents" } }, "en": { "role": { "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]" } } }, "auth_ref": [ "r14", "r87", "r105" ] }, "ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) decrease (increase) in short-term deposits and investments", "terseLabel": "Decrease / (Increase) in short-term deposit accounts" } }, "en": { "role": { "documentation": "The cash inflow (outflow) due to a decrease (increase) in short-term deposits and investments." } } }, "auth_ref": [ "r236" ] }, "ifrs-full_CashFlowsFromUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) financing activities", "totalLabel": "Net cash from (used in) financing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity." } } }, "auth_ref": [ "r80", "r88" ] }, "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) financing activities [abstract]", "terseLabel": "Cash flows used in financing activities" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) investing activities", "totalLabel": "Net cash from (used in) investing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents." } } }, "auth_ref": [ "r80", "r88" ] }, "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) investing activities [abstract]", "terseLabel": "Cash flows used in investing activities" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashFlowsFromUsedInOperatingActivities", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) operating activities", "totalLabel": "Net cash used in operating activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]" } } }, "auth_ref": [ "r80", "r88" ] }, "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) operating activities [abstract]", "terseLabel": "Cash flows used in operating activities" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows used in operations before tax, interest and changes in working capital", "totalLabel": "Cash flows used in operations before tax, interest and changes in working capital" } }, "en": { "role": { "documentation": "The cash inflow (outflow) from the entity's operations before changes in working capital." } } }, "auth_ref": [ "r193", "r239" ] }, "iva_CashUnderLiquidityAgreementCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "CashUnderLiquidityAgreementCurrent", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails": { "parentTag": "ifrs-full_OtherCurrentAssets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of cash under liquidity agreement, classified as current.", "label": "Cash Under Liquidity Agreement, Current", "terseLabel": "Liquidity agreement - Cash" } } }, "auth_ref": [] }, "ifrs-full_CategoriesOfFinancialAssetsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CategoriesOfFinancialAssetsAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Categories of financial assets [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r157" ] }, "ifrs-full_CategoriesOfFinancialLiabilitiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CategoriesOfFinancialLiabilitiesAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "label": "Categories of financial liabilities [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r157" ] }, "ifrs-full_CategoriesOfRelatedPartiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CategoriesOfRelatedPartiesAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFreeShareAwardsAndPerformanceUnitsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityOptionsAndShareWarrantsBsaAndBspceDetails" ], "lang": { "en-us": { "role": { "label": "Categories of related parties [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r57" ] }, "ifrs-full_ChangesInPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ChangesInPropertyPlantAndEquipment", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionPropertyPlantAndEquipmentAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in property, plant and equipment", "terseLabel": "Increase in net value of property, plant and equipment" } }, "en": { "role": { "documentation": "The increase (decrease) in property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r47" ] }, "iva_ChiaTaiTianqingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "ChiaTaiTianqingMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "It Represents the member of chia tai tianqing.", "label": "Chia Tai Tianqing [Member]", "terseLabel": "CTTQ" } } }, "auth_ref": [] }, "iva_CirAndOtherResearchTaxCreditsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "CirAndOtherResearchTaxCreditsReceivable", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails": { "parentTag": "ifrs-full_CurrentTaxAssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of CIR and other research tax credits receivable.", "label": "CIR and Other Research Tax Credits Receivable", "terseLabel": "CIR and other research tax credits receivable", "verboseLabel": "Tax research credit" } } }, "auth_ref": [] }, "iva_ClassOfWarrantOrRightExercisePriceOfWarrantsAsPercentageOfVolumeWeightedAveragePriceOfCompanySShares": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsAsPercentageOfVolumeWeightedAveragePriceOfCompanySShares", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details" ], "lang": { "en-us": { "role": { "documentation": "Exercise price of warrants issued, represented as a percentage of volume-weighted average price of the Company's shares.", "label": "Class Of Warrant Or Right, Exercise Price Of Warrants As A Percentage Of Volume-Weighted Average Price Of The Company's Shares", "terseLabel": "Exercise price of warrants as a percentage of volume-weighted average price of the Company's shares" } } }, "auth_ref": [] }, "iva_ClassOfWarrantOrRightGranted": { "xbrltype": "sharesItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "ClassOfWarrantOrRightGranted", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights granted.", "label": "Class of Warrant or Right, Granted", "terseLabel": "Number of warrants granted", "verboseLabel": "Number of warrants issued" } } }, "auth_ref": [] }, "iva_ClassOfWarrantOrRightMaturityTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "ClassOfWarrantOrRightMaturityTerm", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Maturity term of the warrants issued by the entity.", "label": "Class Of Warrant Or Right, Maturity Term", "terseLabel": "Maturity term of warrants" } } }, "auth_ref": [] }, "ifrs-full_ClassesOfFinancialAssetsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfFinancialAssetsAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Classes of financial assets [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r131", "r150", "r151", "r172", "r173" ] }, "ifrs-full_ClassesOfFinancialLiabilitiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfFinancialLiabilitiesAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtRoyaltyCertificatesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Classes of financial liabilities [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r150", "r151", "r172", "r173" ] }, "ifrs-full_ClassesOfLiabilitiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfLiabilitiesAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtRoyaltyCertificatesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Classes of liabilities [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r116" ] }, "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfPropertyPlantAndEquipmentAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionPropertyPlantAndEquipmentAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Classes of property, plant and equipment [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r48" ] }, "ifrs-full_ClassesOfShareCapitalAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfShareCapitalAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails" ], "lang": { "en-us": { "role": { "label": "Classes of share capital [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r31" ] }, "ifrs-full_ClassesOfShareCapitalMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfShareCapitalMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails" ], "lang": { "en-us": { "role": { "label": "Share capital [member]" } }, "en": { "role": { "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used." } } }, "auth_ref": [ "r31" ] }, "iva_ClinicalTrialsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "ClinicalTrialsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Clinical Trials(CRO).", "label": "Clinical Trials [Member]", "terseLabel": "CRO" } } }, "auth_ref": [] }, "ifrs-full_ClosingForeignExchangeRate": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClosingForeignExchangeRate", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceForeignExchangeRatesDetails" ], "lang": { "en-us": { "role": { "label": "Closing foreign exchange rate", "terseLabel": "Exchange rate at period end" } }, "en": { "role": { "documentation": "The spot exchange rate at the end of the reporting period. Exchange rate is the ratio of exchange for two currencies. Spot exchange rate is the exchange rate for immediate delivery." } } }, "auth_ref": [ "r215" ] }, "iva_CommitmentContractualBonusOrMalusCappedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "CommitmentContractualBonusOrMalusCappedAmount", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of commitment contractual bonus or malus capped amount.", "label": "Commitment Contractual Bonus Or Malus Capped Amount", "terseLabel": "Bonus or malus capped amount" } } }, "auth_ref": [] }, "iva_CommitmentsAmountPayableForServicesReceivedUnderContract": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "CommitmentsAmountPayableForServicesReceivedUnderContract", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Commitment amount payable for services received under contract.", "label": "Commitments Amount Payable For Services Received Under Contract", "verboseLabel": "Amount committed to pay" } } }, "auth_ref": [] }, "iva_CompanyInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "CompanyInformationAbstract", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Company information" } } }, "auth_ref": [] }, "iva_CompanyInformationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "CompanyInformationTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformation" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure on company information.", "label": "Company Information [Text Block]", "terseLabel": "Company information" } } }, "auth_ref": [] }, "ifrs-full_ComponentsOfEquityAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ComponentsOfEquityAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Components of equity [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r6" ] }, "iva_ComponentsOfIncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "ComponentsOfIncomeStatementAbstract", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Notes to the interim condensed consolidated statement of (income) loss" } } }, "auth_ref": [] }, "ifrs-full_ComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ComprehensiveIncome", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Comprehensive income", "totalLabel": "Total comprehensive loss" } }, "en": { "role": { "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners." } } }, "auth_ref": [ "r1", "r34", "r90", "r92", "r102", "r195" ] }, "ifrs-full_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ConstructionInProgressMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property, plant and equipment in progress" } }, "en": { "role": { "documentation": "This member stands for expenditure capitalised during the construction of items of property, plant and equipment that are not yet available for use (ie not yet in the location and condition necessary for it to be capable of operating in the manner intended by the management). [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r225" ] }, "iva_ContractCroWithPharmaceuticalResearchAssociatesB.vMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "ContractCroWithPharmaceuticalResearchAssociatesB.vMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherNonCurrentAssetsLongTermDepositAccountsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Contract CRO with PRA.", "label": "Contract CRO With Pharmaceutical Research Associates B.V [Member]", "terseLabel": "Contract CRO with Pharmaceutical Research Associates B.V." } } }, "auth_ref": [] }, "iva_ContractCroWithResearchAssociatesGroupeB.vMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "ContractCroWithResearchAssociatesGroupeB.vMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Contract CRO with PRA.", "label": "Contract CRO with Pharmaceutical Research Associates B.V.", "terseLabel": "Contract CRO with Pharmaceutical Research Associates B.V." } } }, "auth_ref": [] }, "iva_ContractManufacturingOrganizationsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "ContractManufacturingOrganizationsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Contract Manufacturing Organizations(CMO).", "label": "Contract Manufacturing Organizations [Member]", "terseLabel": "CMO" } } }, "auth_ref": [] }, "iva_ContractualCapitalCommitmentReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "ContractualCapitalCommitmentReceived", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of contractual capital commitment received.", "label": "Contractual Capital Commitment Received", "totalLabel": "Total commitments received" } } }, "auth_ref": [] }, "ifrs-full_ContractualCapitalCommitments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ContractualCapitalCommitments", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" ], "lang": { "en-us": { "role": { "label": "Contractual capital commitments", "terseLabel": "Total commitments given" } }, "en": { "role": { "documentation": "The amount of capital commitments for which the entity has entered into a contract. [Refer: Capital commitments]" } } }, "auth_ref": [ "r215" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Document and Entity Information", "documentation": "Cover page." } } }, "auth_ref": [] }, "ifrs-full_CurrentAccruedIncomeIncludingCurrentContractAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentAccruedIncomeIncludingCurrentContractAssets", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails": { "parentTag": "ifrs-full_OtherCurrentAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Current accrued income including current contract assets", "terseLabel": "Current accrued income" } }, "en": { "role": { "documentation": "The amount of current accrued income including current contract assets. [Refer: Accrued income including contract assets]" } } }, "auth_ref": [ "r218", "r220" ] }, "ifrs-full_CurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentAssets", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current assets", "totalLabel": "Total current assets" } }, "en": { "role": { "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]" } } }, "auth_ref": [ "r23", "r98", "r195" ] }, "ifrs-full_CurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentAssetsAbstract", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current assets [abstract]", "terseLabel": "Current assets" } } }, "auth_ref": [] }, "iva_CurrentAssetsExcludingDeferredAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "CurrentAssetsExcludingDeferredAssets", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails" ], "lang": { "en-us": { "role": { "documentation": "Current assets excluding deferred assets", "label": "Current assets excluding deferred assets", "totalLabel": "Total current assets" } } }, "auth_ref": [] }, "iva_CurrentBorrowingsAndCurrentPortionOfNonCurrentBorrowingsAndCurrentLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "CurrentBorrowingsAndCurrentPortionOfNonCurrentBorrowingsAndCurrentLeaseLiabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "documentation": "Current borrowings and current portion of non-current borrowings and current lease liabilities", "label": "Current borrowings and current portion of non-current borrowings and current lease liabilities", "terseLabel": "Shortterm debt" } } }, "auth_ref": [] }, "ifrs-full_CurrentContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentContractLiabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesShortTermContractLiabilitiesAndOtherCurrentLiabilitiesDetails": { "parentTag": "iva_TradePayablesAndOtherCurrentLiabilities", "weight": 1.0, "order": 1.0 }, "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesShortTermContractLiabilitiesAndOtherCurrentLiabilitiesDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current contract liabilities", "terseLabel": "Short-term contract liabilities" } }, "en": { "role": { "documentation": "The amount of current contract liabilities. [Refer: Contract liabilities]" } } }, "auth_ref": [ "r118" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "ifrs-full_CurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentLiabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current liabilities", "totalLabel": "Total current liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period." } } }, "auth_ref": [ "r24", "r100", "r195" ] }, "ifrs-full_CurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentLiabilitiesAbstract", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current liabilities [abstract]", "terseLabel": "Current liabilities" } } }, "auth_ref": [] }, "ifrs-full_CurrentPrepaidExpenses": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentPrepaidExpenses", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails": { "parentTag": "ifrs-full_OtherCurrentAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Current prepaid expenses", "terseLabel": "Prepaid expenses" } }, "en": { "role": { "documentation": "The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised." } } }, "auth_ref": [ "r215" ] }, "ifrs-full_CurrentServiceCostDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentServiceCostDefinedBenefitPlans", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsForRetirementBenefitObligationsBreakdownOfExpenseRecognizedForYearDetails": { "parentTag": "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsForRetirementBenefitObligationsBreakdownOfExpenseRecognizedForYearDetails" ], "lang": { "en-us": { "role": { "label": "Current service cost, defined benefit plans", "negatedLabel": "Service cost for the period" } }, "en": { "role": { "documentation": "The expense of employee service in the current period arising from defined benefit plans. [Refer: Post-employment benefit expense in profit or loss, defined benefit plans] [Contrast: Increase in net defined benefit liability (asset) resulting from current service cost]" } } }, "auth_ref": [ "r228" ] }, "ifrs-full_CurrentTaxAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentTaxAssetsCurrent", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails": { "parentTag": "iva_OtherCurrentAssetsAndReceivables", "weight": 1.0, "order": 2.0 }, "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current tax assets, current", "terseLabel": "Tax receivables", "totalLabel": "Tax receivables" } }, "en": { "role": { "documentation": "The current amount of current tax assets. [Refer: Current tax assets]" } } }, "auth_ref": [ "r16" ] }, "iva_CurrentTaxCreditResearchCurrentYear": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "CurrentTaxCreditResearchCurrentYear", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of tax credit research from current year, classified as current.", "label": "Current Tax Credit Research, Current Year", "terseLabel": "Receivable for current year", "verboseLabel": "Tax credits of current year" } } }, "auth_ref": [] }, "iva_CurrentTaxCreditResearchIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "CurrentTaxCreditResearchIncome", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossRevenuesAndOtherIncomeDetails": { "parentTag": "iva_OtherIncomeFromOrdinaryActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossRevenuesAndOtherIncomeDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of income from tax credit research.", "label": "Current Tax Credit Research Income", "terseLabel": "Tax Credits" } } }, "auth_ref": [] }, "ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Current tax expense (income) and adjustments for current tax of prior periods", "terseLabel": "Current taxes" } }, "en": { "role": { "documentation": "The amount of current tax expense (income) and adjustments for the current tax of prior periods. [Refer: Current tax expense (income); Adjustments for current tax of prior periods]" } } }, "auth_ref": [ "r223" ] }, "iva_CurrentTradeReceivablesAveragePaymentPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "CurrentTradeReceivablesAveragePaymentPeriod", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the average payment period for trade receivables.", "label": "Current Trade Receivables, Average Payment Period", "terseLabel": "Average payment period for trade receivables" } } }, "auth_ref": [] }, "ifrs-full_CurrentValueAddedTaxPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentValueAddedTaxPayables", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesDetails": { "parentTag": "ifrs-full_OtherCurrentLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Current value added tax payables", "terseLabel": "VAT payables" } }, "en": { "role": { "documentation": "The amount of current value added tax payables. [Refer: Value added tax payables]" } } }, "auth_ref": [ "r220" ] }, "iva_DailyDoseOfEmpagliflozinInTrial": { "xbrltype": "massItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "DailyDoseOfEmpagliflozinInTrial", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of daily dosage of empagliflozin in the trial.", "label": "Daily Dose Of Empagliflozin In Trial", "terseLabel": "Daily dose of empagliflozin in trial" } } }, "auth_ref": [] }, "iva_DailyDoseOfLanifibranorInTrial": { "xbrltype": "massItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "DailyDoseOfLanifibranorInTrial", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Daily dose of lanifibranor in trial", "label": "Daily dose of lanifibranor in trial" } } }, "auth_ref": [] }, "iva_DavidNikodemMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "DavidNikodemMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityOptionsAndShareWarrantsBsaAndBspceDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for David Nikodem, a member of Sapidus Consulting Group LLC, a service provider to the Company.", "label": "David Nikodem", "terseLabel": "David Nikodem" } } }, "auth_ref": [] }, "iva_DecreaseInBorrowingsThroughRepaymentOfLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "DecreaseInBorrowingsThroughRepaymentOfLeaseLiabilities", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtMovementsInPeriodBreakDownDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of decrease in borrowings through repayment of lease liabilities.", "label": "Decrease in borrowings through repayment of lease liabilities", "negatedLabel": "Repayment of lease liabilities" } } }, "auth_ref": [] }, "iva_DecreaseInBorrowingsThroughRepaymentsOfBankBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "DecreaseInBorrowingsThroughRepaymentsOfBankBorrowings", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtMovementsInPeriodBreakDownDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of decrease in borrowings through repayments of bank borrowings", "label": "Decrease in borrowings through repayments of bank borrowings", "negatedLabel": "Repayment of bank borrowings" } } }, "auth_ref": [] }, "iva_DeferredAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "DeferredAssets", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails" ], "lang": { "en-us": { "role": { "documentation": "Deferred assets", "label": "Deferred assets" } } }, "auth_ref": [] }, "ifrs-full_DeferredTaxAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DeferredTaxAssets", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Deferred tax assets", "verboseLabel": "Deferred tax assets" } }, "en": { "role": { "documentation": "The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]" } } }, "auth_ref": [ "r17", "r20", "r45" ] }, "ifrs-full_DefinedBenefitObligationAtPresentValue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DefinedBenefitObligationAtPresentValue", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsForRetirementBenefitObligationsNetProvisionDetails" ], "lang": { "en-us": { "role": { "label": "Defined benefit obligation, at present value", "verboseLabel": "Retirement benefit obligations" } }, "en": { "role": { "documentation": "The present value, without deducting any plan assets, of expected future payments required to settle the obligation resulting from employee service in the current and prior periods. [Refer: Plan assets, at fair value]" } } }, "auth_ref": [ "r231" ] }, "iva_DemonstratedIncreaseOfHemoglobinInPatientsWithMashAndT2d": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "DemonstratedIncreaseOfHemoglobinInPatientsWithMashAndT2d", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "The percentage of increase of Hemoglobin in patients with MASH and T2D.", "label": "Demonstrated Increase of Hemoglobin in Patients With MASH And T2D", "terseLabel": "Percentage of increase observed in the placebo arm" } } }, "auth_ref": [] }, "iva_DemonstratedReductionOfHemoglobinInPatientsWithMashAndT2d": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "DemonstratedReductionOfHemoglobinInPatientsWithMashAndT2d", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "The percentage of reduction in Hemoglobin among patients with MASH and T2D.", "label": "Demonstrated Reduction of Hemoglobin in Patients With MASH And T2D", "terseLabel": "Percentage reduction in results on treatments" } } }, "auth_ref": [] }, "iva_DemonstratedReductionOfHepaticFatMeasuredByProtonMagneticResonanceSpectroscopy": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "DemonstratedReductionOfHepaticFatMeasuredByProtonMagneticResonanceSpectroscopy", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Demonstrated reduction of hepatic fat measured by proton magnetic resonance spectroscopy", "label": "Demonstrated reduction of hepatic fat measured by proton magnetic resonance spectroscopy" } } }, "auth_ref": [] }, "iva_DemonstratedReductionOfHepaticSteatosisMeasuredByMriPdff": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "DemonstratedReductionOfHepaticSteatosisMeasuredByMriPdff", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "The percentage of reduction in Hepatic Steatosis measured by MRI-PDFF.", "label": "Demonstrated Reduction Of Hepatic Steatosis Measured By MRI-PDFF", "terseLabel": "Reduction in hepatic steatosis (in percent)" } } }, "auth_ref": [] }, "iva_DemonstratedSignificantRelativeReductionInVatSatRatioInPatients": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "DemonstratedSignificantRelativeReductionInVatSatRatioInPatients", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "The percentage of significant relative reduction in VAT / SAT ratio in patients.", "label": "Demonstrated Significant Relative Reduction in VAT/SAT Ratio in Patients", "terseLabel": "Significant relative reduction in VAT/SAT ratio (in percent)" } } }, "auth_ref": [] }, "iva_DepreciationAmortizationAndProvisions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "DepreciationAmortizationAndProvisions", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to depreciation, amortization and provisions.", "label": "Depreciation, amortization and provisions", "negatedLabel": "Depreciation, amortization and provisions" } } }, "auth_ref": [] }, "iva_DerivativeInstrumentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "DerivativeInstrumentsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for derivative instruments.", "label": "Derivative instruments", "terseLabel": "Derivative instruments" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for fair value measurement [text block]", "terseLabel": "Fair value measurement" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for fair value measurement. [Refer: At fair value [member]]" } } }, "auth_ref": [ "r216" ] }, "iva_DescriptionOfAccountingPolicyForSpecificDisclosureRequirementsForUnauditedInterimFinancialStatementsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "DescriptionOfAccountingPolicyForSpecificDisclosureRequirementsForUnauditedInterimFinancialStatementsPolicyTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Specific disclosure requirements for unaudited interim financial statements.", "label": "Description Of Accounting Policy For Specific Disclosure Requirements For Unaudited Interim Financial Statements [Policy Text Block]", "terseLabel": "Specific disclosure requirements for unaudited interim financial statements" } } }, "auth_ref": [] }, "ifrs-full_DilutedEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DilutedEarningsLossPerShare", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossBasicAndDilutedLossPerShareDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Diluted earnings (loss) per share", "terseLabel": "Diluted loss per share" } }, "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } } }, "auth_ref": [ "r64", "r65" ] }, "iva_DirectorsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "DirectorsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityOptionsAndShareWarrantsBsaAndBspceDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Directors.", "label": "Directors", "terseLabel": "Directors" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "label": "Disclosure of accounting judgements and estimates [text block]", "terseLabel": "Use of estimates and judgment" } }, "en": { "role": { "documentation": "The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]" } } }, "auth_ref": [ "r211" ] }, "ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossNarrativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of attribution of expenses by nature to their function [line items]", "terseLabel": "Operating expenses", "verboseLabel": "Notes to the income statement" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossNarrativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of attribution of expenses by nature to their function [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to attribution of expenses by nature to analysis of expenses by function in the statement of profit or loss." } } }, "auth_ref": [ "r212", "r215" ] }, "iva_DisclosureOfCashAndCashEquivalentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "DisclosureOfCashAndCashEquivalentsTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables" ], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of cash and cash equivalents.", "label": "Disclosure Of Cash And Cash Equivalents [Table Text Block]", "terseLabel": "Schedule of cash and cash equivalents" } } }, "auth_ref": [] }, "iva_DisclosureOfChangesInBorrowingsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "DisclosureOfChangesInBorrowingsTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables" ], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of changes in borrowings.", "label": "Disclosure Of Changes In Borrowings [Table Text Block]", "verboseLabel": "Schedule of movements in the period break down" } } }, "auth_ref": [] }, "iva_DisclosureOfChangesInProvisionRecordedInRespectOfDefinedBenefitSchemesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "DisclosureOfChangesInProvisionRecordedInRespectOfDefinedBenefitSchemesExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about change in the provision recorded in respect of defined benefit schemes.", "label": "Disclosure Of Changes In Provision Recorded In Respect Of Defined Benefit Schemes, Explanatory", "terseLabel": "Schedule of change in the provision recorded in respect of defined benefit schemes" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of classes of share capital [text block]", "terseLabel": "Schedule of changes in share capital" } }, "en": { "role": { "documentation": "The disclosure of classes of share capital. [Refer: Share capital [member]]" } } }, "auth_ref": [ "r31" ] }, "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityOptionsAndShareWarrantsBsaAndBspceDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of classes of share capital [line items]", "terseLabel": "Shareholders' equity" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfClassesOfShareCapitalTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityOptionsAndShareWarrantsBsaAndBspceDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of classes of share capital [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to classes of share capital." } } }, "auth_ref": [ "r31" ] }, "iva_DisclosureOfComponentsOfIncomeStatementTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "DisclosureOfComponentsOfIncomeStatementTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for components of income statement.", "label": "Disclosure Of Components Of Income Statement [Text Block]", "terseLabel": "Notes to the interim condensed consolidated statement of (income) loss" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfContingentLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfContingentLiabilitiesExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of contingent liabilities [text block]", "terseLabel": "Schedule of commitments given and received" } }, "en": { "role": { "documentation": "The disclosure of contingent liabilities. [Refer: Contingent liabilities [member]]" } } }, "auth_ref": [ "r70" ] }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about borrowings [text block]", "terseLabel": "Schedule of debt" } }, "en": { "role": { "documentation": "The disclosure of detailed information about borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r244" ] }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutBorrowingsLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtRoyaltyCertificatesLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about borrowings [line items]", "terseLabel": "Guarantee Details", "verboseLabel": "Financial debt" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutBorrowingsTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtRoyaltyCertificatesLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about borrowings [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of borrowings." } } }, "auth_ref": [ "r244" ] }, "ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about financial instruments [text block]", "terseLabel": "Schedule of financial assets and liabilities" } }, "en": { "role": { "documentation": "The disclosure of detailed information about financial instruments. [Refer: Financial instruments, class [member]]" } } }, "auth_ref": [ "r141", "r145", "r152" ] }, "ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about intangible assets [text block]", "terseLabel": "Schedule of intangible assets" } }, "en": { "role": { "documentation": "The disclosure of detailed information about intangible assets. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r73" ] }, "ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about property, plant and equipment [text block]", "terseLabel": "Schedule of property, plant and equipment" } }, "en": { "role": { "documentation": "The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r48" ] }, "ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of effect of changes in foreign exchange rates [text block]", "terseLabel": "Schedule of exchange rates" } }, "en": { "role": { "documentation": "The entire disclosure for the effect of changes in foreign exchange rates." } } }, "auth_ref": [ "r56" ] }, "iva_DisclosureOfExpensesRecognizedInStatementOfIncomeLossForRetirementBenefitObligationsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "DisclosureOfExpensesRecognizedInStatementOfIncomeLossForRetirementBenefitObligationsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about expense recognized in the statement of income (loss) for Retirement Benefit Obligations.", "label": "Disclosure Of Expenses Recognized In Statement Of Income (Loss) For Retirement Benefit Obligations, Explanatory", "terseLabel": "Schedule of expense recognized in the statement of income (loss)" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of fair value of financial instruments [text block]", "terseLabel": "Schedule of financial assets and liabilities measured at fair value" } }, "en": { "role": { "documentation": "The disclosure of the fair value of financial instruments. [Refer: Financial instruments, class [member]; At fair value [member]]" } } }, "auth_ref": [ "r211" ] }, "ifrs-full_DisclosureOfFinancialInstrumentsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about financial instruments [line items]", "terseLabel": "Foreign currency forwards contract", "verboseLabel": "Financial assets and liabilities" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialInstrumentsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about financial instruments [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of financial instruments." } } }, "auth_ref": [ "r141", "r145", "r152" ] }, "ifrs-full_DisclosureOfGoingConcernExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfGoingConcernExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "label": "Disclosure of going concern [text block]", "terseLabel": "Going concern" } }, "en": { "role": { "documentation": "The disclosure of the entity's ability to continue as a going concern." } } }, "auth_ref": [ "r211" ] }, "ifrs-full_DisclosureOfIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfIntangibleAssetsLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about intangible assets [line items]", "verboseLabel": "Intangible Assets" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfIntangibleAssetsTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about intangible assets [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of intangible assets." } } }, "auth_ref": [ "r73" ] }, "ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfInterestsInSubsidiariesExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of interests in subsidiaries [text block]", "terseLabel": "Schedule of subsidiaries" } }, "en": { "role": { "documentation": "The disclosure of interests in subsidiaries. [Refer: Subsidiaries [member]]" } } }, "auth_ref": [ "r96" ] }, "ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfMaterialAccountingPolicyInformationExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciples" ], "lang": { "en-us": { "role": { "label": "Disclosure of material accounting policy information [text block]", "terseLabel": "Accounting principles" } }, "en": { "role": { "documentation": "The entire disclosure of material accounting policy information applied by the entity." } } }, "auth_ref": [ "r7" ] }, "iva_DisclosureOfNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "DisclosureOfNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for notes to the interim consolidated balance sheet.", "label": "Disclosure of Notes to the Interim Condensed Consolidated Statement of Financial Position [Text Block]", "terseLabel": "Notes to the interim condensed consolidated statement of financial position" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of number and weighted average exercise prices of other equity instruments [text block]", "terseLabel": "Schedule of movements in BSPCE and BSA share warrants and Bonus shares" } }, "en": { "role": { "documentation": "The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options)." } } }, "auth_ref": [ "r243" ] }, "ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfOtherCurrentAssetsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of other current assets [text block]", "terseLabel": "Schedule of other current assets and receivables" } }, "en": { "role": { "documentation": "The disclosure of other current assets. [Refer: Other current assets]" } } }, "auth_ref": [ "r211" ] }, "ifrs-full_DisclosureOfOtherCurrentLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfOtherCurrentLiabilitiesExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of other current liabilities [text block]", "terseLabel": "Schedule of other current liabilities" } }, "en": { "role": { "documentation": "The disclosure of other current liabilities. [Refer: Other current liabilities]" } } }, "auth_ref": [ "r211" ] }, "iva_DisclosureOfOtherFinancialInformationTextblock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "DisclosureOfOtherFinancialInformationTextblock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformation" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for other financial information.", "label": "Disclosure Of Other Financial Information [TextBlock]", "terseLabel": "Other financial information" } } }, "auth_ref": [] }, "iva_DisclosureOfOtherNoncurrentAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "DisclosureOfOtherNoncurrentAssetsTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables" ], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of other non current assets.", "label": "Disclosure Of Other Noncurrent Assets [Table Text Block]", "terseLabel": "Schedule of other non current assets" } } }, "auth_ref": [] }, "iva_DisclosureOfOtherOperatingIncomeExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "DisclosureOfOtherOperatingIncomeExpenseTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossTables" ], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of other operating income (expense).", "label": "Disclosure Of Other Operating Income Expense [Table Text Block]", "terseLabel": "Schedule of other operating income and expenses" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionPropertyPlantAndEquipmentAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about property, plant and equipment [line items]", "verboseLabel": "Property, Plant and Equipment" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionPropertyPlantAndEquipmentAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about property, plant and equipment [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of property, plant and equipment." } } }, "auth_ref": [ "r48" ] }, "iva_DisclosureOfProvisionRecordedInRespectOfDefinedBenefitSchemesAtEndOfEachReportingPeriodExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "DisclosureOfProvisionRecordedInRespectOfDefinedBenefitSchemesAtEndOfEachReportingPeriodExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about provision recorded in respect of defined benefit schemes at the end of each reporting period.", "label": "Disclosure Of Provision Recorded In Respect Of Defined Benefit Schemes At End Of Each Reporting Period, Explanatory", "terseLabel": "Schedule of provision recorded in respect of defined benefit schemes at the end of each reporting period" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfReconciliationOfSummarisedFinancialInformationOfAssociateAccountedForUsingEquityMethodToCarryingAmountOfInterestInAssociateExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfReconciliationOfSummarisedFinancialInformationOfAssociateAccountedForUsingEquityMethodToCarryingAmountOfInterestInAssociateExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of reconciliation of summarised financial information of associate accounted for using equity method to carrying amount of interest in associate [text block]", "terseLabel": "Schedule of investment in Hepalys is accounted for using the equity method of accounting" } }, "en": { "role": { "documentation": "The disclosure of the reconciliation of the summarised financial information of an associate accounted for using the equity method to the carrying amount of the reporting entity's interest in the associate. [Refer: Carrying amount [member]; Associates [member]]" } } }, "auth_ref": [ "r108" ] }, "iva_DisclosureOfShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodInvestmentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "DisclosureOfShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodInvestmentsTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossTables" ], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of share of profit loss of associates and joint ventures accounted for using equity method investments.", "label": "Disclosure Of Share Of Profit Loss Of Associates And Joint Ventures Accounted For Using Equity Method Investments [Table Text Block]", "terseLabel": "Schedule of share of net profit - Equity method" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfSignificantInvestmentsInAssociatesLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" ], "lang": { "en-us": { "role": { "label": "Other financial information [line items]", "terseLabel": "Investments accounted for using the equity method" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfSignificantInvestmentsInAssociatesTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of associates [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to associates." } } }, "auth_ref": [ "r60", "r62", "r111" ] }, "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of subsidiaries [line items]", "terseLabel": "General principles and statement of compliance" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of subsidiaries [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to subsidiaries." } } }, "auth_ref": [ "r60", "r62", "r110" ] }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFreeShareAwardsAndPerformanceUnitsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]", "verboseLabel": "Notes to the interim condensed consolidated statement of financial position" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFreeShareAwardsAndPerformanceUnitsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of terms and conditions of share-based payment arrangement [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements." } } }, "auth_ref": [ "r134" ] }, "ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTradeAndOtherPayablesExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of trade and other payables [text block]", "terseLabel": "Schedule of trade payables break down by payment" } }, "en": { "role": { "documentation": "The disclosure of trade and other payables. [Refer: Trade and other payables]" } } }, "auth_ref": [ "r211" ] }, "iva_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables" ], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure for trade payables and other current liabilities.", "label": "Disclosure Of Trade Payables and Other Current Liabilities [Table Text Block]", "terseLabel": "Schedule of trade payables and other current liabilities" } } }, "auth_ref": [] }, "iva_DisclosureOfTradeReceivablesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "DisclosureOfTradeReceivablesTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables" ], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of trade receivables.", "label": "Disclosure of Trade Receivables [Table Text Block]", "terseLabel": "Schedule of trade receivables and others break down" } } }, "auth_ref": [] }, "iva_DisclosureOfValuationApproachForBsaShareBasedPaymentArrangementTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "DisclosureOfValuationApproachForBsaShareBasedPaymentArrangementTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of valuation approach for BSA share-based payment arrangement", "label": "Disclosure of valuation approach for BSA share-based payment arrangement [table text block]", "terseLabel": "Schedule of valuation approach for BSA arrangement" } } }, "auth_ref": [] }, "ifrs-full_DiscountRateMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DiscountRateMeasurementInputMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtRoyaltyCertificatesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Discount rate, measurement input [member]", "terseLabel": "Discount rate" } }, "en": { "role": { "documentation": "This member stands for a discount rate used as a measurement input used in valuation techniques based on a present value calculation." } } }, "auth_ref": [ "r241" ] }, "iva_Disposables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "Disposables", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to disposables.", "label": "Disposables", "negatedLabel": "Disposables" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "iva_DrawdownOfBorrowingsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "DrawdownOfBorrowingsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details" ], "lang": { "en-us": { "role": { "documentation": "This member stands for drawdown of borrowings", "label": "Drawdown of borrowings [Member]", "terseLabel": "Drawdown of borrowings" } } }, "auth_ref": [] }, "ifrs-full_EarningsPerShareExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EarningsPerShareExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossTables" ], "lang": { "en-us": { "role": { "label": "Earnings per share [text block]", "terseLabel": "Schedule of basic and diluted loss per share" } }, "en": { "role": { "documentation": "The disclosure of earnings per share." } } }, "auth_ref": [ "r64" ] }, "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Effect of exchange rate changes on cash and cash equivalents", "terseLabel": "Exchange gains / (losses)" } }, "en": { "role": { "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r84", "r85" ] }, "iva_EliminationOfDownstreamSales": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "EliminationOfDownstreamSales", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails": { "parentTag": "ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of elimination of downstream sales.", "label": "Elimination Of Downstream Sales", "negatedLabel": "Elimination of downstream sales" } } }, "auth_ref": [] }, "ifrs-full_EmployeeBenefitsExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EmployeeBenefitsExpense", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 3.0 }, "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesPersonnelCostsAndHeadcountDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "label": "Employee benefits expense", "negatedTerseLabel": "Personnel costs", "negatedTotalLabel": "Total personnel costs" } }, "en": { "role": { "documentation": "The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment." } } }, "auth_ref": [ "r0", "r40", "r174" ] }, "iva_EmployeeRelatedPayables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "EmployeeRelatedPayables", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesDetails": { "parentTag": "ifrs-full_OtherCurrentLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount pertaining to employee related payables.", "label": "Employee related payables", "verboseLabel": "Employeerelated payables" } } }, "auth_ref": [] }, "iva_EnergyAndLiquids": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "EnergyAndLiquids", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to energy and liquids.", "label": "Energy and liquids", "negatedLabel": "Energy and liquids" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r210" ] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossNarrativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesPersonnelCostsAndHeadcountDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails" ], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r210" ] }, "iva_EntitySShareOfNetAssetsInInvestmentsAccountedForUsingEquityMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "EntitySShareOfNetAssetsInInvestmentsAccountedForUsingEquityMethod", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails" ], "lang": { "en-us": { "role": { "documentation": "Entity's share of net assets in investments accounted for using the equity method", "label": "Entity's share of net assets in investments accounted for using the equity method", "terseLabel": "Group's share" } } }, "auth_ref": [] }, "ifrs-full_EntitysTotalForAssociatesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EntitysTotalForAssociatesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" ], "lang": { "en-us": { "role": { "label": "Entity's total for associates [member]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Associates' axis if no other member is used." } } }, "auth_ref": [ "r60", "r62", "r111" ] }, "ifrs-full_EntitysTotalForRelatedPartiesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EntitysTotalForRelatedPartiesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFreeShareAwardsAndPerformanceUnitsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityOptionsAndShareWarrantsBsaAndBspceDetails" ], "lang": { "en-us": { "role": { "label": "Entity's total for related parties [member]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used." } } }, "auth_ref": [ "r57" ] }, "ifrs-full_EntitysTotalForSubsidiariesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EntitysTotalForSubsidiariesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails" ], "lang": { "en-us": { "role": { "label": "Entity's total for subsidiaries [member]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Subsidiaries' axis if no other member is used." } } }, "auth_ref": [ "r60", "r62", "r110" ] }, "ifrs-full_Equity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Equity", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Equity", "periodEndLabel": "Balance at the end", "periodStartLabel": "Balance at the beginning", "totalLabel": "Shareholders' equity", "verboseLabel": "Shareholders' equity" } }, "en": { "role": { "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities." } } }, "auth_ref": [ "r19", "r28", "r89", "r91", "r112", "r113", "r115" ] }, "ifrs-full_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EquityAbstract", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Equity [abstract]", "terseLabel": "Shareholders' equity" } } }, "auth_ref": [] }, "ifrs-full_EquityAndLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EquityAndLiabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Equity and liabilities", "terseLabel": "Total equity and liabilities", "totalLabel": "Total equity and liabilities" } }, "en": { "role": { "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]" } } }, "auth_ref": [ "r19" ] }, "ifrs-full_EquityAndLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EquityAndLiabilitiesAbstract", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Equity and liabilities [abstract]", "terseLabel": "LIABILITIES AND SHAREHOLDERS' EQUITY" } } }, "auth_ref": [] }, "ifrs-full_EquityMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EquityMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Equity [member]" } }, "en": { "role": { "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used." } } }, "auth_ref": [ "r6" ] }, "iva_EquityRecoveryLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "EquityRecoveryLoansMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for equity recovery loans.", "label": "Equity Recovery Loans [Member]", "terseLabel": "Equity recovery loans" } } }, "auth_ref": [] }, "iva_ExpectedVolatility": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "ExpectedVolatility", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Expected volatility used to calculate fair value of warrants.", "label": "Expected volatility", "verboseLabel": "Volatility" } } }, "auth_ref": [] }, "ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFreeShareAwardsAndPerformanceUnitsDetails" ], "lang": { "en-us": { "role": { "label": "Expense from share-based payment transactions" } }, "en": { "role": { "documentation": "The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets." } } }, "auth_ref": [ "r136" ] }, "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ExpenseFromSharebasedPaymentTransactionsWithEmployees", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesPersonnelCostsAndHeadcountDetails": { "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "label": "Expense from share-based payment transactions with employees", "negatedLabel": "Share-based payments" } }, "en": { "role": { "documentation": "The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]" } } }, "auth_ref": [ "r215" ] }, "iva_FairValueOfWarrantsOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "FairValueOfWarrantsOutstanding", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Fair value of warrants outstanding", "label": "Fair value of warrants outstanding", "terseLabel": "Fair Value (k\u20ac)" } } }, "auth_ref": [] }, "iva_FairValueVariationGains": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "FairValueVariationGains", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of gains recognized for variation in fair value.", "label": "Fair Value Variation Gains", "terseLabel": "Gain on fair value variation" } } }, "auth_ref": [] }, "iva_Fees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "Fees", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to fees.", "label": "Fees", "negatedLabel": "Fees" } } }, "auth_ref": [] }, "iva_FibroscanMachinesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "FibroscanMachinesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionPropertyPlantAndEquipmentAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for fibroscan machines.", "label": "Fibroscan machines" } } }, "auth_ref": [] }, "iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "FinanceContractWithEuropeanInvestmentBankFirstTrancheMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to first tranche of the finance contract with European Investment Bank (\"EIB\").", "label": "Finance Contract With European Investment Bank, First Tranche [Member]", "terseLabel": "Finance contract with EIB, first tranche (Tranche A)", "verboseLabel": "Finance contract with EIB, Tranche A" } } }, "auth_ref": [] }, "iva_FinanceContractWithEuropeanInvestmentBankMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "FinanceContractWithEuropeanInvestmentBankMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the Finance contract with the European Investment Bank", "label": "Finance contract with European Investment Bank [Member]", "terseLabel": "Finance contract with EIB" } } }, "auth_ref": [] }, "iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "FinanceContractWithEuropeanInvestmentBankSecondTrancheMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to second tranche of the finance contract with European investment bank (\"EIB\").", "label": "Finance Contract With European Investment Bank, Second Tranche [Member]", "terseLabel": "Finance contract with EIB, second tranche (Tranche B)", "verboseLabel": "Finance contract with EIB, Tranche B" } } }, "auth_ref": [] }, "ifrs-full_FinanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinanceCosts", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss": { "parentTag": "ifrs-full_FinanceIncomeCost", "weight": -1.0, "order": 1.0 }, "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Finance costs", "negatedTerseLabel": "Financial expenses", "negatedTotalLabel": "Total financial expenses" } }, "en": { "role": { "documentation": "The amount of costs associated with financing activities of the entity." } } }, "auth_ref": [ "r36" ] }, "ifrs-full_FinanceIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinanceIncome", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss": { "parentTag": "ifrs-full_FinanceIncomeCost", "weight": 1.0, "order": 2.0 }, "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Finance income", "terseLabel": "Financial income", "totalLabel": "Total financial income" } }, "en": { "role": { "documentation": "The amount of income associated with interest and other financing activities of the entity." } } }, "auth_ref": [ "r222" ] }, "ifrs-full_FinanceIncomeCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinanceIncomeCost", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Finance income (cost)", "terseLabel": "Net financial income", "totalLabel": "Net financial income" } }, "en": { "role": { "documentation": "The amount of income or cost associated with interest and other financing activities of the entity." } } }, "auth_ref": [ "r222" ] }, "ifrs-full_FinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialAssets", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial assets", "terseLabel": "Financial assets" } }, "en": { "role": { "documentation": "The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose the entity\u2019s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]" } } }, "auth_ref": [ "r140", "r143", "r144", "r147", "r200" ] }, "ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialAssetsAtAmortisedCostCategoryMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial assets carried at amortized cost", "terseLabel": "Financial assets carried at amortized cost" } }, "en": { "role": { "documentation": "This member stands for the financial assets at amortised cost category. [Refer: Financial assets at amortised cost]" } } }, "auth_ref": [ "r155" ] }, "ifrs-full_FinancialAssetsAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialAssetsAtFairValue", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial assets, at fair value", "terseLabel": "Financial assets, at fair value" } }, "en": { "role": { "documentation": "The fair value of financial assets. [Refer: At fair value [member]; Financial assets]" } } }, "auth_ref": [ "r140" ] }, "ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial assets carried at fair value through profit or loss", "terseLabel": "Financial assets carried at fair value through profit or loss" } }, "en": { "role": { "documentation": "This member stands for the financial assets at fair value through profit or loss category. [Refer: Financial assets at fair value through profit or loss]" } } }, "auth_ref": [ "r153" ] }, "ifrs-full_FinancialAssetsCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialAssetsCategoryMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial assets, category [member]" } }, "en": { "role": { "documentation": "This member stands for aggregated categories of financial assets. It also represents the standard value for the 'Categories of financial assets' axis if no other member is used. [Refer: Financial assets]" } } }, "auth_ref": [ "r157" ] }, "ifrs-full_FinancialAssetsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialAssetsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial assets, class [member]" } }, "en": { "role": { "documentation": "This member stands for aggregated classes of financial assets. It also represents the standard value for the 'Classes of financial assets' axis if no other member is used. [Refer: Financial assets]" } } }, "auth_ref": [ "r131", "r150", "r151", "r172", "r173" ] }, "iva_FinancialIncomeAndExpensesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "FinancialIncomeAndExpensesTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossTables" ], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of financial income and expense.", "label": "Financial Income and Expenses [Table Text Block]", "terseLabel": "Schedule of financial income and expenses" } } }, "auth_ref": [] }, "ifrs-full_FinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialLiabilities", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtRoyaltyCertificatesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial liabilities", "terseLabel": "Financial liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity\u2019s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity\u2019s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]" } } }, "auth_ref": [ "r140" ] }, "ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialLiabilitiesAtAmortisedCostCategoryMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial liabilities carried at amortized cost", "verboseLabel": "Liabilities carried at amortized cost" } }, "en": { "role": { "documentation": "This member stands for the financial liabilities at amortised cost category. [Refer: Financial liabilities at amortised cost]" } } }, "auth_ref": [ "r156" ] }, "ifrs-full_FinancialLiabilitiesAtAmortisedCostMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialLiabilitiesAtAmortisedCostMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "label": "Financial liabilities at amortised cost, class [member]", "terseLabel": "Financial liabilities at amortized cost" } }, "en": { "role": { "documentation": "This member stands for the financial liabilities measured at amortised cost class. [Refer: Financial liabilities at amortised cost]" } } }, "auth_ref": [ "r158" ] }, "ifrs-full_FinancialLiabilitiesAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialLiabilitiesAtFairValue", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtRoyaltyCertificatesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial liabilities, at fair value", "verboseLabel": "Financial liabilities, at fair value" } }, "en": { "role": { "documentation": "The fair value of financial liabilities. [Refer: At fair value [member]; Financial liabilities]" } } }, "auth_ref": [ "r140" ] }, "ifrs-full_FinancialLiabilitiesAtFairValueMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialLiabilitiesAtFairValueMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtRoyaltyCertificatesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial liabilities at fair value, class [member]", "terseLabel": "Financial liabilities at fair value" } }, "en": { "role": { "documentation": "This member stands for the financial liabilities measured at fair value class. [Refer: Financial liabilities; At fair value [member]]" } } }, "auth_ref": [ "r158" ] }, "ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial liabilities at fair value through profit or loss, category [member]", "terseLabel": "Financial liabilities carried at fair value through profit or loss" } }, "en": { "role": { "documentation": "This member stands for the financial liabilities at fair value through profit or loss category. [Refer: Financial liabilities at fair value through profit or loss]" } } }, "auth_ref": [ "r154" ] }, "ifrs-full_FinancialLiabilitiesCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialLiabilitiesCategoryMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "label": "Financial liabilities, category [member]" } }, "en": { "role": { "documentation": "This member stands for aggregated categories of financial liabilities. It also represents the standard value for the 'Categories of financial liabilities' axis if no other member is used. [Refer: Financial assets]" } } }, "auth_ref": [ "r157" ] }, "ifrs-full_FinancialLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialLiabilitiesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtRoyaltyCertificatesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial liabilities, class [member]" } }, "en": { "role": { "documentation": "This member stands for aggregated classes financial liabilities. It also represents the standard value for the 'Classes of financial liabilities' axis if no other member is used. [Refer: Financial liabilities]" } } }, "auth_ref": [ "r150", "r151", "r172", "r173" ] }, "iva_FinancingAgreementInThreePhasesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "FinancingAgreementInThreePhasesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for financing agreement entered in three phases.", "label": "Financing Agreement in Three Phases [Member]", "terseLabel": "Financing agreement in three phases" } } }, "auth_ref": [] }, "iva_FinancingFromSyndicateOfFrenchBanksMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "FinancingFromSyndicateOfFrenchBanksMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for financing from a syndicate of French banks.", "label": "Financing from a syndicate of French banks" } } }, "auth_ref": [] }, "iva_FinancingPeriodOfLoan": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "FinancingPeriodOfLoan", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the financing period of loan.", "label": "Financing Period of Loan", "terseLabel": "Financing period of loan" } } }, "auth_ref": [] }, "iva_FinancingThroughFundRaisingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "FinancingThroughFundRaisingMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for financing through fund raising.", "label": "Financing Through Fund Raising [Member]", "terseLabel": "Financing through fund raising" } } }, "auth_ref": [] }, "ifrs-full_ForeignExchangeGain": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ForeignExchangeGain", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Foreign exchange gain", "terseLabel": "Foreign exchange gains" } }, "en": { "role": { "documentation": "The gross gain arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]" } } }, "auth_ref": [ "r9", "r54" ] }, "ifrs-full_ForeignExchangeLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ForeignExchangeLoss", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Foreign exchange loss", "negatedLabel": "Foreign exchange losses" } }, "en": { "role": { "documentation": "The gross loss arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]" } } }, "auth_ref": [ "r9", "r54" ] }, "ifrs-full_ForeignExchangeRatesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ForeignExchangeRatesAbstract", "lang": { "en-us": { "role": { "label": "Exchange rate (USD per EUR)" } } }, "auth_ref": [] }, "iva_FredericCrenMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "FredericCrenMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFreeShareAwardsAndPerformanceUnitsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Frederic Cren", "label": "Frederic Cren [Member]" } } }, "auth_ref": [] }, "ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsForRetirementBenefitObligationsChangesInNetProvisionDetails" ], "lang": { "en-us": { "role": { "label": "Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income", "terseLabel": "Actuarial gains or losses recognized in other comprehensive income" } }, "en": { "role": { "documentation": "The decrease (increase) in a net defined benefit liability (asset) resulting from the remeasurement of that net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]" } } }, "auth_ref": [ "r51" ] }, "ifrs-full_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "General and administrative expense", "negatedLabel": "General and administrative expenses" } }, "en": { "role": { "documentation": "The amount of expense relating to general and administrative activities of the entity." } } }, "auth_ref": [ "r215" ] }, "ifrs-full_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Goodwill", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails" ], "lang": { "en-us": { "role": { "label": "Goodwill", "terseLabel": "Goodwill" } }, "en": { "role": { "documentation": "The amount of assets representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognised. [Refer: Business combinations [member]]" } } }, "auth_ref": [ "r10", "r67", "r68", "r137" ] }, "ifrs-full_GrossCarryingAmountMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "GrossCarryingAmountMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionIntangibleAssetsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInventoriesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Gross", "terseLabel": "Laboratory inventories" } }, "en": { "role": { "documentation": "This member stands for the amount at which an asset is recognised before deducting any accumulated depreciation (amortisation) and accumulated impairment losses thereon. [Refer: Depreciation and amortisation expense; Impairment loss]" } } }, "auth_ref": [ "r46", "r71", "r76", "r79", "r137", "r144", "r147", "r200" ] }, "iva_HepalysPharmaIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "HepalysPharmaIncMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Hepalys Pharma, Inc.", "label": "Hepalys Pharma, Inc [Member]", "terseLabel": "Hepalys Pharma, Inc" } } }, "auth_ref": [] }, "iva_IfrsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "IfrsCashAndCashEquivalentsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for cash and cash equivalents.", "label": "Cash and Cash equivalents", "terseLabel": "Cash and cash equivalents" } } }, "auth_ref": [] }, "iva_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights": { "xbrltype": "perShareItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "IFRS Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Exercise price of warrant" } } }, "auth_ref": [] }, "iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "xbrltype": "sharesItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.", "label": "Ifrs Class of Warrant or Right, Number of Securities Called by Each Warrant or Right", "terseLabel": "Number of shares per warrant", "verboseLabel": "Number of shares per instrument" } } }, "auth_ref": [] }, "iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "IFRS Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Number of shares underlying in EIB" } } }, "auth_ref": [] }, "iva_IfrsClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "IfrsClassOfWarrantOrRightOutstanding", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "IFRS Class of Warrant or Right, Outstanding", "terseLabel": "Number of share warrants outstanding", "verboseLabel": "Number of BSA outstanding" } } }, "auth_ref": [] }, "iva_IfrsClassOfWarrantOrRightValueOfNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "IfrsClassOfWarrantOrRightValueOfNumberOfSecuritiesCalledByWarrantsOrRights", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Value of securities into which the class of warrant or right may be converted.", "label": "IFRS Class of Warrant or Right, Value of Number of Securities Called by Warrants or Rights", "terseLabel": "Class of warrant or right, value of number of securities" } } }, "auth_ref": [] }, "iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherNonCurrentAssetsLongTermDepositAccountsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossNarrativesDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "IFRS Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "auth_ref": [] }, "iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherNonCurrentAssetsLongTermDepositAccountsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossNarrativesDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "IFRS Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "auth_ref": [] }, "iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Ifrs Collaborative Arrangement And Arrangement Other Than Collaborative [Line items]", "verboseLabel": "Collaborative Arrangements" } } }, "auth_ref": [] }, "iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "IFRS Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "auth_ref": [] }, "iva_IfrsDebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "IfrsDebtInstrumentTerm", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Ifrs Debt Instrument, Term", "verboseLabel": "Maturity term after the disbursement of the tranche" } } }, "auth_ref": [] }, "iva_IfrsFairValueAdjustmentOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "IfrsFairValueAdjustmentOfWarrants", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "IFRS Fair Value Adjustment of Warrants", "terseLabel": "Fair value of the EIB warrants" } } }, "auth_ref": [] }, "iva_IfrsGeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "IfrsGeneralAndAdministrativeExpenseMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for general and administrative expense member.", "label": "General and administrative expenses" } } }, "auth_ref": [] }, "iva_IfrsOtherOperatingIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "IfrsOtherOperatingIncome", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossRevenuesAndOtherIncomeDetails": { "parentTag": "iva_OtherIncomeFromOrdinaryActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossRevenuesAndOtherIncomeDetails" ], "lang": { "en-us": { "role": { "documentation": "The total amount of other operating income, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operation.", "label": "Ifrs Other Operating Income", "terseLabel": "Other" } } }, "auth_ref": [] }, "iva_IfrsResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "IfrsResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for research and development expense member.", "label": "Ifrs Research And Development Expense [Member]", "terseLabel": "Research and development costs" } } }, "auth_ref": [] }, "iva_IfrsSalesAndMarketingExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "IfrsSalesAndMarketingExpenseMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for sales and marketing expense member.", "label": "Marketing - Business development expenses", "terseLabel": "Marketing - Business development expenses" } } }, "auth_ref": [] }, "iva_IfrsScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "IfrsScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "IFRS Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of inventories" } } }, "auth_ref": [] }, "iva_IfrsotherFinancialInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "IfrsotherFinancialInformationLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.", "label": "IFRSOther Financial Information [Line Items]", "terseLabel": "Events after the reporting date" } } }, "auth_ref": [] }, "iva_IfrsotherFinancialInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "IfrsotherFinancialInformationTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Schedule disclosing information related to other financial information.", "label": "IFRSOther Financial Information [Table]" } } }, "auth_ref": [] }, "ifrs-full_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Unaudited interim condensed consolidated statement of income (loss)" } } }, "auth_ref": [] }, "ifrs-full_IncomeTaxExpenseContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncomeTaxExpenseContinuingOperations", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss": { "parentTag": "ifrs-full_ProfitLoss", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossIncomeTaxDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossNarrativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Tax expense (income)", "negatedLabel": "Income tax", "terseLabel": "Tax income" } }, "en": { "role": { "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]" } } }, "auth_ref": [ "r37", "r42", "r43", "r44", "r58", "r107", "r161" ] }, "ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncomeTaxesPaidRefundClassifiedAsOperatingActivities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Income taxes paid (refund), classified as operating activities", "negatedLabel": "Tax credit received" } }, "en": { "role": { "documentation": "The cash flows from income taxes paid or refunded, classified as operating activities. [Refer: Income taxes paid (refund)]" } } }, "auth_ref": [ "r86", "r187" ] }, "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in cash and cash equivalents before effect of exchange rate changes", "totalLabel": "Net increase (decrease) in cash and cash equivalents" } }, "en": { "role": { "documentation": "The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]" } } }, "auth_ref": [ "r87" ] }, "iva_IncreaseDecreaseInLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "IncreaseDecreaseInLeaseLiabilities", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in lease liabilities during the period.", "label": "Increase (Decrease) in Lease Liabilities", "terseLabel": "Increase (decrease) in lease liabilities" } } }, "auth_ref": [] }, "iva_IncreaseDecreaseInLongTermDepositAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "IncreaseDecreaseInLongTermDepositAccounts", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherNonCurrentAssetsLongTermDepositAccountsDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in long-term deposit accounts", "label": "Increase (decrease) in long-term deposit accounts", "terseLabel": "Increase (decrease) in long-term deposit accounts" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsForRetirementBenefitObligationsChangesInNetProvisionDetails" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in net defined benefit liability (asset) resulting from expense (income) in profit or loss", "negatedLabel": "Expense for the period" } }, "en": { "role": { "documentation": "The increase (decrease) in the net defined benefit liability (asset) resulting from expense (income) included in profit or loss. [Refer: Net defined benefit liability (asset); Profit (loss)] [Contrast: Post-employment benefit expense in profit or loss, defined benefit plans]" } } }, "auth_ref": [ "r229" ] }, "ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseInNumberOfSharesOutstanding", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityChangesInShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in number of shares outstanding" } }, "en": { "role": { "documentation": "The increase (decrease) in the number of shares outstanding. [Refer: Number of shares outstanding]" } } }, "auth_ref": [ "r30" ] }, "iva_IncreaseDecreaseInShortTermDepositAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "IncreaseDecreaseInShortTermDepositAccounts", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in short-term deposit accounts.", "label": "Increase (Decrease) In Short-Term Deposit Accounts", "terseLabel": "Increase in short-term deposit accounts" } } }, "auth_ref": [] }, "iva_IncreaseDecreaseInTradeAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "IncreaseDecreaseInTradeAccountsPayable", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesBreakDownDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in trade accounts payable", "label": "Increase (decrease) in trade accounts payable", "terseLabel": "Increase in trade accounts payable" } } }, "auth_ref": [] }, "iva_IncreaseDecreaseInTradeAndOtherCurrentReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "IncreaseDecreaseInTradeAndOtherCurrentReceivables", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in trade and other current receivables.", "label": "Increase (Decrease) in Trade and other current receivables", "terseLabel": "Trade receivables decreased" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseInWorkingCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseInWorkingCapital", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in working capital", "negatedTotalLabel": "Tax, interest and changes in operating working capital" } }, "en": { "role": { "documentation": "The increase (decrease) in working capital." } } }, "auth_ref": [ "r239" ] }, "ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseThroughAppropriationOfRetainedEarnings", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) through appropriation of retained earnings, equity", "terseLabel": "Appropriation of net income (loss)" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from the appropriation of retained earnings. [Refer: Retained earnings]" } } }, "auth_ref": [ "r213" ] }, "iva_IncreaseDecreaseThroughCapitalVariations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "IncreaseDecreaseThroughCapitalVariations", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) through capital variations, equity", "label": "Increase (decrease) through capital variations", "terseLabel": "Capital variations" } } }, "auth_ref": [] }, "iva_IncreaseDecreaseThroughShareWarrantsSubscriptionPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "IncreaseDecreaseThroughShareWarrantsSubscriptionPremium", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "The increase decrease in reserves resulting from BSA share warrants subscription premium.", "label": "Increase (Decrease) Through Share Warrants Subscription Premium", "terseLabel": "BSA share warrants subscription premium" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFreeShareAwardsAndPerformanceUnitsDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) through share-based payment transactions, equity", "terseLabel": "Share-based payment compensation expenses", "verboseLabel": "Capital increase arising from the vesting of bonus share awards" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]" } } }, "auth_ref": [ "r4" ] }, "ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseThroughTransfersAndOtherChangesEquity", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) through other changes, equity", "terseLabel": "Other" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from changes that the entity does not separately disclose in the same statement or note. [Refer: Equity]" } } }, "auth_ref": [ "r5" ] }, "ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseThroughTreasuryShareTransactions", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) through treasury share transactions, equity", "terseLabel": "Treasury shares" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from treasury share transactions. [Refer: Equity; Treasury shares]" } } }, "auth_ref": [ "r5" ] }, "iva_IncreaseInBorrowingsThroughCapitalizedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "IncreaseInBorrowingsThroughCapitalizedInterest", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtMovementsInPeriodBreakDownDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase in borrowings through capitalized interest.", "label": "Increase in borrowings through capitalized interest", "terseLabel": "Capitalized interests" } } }, "auth_ref": [] }, "iva_IncreaseInBorrowingsThroughSubscriptionOfDerivativesInstruments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "IncreaseInBorrowingsThroughSubscriptionOfDerivativesInstruments", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtMovementsInPeriodBreakDownDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase in borrowings through Subscription of derivatives instruments.", "label": "Increase in Borrowings Through Subscription Of Derivatives Instruments", "terseLabel": "Subscription of derivatives instruments" } } }, "auth_ref": [] }, "iva_IncreaseOrDecreaseInBorrowingsDueToChangeInFairValueOfDerivativesInstruments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "IncreaseOrDecreaseInBorrowingsDueToChangeInFairValueOfDerivativesInstruments", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtMovementsInPeriodBreakDownDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase or decrease in borrowings due to change in fair value of derivatives instruments.", "label": "Increase Or Decrease In Borrowings Due To Change in Fair Value of Derivatives Instruments", "terseLabel": "Change in fair value of derivatives instruments" } } }, "auth_ref": [] }, "iva_IncreaseOrDecreaseInBorrowingsDueToChangesInExchangeRates": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "IncreaseOrDecreaseInBorrowingsDueToChangesInExchangeRates", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtMovementsInPeriodBreakDownDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase or decrease in borrowings due to exchange rate change.", "label": "Increase or Decrease in Borrowings Due to Changes in Exchange Rates", "terseLabel": "Exchange rate change" } } }, "auth_ref": [] }, "iva_Increaseinborrowingsthroughborrowingsreceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "Increaseinborrowingsthroughborrowingsreceived", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtMovementsInPeriodBreakDownDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase in borrowings through borrowings received.", "label": "IncreaseInBorrowingsThroughBorrowingsReceived", "terseLabel": "Subscription of bank borrowings" } } }, "auth_ref": [] }, "iva_IncreasesInPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "IncreasesInPropertyPlantAndEquipment", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionPropertyPlantAndEquipmentAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of increases in property, plant and equipment", "label": "Increases in property, plant and equipment", "terseLabel": "Increases" } } }, "auth_ref": [] }, "iva_IndicationOfContinuationOfRecruitmentForPhaseIiiTrialNativ3OfLanifibranorInNonCirrhoticNashashMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "IndicationOfContinuationOfRecruitmentForPhaseIiiTrialNativ3OfLanifibranorInNonCirrhoticNashashMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for indication of continuation of recruitment for Phase III trial NATiV3 of lanifibranor in non-cirrhotic NASH.", "label": "Indication Of Continuation Of Recruitment For Phase Iii Trial Nativ3 Of Lanifibranor In Non-Cirrhotic NashASH [Member]", "terseLabel": "Indication of continuation of recruitment for Phase III trial NATiV3 of lanifibranor in non-cirrhotic NASH" } } }, "auth_ref": [] }, "ifrs-full_InsuranceExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "InsuranceExpense", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Insurance expense", "negatedLabel": "Insurances" } }, "en": { "role": { "documentation": "The amount of expense arising from purchased insurance." } } }, "auth_ref": [ "r215" ] }, "ifrs-full_IntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IntangibleAssetsOtherThanGoodwill", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 1.0 }, "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails": { "parentTag": "iva_NonCurrentAssetsExcludingDeferredAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionIntangibleAssetsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Intangible assets other than goodwill", "periodEndLabel": "Balance at the end", "periodStartLabel": "Balance at the beginning", "terseLabel": "Intangible assets" } }, "en": { "role": { "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]" } } }, "auth_ref": [ "r10", "r72" ] }, "iva_IntercompanyEliminationsInAssociates": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "IntercompanyEliminationsInAssociates", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of intercompany eliminations in associates", "label": "Intercompany Eliminations in Associates", "negatedLabel": "Elimination of unrealised profit on downstream sales" } } }, "auth_ref": [] }, "ifrs-full_InterestCostsCapitalised": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "InterestCostsCapitalised", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "label": "Interest costs capitalised", "terseLabel": "Capitalized interest" } }, "en": { "role": { "documentation": "The amount of interest costs that an entity incurs in connection with the borrowing of funds that are directly attributable to the acquisition, construction or production of a qualifying asset and which form part of the cost of that asset." } } }, "auth_ref": [ "r215" ] }, "ifrs-full_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Interest expense", "negatedLabel": "Interest cost" } }, "en": { "role": { "documentation": "The amount of expense arising from interest." } } }, "auth_ref": [ "r106", "r160", "r168" ] }, "ifrs-full_InterestExpenseDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "InterestExpenseDefinedBenefitPlans", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsForRetirementBenefitObligationsBreakdownOfExpenseRecognizedForYearDetails": { "parentTag": "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsForRetirementBenefitObligationsBreakdownOfExpenseRecognizedForYearDetails" ], "lang": { "en-us": { "role": { "label": "Interest expense, defined benefit plans", "negatedLabel": "Interest cost for the period" } }, "en": { "role": { "documentation": "The amount of interest expense arising from defined benefit plans. [Refer: Interest expense; Post-employment benefit expense in profit or loss, defined benefit plans] [Contrast: Increase (decrease) in net defined benefit liability (asset) resulting from interest expense (income)]" } } }, "auth_ref": [ "r228" ] }, "ifrs-full_InterestIncomeOnCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "InterestIncomeOnCashAndCashEquivalents", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Interest income on cash and cash equivalents", "terseLabel": "Income from cash equivalents" } }, "en": { "role": { "documentation": "The amount of interest income on cash and cash equivalents. [Refer: Interest income; Cash and cash equivalents]" } } }, "auth_ref": [ "r215" ] }, "iva_InterestOnRoyaltyCertificates": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "InterestOnRoyaltyCertificates", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtMovementsInPeriodBreakDownDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase in borrowings through interests on royalty certificates.", "label": "Interest On Royalty Certificates", "verboseLabel": "Issue of royalty certificates" } } }, "auth_ref": [] }, "iva_InventivaIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "InventivaIncMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossNarrativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Inventiva Inc, U.S. affiliate.", "label": "Inventiva Inc [Member]", "terseLabel": "Inventiva Inc." } } }, "auth_ref": [] }, "iva_InventivaS.aMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "InventivaS.aMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Inventiva S.A, U.S. affiliate.", "label": "Inventiva S.A [Member]" } } }, "auth_ref": [] }, "ifrs-full_Inventories": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Inventories", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInventoriesDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current inventories", "terseLabel": "Inventories" } }, "en": { "role": { "documentation": "The amount of current inventories. [Refer: Inventories]" } } }, "auth_ref": [ "r12", "r53", "r177" ] }, "ifrs-full_InvestmentAccountedForUsingEquityMethod": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "InvestmentAccountedForUsingEquityMethod", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Investments accounted for using equity method", "netLabel": "Carrying amount", "terseLabel": "Investments accounted for using the equity method" } }, "en": { "role": { "documentation": "The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]" } } }, "auth_ref": [ "r11", "r109", "r163" ] }, "iva_IssuanceOfRoyaltyCertificatesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "IssuanceOfRoyaltyCertificatesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for issuance of royalty certificates.", "label": "Issuance of Royalty Certificates [Member]", "terseLabel": "Issuance of royalty certificates" } } }, "auth_ref": [] }, "iva_IssuanceOfSharesOrWarrantsSubjectToConditionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "IssuanceOfSharesOrWarrantsSubjectToConditionsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for issue of shares or warrants subject to conditions.", "label": "Issuance of Shares or Warrants Subject to Conditions [Member]", "terseLabel": "Issuance of shares or warrants subject to conditions" } } }, "auth_ref": [] }, "iva_IssuanceOfSharesOrWarrantsWithoutPreferentialSubscriptionRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "IssuanceOfSharesOrWarrantsWithoutPreferentialSubscriptionRightsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for issue of shares or warrants without preferential subscription rights.", "label": "Issuance of Shares or Warrants Without Preferential Subscription Rights [Member]", "terseLabel": "Issuance of shares or warrants without preferential subscription rights" } } }, "auth_ref": [] }, "iva_IssuanceOfSharesWithoutPreferentialSubscriptionRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "IssuanceOfSharesWithoutPreferentialSubscriptionRightsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for issue of shares without preferential subscription rights.", "label": "Issuance of Shares Without Preferential Subscription Rights [Member]", "terseLabel": "Issuance of shares without preferential subscription rights" } } }, "auth_ref": [] }, "ifrs-full_IssueOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IssueOfEquity", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityChangesInShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Issue of equity", "terseLabel": "Issue of ordinary shares" } }, "en": { "role": { "documentation": "The increase in equity through the issue of equity instruments." } } }, "auth_ref": [ "r4" ] }, "iva_IssueOfRoyaltyCertificates": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "IssueOfRoyaltyCertificates", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtMovementsInPeriodBreakDownDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of increase in borrowings through issue of royalty certificates.", "label": "Issue of Royalty Certificates", "terseLabel": "Issue of royalty certificates" } } }, "auth_ref": [] }, "ifrs-full_IssuedCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IssuedCapital", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityShareCapitalDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Issued capital", "terseLabel": "Share capital", "verboseLabel": "Capital stock" } }, "en": { "role": { "documentation": "The nominal value of capital issued." } } }, "auth_ref": [ "r180" ] }, "ifrs-full_IssuedCapitalMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IssuedCapitalMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Share capital" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing issued capital." } } }, "auth_ref": [ "r6" ] }, "iva_ItSystems": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "ItSystems", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to it systems.", "label": "IT Systems", "negatedLabel": "IT systems" } } }, "auth_ref": [] }, "ifrs-full_LaterThanFiveYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LaterThanFiveYearsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails" ], "lang": { "en-us": { "role": { "label": "More than 5 years" } }, "en": { "role": { "documentation": "This member stands for a time band of later than five years." } } }, "auth_ref": [ "r125", "r126", "r130", "r202", "r206", "r209" ] }, "ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LaterThanOneMonthAndNotLaterThanTwoMonthsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesBreakDownDetails" ], "lang": { "en-us": { "role": { "label": "Due in 30 60 days", "terseLabel": "Due in 30-60 days" } }, "en": { "role": { "documentation": "This member stands for a time band of later than one month and not later than two months." } } }, "auth_ref": [ "r200", "r208", "r215" ] }, "ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LaterThanOneYearAndNotLaterThanThreeYearsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails" ], "lang": { "en-us": { "role": { "label": "Between 1 and 3 years" } }, "en": { "role": { "documentation": "This member stands for a time band of later than one year and not later than three years." } } }, "auth_ref": [ "r202", "r204", "r209" ] }, "ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LaterThanThreeYearsAndNotLaterThanFiveYearsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails" ], "lang": { "en-us": { "role": { "label": "Between 3 and 5 years" } }, "en": { "role": { "documentation": "This member stands for a time band of later than three years and not later than five years." } } }, "auth_ref": [ "r202", "r205", "r209" ] }, "iva_LaterThanTwoMonthsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "LaterThanTwoMonthsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesBreakDownDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for a time band of later than two months.", "label": "Due in more than 60 days", "terseLabel": "Due in more than 60 days" } } }, "auth_ref": [] }, "ifrs-full_LeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LeaseLiabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFinancialDebtDetails": { "parentTag": "ifrs-full_Borrowings", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFinancialDebtDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails" ], "lang": { "en-us": { "role": { "label": "Lease liabilities", "terseLabel": "Lease liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration." } } }, "auth_ref": [ "r123" ] }, "ifrs-full_LeaseLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LeaseLiabilitiesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" ], "lang": { "en-us": { "role": { "label": "Lease liabilities [member]", "terseLabel": "Lease liabilities", "verboseLabel": "Lease" } }, "en": { "role": { "documentation": "This member stands for lease liabilities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r192", "r194" ] }, "iva_LeaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "LeaseTerm", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Lease term.", "label": "Lease Term", "terseLabel": "Lease term" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossNarrativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesPersonnelCostsAndHeadcountDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "iva_LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to the LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D", "label": "LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D [Member]", "terseLabel": "Combination of lanifibranor" } } }, "auth_ref": [] }, "ifrs-full_Level3OfFairValueHierarchyMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Level3OfFairValueHierarchyMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails" ], "lang": { "en-us": { "role": { "label": "Level 3" } }, "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are unobservable inputs for the asset or liability. Unobservable inputs are inputs for which market data are not available and that are developed using the best information available about the assumptions that the market participants would use when pricing the asset or liability." } } }, "auth_ref": [ "r113" ] }, "ifrs-full_LevelsOfFairValueHierarchyAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LevelsOfFairValueHierarchyAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails" ], "lang": { "en-us": { "role": { "label": "Levels of fair value hierarchy [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r52", "r113" ] }, "ifrs-full_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities" } }, "en": { "role": { "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } } }, "auth_ref": [ "r19", "r112", "r113", "r115", "r162", "r167" ] }, "ifrs-full_LiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LiabilitiesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtRoyaltyCertificatesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Liabilities [member]" } }, "en": { "role": { "documentation": "This member stands for a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of liabilities' axis if no other member is used. [Refer: Liabilities]" } } }, "auth_ref": [ "r116" ] }, "ifrs-full_LiabilityAssetOfDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LiabilityAssetOfDefinedBenefitPlans", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsForRetirementBenefitObligationsChangesInNetProvisionDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsForRetirementBenefitObligationsNetProvisionDetails" ], "lang": { "en-us": { "role": { "label": "Net defined benefit liability (asset)", "negatedPeriodEndLabel": "At end of period", "negatedPeriodStartLabel": "At beginning of period", "totalLabel": "Total Obligation" } }, "en": { "role": { "documentation": "The amount of deficit or surplus in a defined benefit plan, adjusted for any effect of limiting a net defined benefit asset to the asset ceiling. [Refer: Defined benefit plans [member]]" } } }, "auth_ref": [ "r50" ] }, "iva_LicenseAndCollaborationAgreementMaximumAdditionalAmountReceivableUponAchievementOfCertainMilestones": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "LicenseAndCollaborationAgreementMaximumAdditionalAmountReceivableUponAchievementOfCertainMilestones", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Maximum additional amount receivable by the entity, upon the achievement of certain milestones, pursuant to licensing and collaborative arrangements.", "label": "License And Collaboration Agreement, Maximum Additional Amount Receivable Upon Achievement Of Certain Milestones", "terseLabel": "Maximum milestone payments receivable" } } }, "auth_ref": [] }, "iva_LicenseAndCollaborationAgreementUpfrontFeeReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "LicenseAndCollaborationAgreementUpfrontFeeReceivable", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of upfront fee receivable by the entity, pursuant to licensing and collaborative arrangements.", "label": "License And Collaboration Agreement Upfront Fee Receivable", "terseLabel": "Upfront payment receivable" } } }, "auth_ref": [] }, "iva_LicensingAgreementWithHepalysMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "LicensingAgreementWithHepalysMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Licensing agreement with Hepalys.", "label": "Licensing Agreement With Hepalys [Member]", "terseLabel": "Licensing agreement with Hepalys" } } }, "auth_ref": [] }, "iva_LicensingAndCollaborationAgreementWithCttqMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "LicensingAndCollaborationAgreementWithCttqMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossNarrativesDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Licensing and collaboration agreement with CTTQ.", "label": "Licensing and collaboration agreement with CTTQ [Member]", "terseLabel": "Licensing and collaboration agreement with CTTQ" } } }, "auth_ref": [] }, "ifrs-full_LineItemsByFunctionMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LineItemsByFunctionMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "label": "Line items by function [member]" } }, "en": { "role": { "documentation": "This member stands for the standard value of the \u2018Attribution of expenses by nature to their function' axis if no other member is used." } } }, "auth_ref": [ "r212", "r215" ] }, "iva_LiquidityAgreementTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "LiquidityAgreementTerm", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityLiquidityAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of days used to determine liquidity agreement term in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Liquidity Agreement Term", "terseLabel": "Liquidity agreement term" } } }, "auth_ref": [] }, "iva_LoanAgreementsWithSyndicateOfFrenchBanksMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "LoanAgreementsWithSyndicateOfFrenchBanksMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for loan agreements with a syndicate of French banks.", "label": "Loan Agreements With Syndicate of French Banks [Member]", "verboseLabel": "Loan agreements with a syndicate of French banks" } } }, "auth_ref": [] }, "iva_LoanAgreementsWithSyndicateOfFrenchBanksStateGuaranteedLoanPretGarantiParLetatMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "LoanAgreementsWithSyndicateOfFrenchBanksStateGuaranteedLoanPretGarantiParLetatMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for loan agreements with syndicate of French banks, state guaranteed loan (Pret Garanti par l'Etat)", "label": "Loan agreements with syndicate of French banks, state guaranteed loan (Pret Garanti par l'Etat) [Member]", "terseLabel": "Loan agreements with syndicate of French banks, state guaranteed loan (Pret Garanti par l'Etat)" } } }, "auth_ref": [] }, "iva_LoanAgreementsWithSyndicateOfFrenchBanksUnderStimulusEconomicPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "LoanAgreementsWithSyndicateOfFrenchBanksUnderStimulusEconomicPlanMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for loan agreements with a syndicate of French banks, under a stimulus economic plan.", "label": "Loan agreements with syndicate of French banks, under stimulus economic plan [Member]", "terseLabel": "Loan agreements with syndicate of French banks, under stimulus economic plan" } } }, "auth_ref": [] }, "ifrs-full_LoansReceived": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LoansReceived", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFinancialDebtDetails": { "parentTag": "ifrs-full_Borrowings", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFinancialDebtDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails" ], "lang": { "en-us": { "role": { "label": "Loans received", "terseLabel": "Bank borrowings" } }, "en": { "role": { "documentation": "The amount of loans received." } } }, "auth_ref": [ "r215" ] }, "iva_LongTermDepositAccountsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "LongTermDepositAccountsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for long term deposit accounts.", "label": "Long-term deposit accounts", "terseLabel": "Long-term deposit accounts" } } }, "auth_ref": [] }, "iva_LongTermDepositsTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "LongTermDepositsTerm", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherNonCurrentAssetsLongTermDepositAccountsDetails" ], "lang": { "en-us": { "role": { "documentation": "Term of the long-term deposits of the entity.", "label": "Long-Term Deposits Term", "terseLabel": "Period of long-term deposit" } } }, "auth_ref": [] }, "iva_LongTermFinancialDebtDerivativesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "LongTermFinancialDebtDerivativesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Long-term financial debt, derivatives.", "label": "Derivatives", "terseLabel": "Long-term financial debt - derivatives" } } }, "auth_ref": [] }, "iva_LongTermIncentivePlanInPerformanceUnits2023Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "LongTermIncentivePlanInPerformanceUnits2023Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFreeShareAwardsAndPerformanceUnitsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables" ], "lang": { "en-us": { "role": { "documentation": "This member stands for 2023 long-term incentive plan in performance units or \"PAGUP 2023\".", "label": "Long-Term Incentive Plan In Performance Units, 2023 [Member]", "terseLabel": "PAGUP 2023" } } }, "auth_ref": [] }, "iva_LongTermIncentivePlanInPerformanceUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "LongTermIncentivePlanInPerformanceUnitsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFreeShareAwardsAndPerformanceUnitsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for long-term incentive plan in performance units or \"PAGUP\".", "label": "Long-Term Incentive Plan In Performance Units [Member]", "terseLabel": "PAGUP" } } }, "auth_ref": [] }, "iva_LongTermSecurityDepositsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "LongTermSecurityDepositsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for long-term security deposits.", "label": "Long-term security deposits", "terseLabel": "Long-term security deposits" } } }, "auth_ref": [] }, "ifrs-full_LongtermBorrowingsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LongtermBorrowingsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Long-term debt", "terseLabel": "Long-term debt" } }, "en": { "role": { "documentation": "This member stands for long-term borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r192", "r194" ] }, "ifrs-full_LongtermDeposits": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LongtermDeposits", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherNonCurrentAssetsLongTermDepositAccountsDetails" ], "lang": { "en-us": { "role": { "label": "Long-term deposits" } }, "en": { "role": { "documentation": "The amount of long-term deposits held by the entity." } } }, "auth_ref": [ "r218" ] }, "ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "MaturityAnalysisForNonderivativeFinancialLiabilities", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of maturity analysis for non-derivative financial liabilities [text block]", "terseLabel": "Schedule of maturity of long-term and short-term debt" } }, "en": { "role": { "documentation": "The disclosure of a maturity analysis for non-derivative financial liabilities (including issued financial guarantee contracts) that shows the remaining contractual maturities. [Refer: Derivative financial liabilities]" } } }, "auth_ref": [ "r148" ] }, "ifrs-full_MaturityAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "MaturityAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesBreakDownDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Maturity [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r22", "r121", "r125", "r126", "r127", "r128", "r129", "r130", "r139", "r149", "r183", "r202" ] }, "iva_MaximumDurationOfClinicalTrial": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "MaximumDurationOfClinicalTrial", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Maximum duration of the clinical trial of the entity.", "label": "Maximum Duration Of The Clinical Trial", "verboseLabel": "Maximum duration of Phase III trial" } } }, "auth_ref": [] }, "iva_MaximumGrossProceedsReceivableUponExerciseOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "MaximumGrossProceedsReceivableUponExerciseOfWarrants", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details" ], "lang": { "en-us": { "role": { "documentation": "The maximum gross proceeds from receivable upon exercise of warrants.", "label": "Maximum Gross Proceeds Receivable upon Exercise of Warrants", "terseLabel": "Maximum gross proceeds" } } }, "auth_ref": [] }, "iva_MaximumPotentialGrossProceedsFromExerciseOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "MaximumPotentialGrossProceedsFromExerciseOfWarrants", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Maximum potential amount of gross proceeds that the company will receive from exercise of warrants.", "label": "Maximum Potential Gross Proceeds From Exercise Of Warrants", "terseLabel": "Maximum potential gross proceeds from exercise of warrants" } } }, "auth_ref": [] }, "iva_MinimumAmountCommittedForFundRaising": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "MinimumAmountCommittedForFundRaising", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "The minimum amount committed for borrowing under the agreement.", "label": "Minimum Amount Committed For Fund Raising", "terseLabel": "Minimum amount committed for fund raising" } } }, "auth_ref": [] }, "iva_MinimumUpfrontPaymentsForOutLicensingPartnershipOrRoyaltyTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "MinimumUpfrontPaymentsForOutLicensingPartnershipOrRoyaltyTransaction", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details" ], "lang": { "en-us": { "role": { "documentation": "The amount of minimum upfront payments for out-licensing, partnership or royalty transaction.", "label": "Minimum Upfront Payments For Out-Licensing, Partnership Or Royalty Transaction", "verboseLabel": "Minimum upfront payments for out-licensing, partnership or royalty transaction" } } }, "auth_ref": [] }, "ifrs-full_MiscellaneousOtherOperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "MiscellaneousOtherOperatingExpense", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOtherOperatingIncomeAndExpensesDetails": { "parentTag": "ifrs-full_OtherOperatingIncomeExpense", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOtherOperatingIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Miscellaneous other operating expense", "negatedLabel": "Other operating expenses" } }, "en": { "role": { "documentation": "The amount of miscellaneous other operating expenses. [Refer: Other operating income (expense)]" } } }, "auth_ref": [ "r215" ] }, "ifrs-full_MiscellaneousOtherOperatingIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "MiscellaneousOtherOperatingIncome", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOtherOperatingIncomeAndExpensesDetails": { "parentTag": "ifrs-full_OtherOperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOtherOperatingIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Miscellaneous other operating income", "terseLabel": "Other operating income" } }, "en": { "role": { "documentation": "The amount of miscellaneous other operating income. [Refer: Other operating income (expense)]" } } }, "auth_ref": [ "r215" ] }, "iva_Nativ3PhaseIiiClinicalTrialWithLanifibranorInPatientsWithMashNashMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "Nativ3PhaseIiiClinicalTrialWithLanifibranorInPatientsWithMashNashMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for NATiV3 Phase III clinical trial with lanifibranor in patients with\nMASH/NASH.", "label": "NATiV3 Phase III Clinical Trial With Lanifibranor In Patients With MASH/NASH [Member]", "terseLabel": "NATiV3 Phase III clinical trial" } } }, "auth_ref": [] }, "iva_Nativ3PhaseIiiTrialOfLanifibranorInNonCirrhoticNashMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "Nativ3PhaseIiiTrialOfLanifibranorInNonCirrhoticNashMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to the NATiV3 Phase III trial of lanifibranor in non-cirrhotic NASH", "label": "NATiV3 Phase III trial of lanifibranor in non-cirrhotic NASH [Member]", "terseLabel": "NATiV3 Phase III trial of lanifibranor in non-cirrhotic NASH" } } }, "auth_ref": [] }, "iva_NetProceedsFromIssuingShares": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "NetProceedsFromIssuingShares", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The amount of net proceeds from issuing shares", "label": "Net Proceeds From Issuing Shares", "verboseLabel": "Capital increase net of transaction cost" } } }, "auth_ref": [] }, "iva_NewBonusShareAwardPlan20231Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "NewBonusShareAwardPlan20231Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFreeShareAwardsAndPerformanceUnitsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables" ], "lang": { "en-us": { "role": { "documentation": "This member stands for New bonus share award plans (AGA 2023-1).", "label": "New Bonus Share Award Plan 2023-1 [Member]", "terseLabel": "AGA Plan 2023-1" } } }, "auth_ref": [] }, "iva_NewBonusShareAwardPlan20232Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "NewBonusShareAwardPlan20232Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFreeShareAwardsAndPerformanceUnitsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for New bonus share award plans (AGA 2023-2).", "label": "AGA 2023-2 [Member]", "terseLabel": "AGA 2023-2" } } }, "auth_ref": [] }, "iva_NewBonusShareAwardPlanAga20211Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "NewBonusShareAwardPlanAga20211Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFreeShareAwardsAndPerformanceUnitsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for New bonus share award plans (AGA 2021-1)", "label": "AGA 2021-1" } } }, "auth_ref": [] }, "iva_NewBonusShareAwardPlanAga2021BisMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "NewBonusShareAwardPlanAga2021BisMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFreeShareAwardsAndPerformanceUnitsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for New bonus share award plans (AGA 2021-bis).", "label": "AGA 2021-bis" } } }, "auth_ref": [] }, "iva_NewBsa2021ShareWarrantPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "NewBsa2021ShareWarrantPlanMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for new BSA 2021 share warrant plan.", "label": "BSA 2021" } } }, "auth_ref": [] }, "iva_NewShareWarrantPlansBsa2019BisMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "NewShareWarrantPlansBsa2019BisMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for a new share warrant plan (\"BSA 2019 bis).", "label": "BSA 2019 bis" } } }, "auth_ref": [] }, "iva_NewShareWarrantPlansBsa2019Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "NewShareWarrantPlansBsa2019Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for new share warrant plans (\"BSA 2019\").", "label": "BSA 2019" } } }, "auth_ref": [] }, "iva_NewShareWarrantPlansBsa2019TerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "NewShareWarrantPlansBsa2019TerMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for a new share warrant plan (\"BSA 2019 ter).", "label": "BSA 2019 ter" } } }, "auth_ref": [] }, "iva_NonCurrentAdvancesToSuppliers": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "NonCurrentAdvancesToSuppliers", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherNonCurrentAssetsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherNonCurrentAssetsLongTermDepositAccountsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount represents the non current advances of suppliers.", "label": "Non Current Advances To Suppliers", "terseLabel": "Advance payments - non-current", "verboseLabel": "Non-current advances to suppliers" } } }, "auth_ref": [] }, "iva_NonCurrentAssetsExcludingDeferredAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "NonCurrentAssetsExcludingDeferredAssets", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails" ], "lang": { "en-us": { "role": { "documentation": "Non-current assets excluding deferred assets", "label": "Non-current assets excluding deferred assets", "totalLabel": "Total non-current assets" } } }, "auth_ref": [] }, "iva_NonCurrentLongTermDepositsFromCustomers": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "NonCurrentLongTermDepositsFromCustomers", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherNonCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "It represents information about non current long term deposits from customers.", "label": "Non Current Long Term Deposits From Customers", "terseLabel": "Longterm deposit accounts" } } }, "auth_ref": [] }, "iva_NonCurrentPortionOfNonCurrentBorrowingsAndNonCurrentLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "NonCurrentPortionOfNonCurrentBorrowingsAndNonCurrentLeaseLiabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "documentation": "Non-current portion of non-current borrowings and non-current lease liabilities", "label": "Non-current portion of non-current borrowings and non-current lease liabilities", "terseLabel": "Long-term debt" } } }, "auth_ref": [] }, "iva_NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 2.0 }, "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFinancialDebtDetails": { "parentTag": "ifrs-full_Borrowings", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFinancialDebtDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "documentation": "The non-current portion of non-current royalty certificates issued.", "label": "Non-current Portion of Non-current Royalty Certificates Issued", "terseLabel": "Royalty certificates liabilities" } } }, "auth_ref": [] }, "iva_NonCurrentSecurityDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "NonCurrentSecurityDeposits", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherNonCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "The non-current amount of security deposits.", "label": "Non-current Security Deposits", "terseLabel": "Security deposits" } } }, "auth_ref": [] }, "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NonadjustingEventsAfterReportingPeriodAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "label": "Non-adjusting events after reporting period [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r41" ] }, "ifrs-full_NonadjustingEventsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NonadjustingEventsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "label": "Non-adjusting events after reporting period [member]", "terseLabel": "Non-adjusting events after reporting period [member]" } }, "en": { "role": { "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used." } } }, "auth_ref": [ "r41" ] }, "ifrs-full_NoncontrollingInterests": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncontrollingInterests", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails" ], "lang": { "en-us": { "role": { "label": "Non-controlling interests", "terseLabel": "Non-controlling interest" } }, "en": { "role": { "documentation": "The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Subsidiaries [member]]" } } }, "auth_ref": [ "r18", "r93", "r94" ] }, "ifrs-full_NoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentAssets", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current assets", "totalLabel": "Total non-current assets" } }, "en": { "role": { "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]" } } }, "auth_ref": [ "r23", "r99", "r195" ] }, "ifrs-full_NoncurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentAssetsAbstract", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current assets [abstract]", "terseLabel": "Noncurrent assets" } } }, "auth_ref": [] }, "ifrs-full_NoncurrentContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentContractLiabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current contract liabilities", "terseLabel": "Long-term contract liabilities" } }, "en": { "role": { "documentation": "The amount of non-current contract liabilities. [Refer: Contract liabilities]" } } }, "auth_ref": [ "r118" ] }, "ifrs-full_NoncurrentDerivativeFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentDerivativeFinancialLiabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 1.0 }, "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFinancialDebtDetails": { "parentTag": "ifrs-full_Borrowings", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFinancialDebtDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current derivative financial liabilities", "netLabel": "Derivatives instruments", "terseLabel": "Long-term debt - derivatives", "verboseLabel": "Derivatives" } }, "en": { "role": { "documentation": "The amount of non-current derivative financial liabilities. [Refer: Derivative financial liabilities]" } } }, "auth_ref": [ "r218" ] }, "ifrs-full_NoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentLiabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current liabilities", "totalLabel": "Total non-current liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]" } } }, "auth_ref": [ "r24", "r101", "r195" ] }, "ifrs-full_NoncurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentLiabilitiesAbstract", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current liabilities [abstract]", "terseLabel": "Noncurrent liabilities" } } }, "auth_ref": [] }, "ifrs-full_NoncurrentProvisionsForEmployeeBenefits": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentProvisionsForEmployeeBenefits", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current provisions for employee benefits", "terseLabel": "Provisions for retirement benefit obligations" } }, "en": { "role": { "documentation": "The amount of non-current provisions for employee benefits. [Refer: Provisions for employee benefits]" } } }, "auth_ref": [ "r27" ] }, "ifrs-full_NotLaterThanOneMonthMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NotLaterThanOneMonthMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesBreakDownDetails" ], "lang": { "en-us": { "role": { "label": "Due in 30 days", "terseLabel": "Due in 30 days" } }, "en": { "role": { "documentation": "This member stands for a time band of not later than one month." } } }, "auth_ref": [ "r201", "r203", "r209" ] }, "ifrs-full_NotLaterThanOneYearMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NotLaterThanOneYearMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails" ], "lang": { "en-us": { "role": { "label": "Less than 1 year" } }, "en": { "role": { "documentation": "This member stands for a time band of not later than one year." } } }, "auth_ref": [ "r21", "r125", "r126", "r130", "r202", "r209" ] }, "ifrs-full_NotLaterThanThreeMonthsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NotLaterThanThreeMonthsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "3 months or less" } }, "en": { "role": { "documentation": "This member stands for a time band of not later than three months." } } }, "auth_ref": [ "r215" ] }, "iva_NotesToConsolidatedBalanceSheet": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "NotesToConsolidatedBalanceSheet", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Trade payables, short-term contract liabilities and other current liabilities" } } }, "auth_ref": [] }, "iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Notes to the interim condensed consolidated statement of financial position" } } }, "auth_ref": [] }, "ifrs-full_NotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NotionalAmount", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtRoyaltyCertificatesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Notional Amount", "terseLabel": "Notional amount", "verboseLabel": "Total amount of loan" } }, "en": { "role": { "documentation": "The nominal or face amount of a financial instrument, used to calculate payments made on that instrument." } } }, "auth_ref": [ "r215" ] }, "iva_NotionalAmountPerTranche": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "NotionalAmountPerTranche", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "Notional amount per tranche", "label": "Notional Amount Per Tranche", "terseLabel": "Notional amount per tranche" } } }, "auth_ref": [] }, "iva_NumberOfAwardPlansAttributed": { "xbrltype": "sharesItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "NumberOfAwardPlansAttributed", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFreeShareAwardsAndPerformanceUnitsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of award plans attributed during the period.", "label": "Number Of Award Plans Attributed", "terseLabel": "Number of plans attributed" } } }, "auth_ref": [] }, "iva_NumberOfBiopsiesUnderClinicalTrials": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "NumberOfBiopsiesUnderClinicalTrials", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "It represents the number of clinical trial.", "label": "Number Of Biopsies Under Clinical Trials", "terseLabel": "Number of Biopsies Under the Phase III trial" } } }, "auth_ref": [] }, "ifrs-full_NumberOfEmployees": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfEmployees", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "label": "Number of employees", "verboseLabel": "Number of employees" } }, "en": { "role": { "documentation": "The number of personnel employed by the entity at a date." } } }, "auth_ref": [ "r215" ] }, "iva_NumberOfEntitiesBeingConsolidated": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "NumberOfEntitiesBeingConsolidated", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of entities being consolidated", "label": "Number of entities being consolidated", "terseLabel": "Number of entities being consolidated" } } }, "auth_ref": [] }, "iva_NumberOfEqualTranches": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "NumberOfEqualTranches", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Represent the information of number of equal tranches .", "label": "Number of Equal Tranches", "terseLabel": "Number of equal tranches" } } }, "auth_ref": [] }, "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFreeShareAwardsAndPerformanceUnitsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "lang": { "en-us": { "role": { "label": "Number of other equity instruments granted in share-based payment arrangement", "terseLabel": "Issued", "verboseLabel": "Number of equity instruments granted" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement." } } }, "auth_ref": [ "r135", "r243" ] }, "iva_NumberOfLoanAgreements": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "NumberOfLoanAgreements", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the number of loan agreements.", "label": "Number of Loan Agreements", "terseLabel": "Number of loan agreements" } } }, "auth_ref": [] }, "iva_NumberOfLoansObtainedGuaranteedByFrenchState": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "NumberOfLoansObtainedGuaranteedByFrenchState", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of loans obtained which are guaranteed by the french state.", "label": "Number Of Loans Obtained Guaranteed By The French State", "verboseLabel": "Number of loans obtained guaranteed by the french state" } } }, "auth_ref": [] }, "ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFreeShareAwardsAndPerformanceUnitsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "lang": { "en-us": { "role": { "label": "Number of other equity instruments exercisable in share-based payment arrangement", "terseLabel": "Number of exercisable shares" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) exercisable in a share-based payment arrangement." } } }, "auth_ref": [ "r243" ] }, "ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFreeShareAwardsAndPerformanceUnitsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "lang": { "en-us": { "role": { "label": "Number of other equity instruments exercised or vested in share-based payment arrangement", "negatedLabel": "Exercised/Vesting" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement." } } }, "auth_ref": [ "r243" ] }, "ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFreeShareAwardsAndPerformanceUnitsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityOptionsAndShareWarrantsBsaAndBspceDetails" ], "lang": { "en-us": { "role": { "label": "Number of other equity instruments expired in share-based payment arrangement", "verboseLabel": "Instruments lapsed" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) expired in a share-based payment arrangement." } } }, "auth_ref": [ "r243" ] }, "ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFreeShareAwardsAndPerformanceUnitsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "lang": { "en-us": { "role": { "label": "Number of other equity instruments forfeited in share-based payment arrangement", "negatedLabel": "Forfeited/ Lapsed" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement." } } }, "auth_ref": [ "r243" ] }, "ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFreeShareAwardsAndPerformanceUnitsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "lang": { "en-us": { "role": { "label": "Number of other equity instruments outstanding in share-based payment arrangement", "periodEndLabel": "Outstanding, Ending balance", "periodStartLabel": "Outstanding, Beginning balance" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement." } } }, "auth_ref": [ "r243" ] }, "iva_NumberOfPatientsRandomizedClinicalTrialMainCohort": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "NumberOfPatientsRandomizedClinicalTrialMainCohort", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the number of subjects randomized for main cohort.", "label": "Number of Patients Randomized, Clinical Trial, Main Cohort", "terseLabel": "Number of patients in main cohort" } } }, "auth_ref": [] }, "iva_NumberOfPatientsRandomizedForTreatment": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "NumberOfPatientsRandomizedForTreatment", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of patients randomized for treatment.", "label": "Number of Patients Randomized For Treatment", "terseLabel": "Number of patients randomized" } } }, "auth_ref": [] }, "iva_NumberOfPatientsToBeTreatedForFortyEightWeeks": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "NumberOfPatientsToBeTreatedForFortyEightWeeks", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of patients to be treated for 48 weeks.", "label": "Number of Patients to Be Treated For Forty Eight Weeks", "terseLabel": "Number of patients to be treated for 48 weeks" } } }, "auth_ref": [] }, "iva_NumberOfPatientsToBeTreatedForSeventyTwoWeeks": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "NumberOfPatientsToBeTreatedForSeventyTwoWeeks", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of patients to be treated for 72 weeks.", "label": "Number of Patients to Be Treated For Seventy Two Weeks", "terseLabel": "Number of patients to be treated for 72 weeks" } } }, "auth_ref": [] }, "iva_NumberOfPlansOutstanding": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "NumberOfPlansOutstanding", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFreeShareAwardsAndPerformanceUnitsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of plans outstanding", "label": "Number of plans outstanding", "terseLabel": "Number of award plans outstanding" } } }, "auth_ref": [] }, "iva_NumberOfRoyaltyCertificatesIssued": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "NumberOfRoyaltyCertificatesIssued", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of royalty certificates issued.", "label": "Number of Royalty Certificates Issued", "terseLabel": "Number of royalty certificates issued" } } }, "auth_ref": [] }, "iva_NumberOfSharesAcquiredInAssociate": { "xbrltype": "sharesItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "NumberOfSharesAcquiredInAssociate", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of shares acquired in associate", "label": "Number of shares acquired in associate", "terseLabel": "Number of shares acquired in associate" } } }, "auth_ref": [] }, "iva_NumberOfSharesConverted": { "xbrltype": "sharesItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "NumberOfSharesConverted", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFreeShareAwardsAndPerformanceUnitsDetails" ], "lang": { "en-us": { "role": { "documentation": "It represents the information relating to number of shares converted.", "label": "Number Of Shares Converted", "terseLabel": "Number of shares converted" } } }, "auth_ref": [] }, "ifrs-full_NumberOfSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfSharesOutstanding", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityShareCapitalDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Number of shares outstanding", "periodEndLabel": "Balance at the end (in shares)", "periodStartLabel": "Balance at the beginning (in shares)", "terseLabel": "Number of shares outstanding", "verboseLabel": "Number of fully authorized, subscribed and paid up shares" } }, "en": { "role": { "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]" } } }, "auth_ref": [ "r30" ] }, "iva_NumberOfSharesPerOtherEquityInstrumentGranted": { "xbrltype": "sharesItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "NumberOfSharesPerOtherEquityInstrumentGranted", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that each equity instruments other than share options granted in a share-based payment arrangement, entitles the holder.", "label": "Number Of Shares Per Other Equity Instrument Granted", "terseLabel": "Number of shares per AGA" } } }, "auth_ref": [] }, "iva_NumberOfSitesOperatingUnderCentralIrbOverseeing": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "NumberOfSitesOperatingUnderCentralIrbOverseeing", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details" ], "lang": { "en-us": { "role": { "documentation": "Number of sites operating under central IRB overseeing", "label": "Number of sites operating under central IRB overseeing" } } }, "auth_ref": [] }, "iva_NumberOfWarrantsIssued": { "xbrltype": "sharesItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "NumberOfWarrantsIssued", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details" ], "lang": { "en-us": { "role": { "documentation": "Number of warrants issued", "label": "Number of warrants issued", "terseLabel": "Number of warrants issued" } } }, "auth_ref": [] }, "iva_NumberOfWeeksUnderActiveTreatmentExtensionStudy": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "NumberOfWeeksUnderActiveTreatmentExtensionStudy", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of weeks under the active treatment extension study of the entity.", "label": "Number Of Weeks Under The Active Treatment Extension Study", "verboseLabel": "Number of weeks under the active treatment extension study" } } }, "auth_ref": [] }, "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "OperatingExpenseExcludingOtherOperatingIncomeExpense", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to amount of all operating expenses.", "label": "Operating Expense Excluding Other Operating Income Expense", "negatedTotalLabel": "Total operating expenses" } } }, "auth_ref": [] }, "iva_OptionToAcquireSharesInCompanyPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "OptionToAcquireSharesInCompanyPercentage", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Option to acquire shares in company, percentage", "label": "Option to acquire shares in company, percentage", "terseLabel": "Percent of acquisition", "verboseLabel": "Option to acquire shares in company, percentage" } } }, "auth_ref": [] }, "ifrs-full_OrdinarySharesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OrdinarySharesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails" ], "lang": { "en-us": { "role": { "label": "Ordinary shares", "terseLabel": "Ordinary shares" } }, "en": { "role": { "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments. It also represents the standard value for the 'Classes of ordinary shares' axis if no other member is used." } } }, "auth_ref": [ "r64", "r221" ] }, "iva_OtherAccruedTaxesAndEmployeeRelatedExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "OtherAccruedTaxesAndEmployeeRelatedExpenses", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesDetails": { "parentTag": "ifrs-full_OtherCurrentLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of accrued taxes and employee related expenses.", "label": "Other Accrued taxes And Employee Related Expenses", "terseLabel": "Other accrued taxes and employeerelated expenses" } } }, "auth_ref": [] }, "ifrs-full_OtherAdjustmentsForNoncashItems": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherAdjustmentsForNoncashItems", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Other adjustments for non-cash items", "terseLabel": "Other" } }, "en": { "role": { "documentation": "Adjustments for non-cash items to reconcile profit (loss) to net cash flow from (used in) operating activities that the entity does not separately disclose in the same statement or note. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r238" ] }, "ifrs-full_OtherBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherBorrowings", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFinancialDebtDetails": { "parentTag": "ifrs-full_Borrowings", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFinancialDebtDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails" ], "lang": { "en-us": { "role": { "label": "Other borrowings", "terseLabel": "Other loans and similar borrowings", "verboseLabel": "Other loans and similar borrowings" } }, "en": { "role": { "documentation": "The amount of borrowings that the entity does not separately disclose in the same statement or note. [Refer: Borrowings]" } } }, "auth_ref": [ "r215" ] }, "ifrs-full_OtherComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherComprehensiveIncome", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails" ], "lang": { "en-us": { "role": { "label": "Other comprehensive income", "verboseLabel": "Other comprehensive income" } }, "en": { "role": { "documentation": "The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]" } } }, "auth_ref": [ "r3", "r33", "r39", "r104" ] }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss": { "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations", "terseLabel": "Currency translation differences", "verboseLabel": "Exchange difference on translation of foreign operations" } }, "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r25", "r39" ] }, "iva_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOfForeignOperationsIncludingEffectsOfTranslationOfInvestmentsAccountedForUsingEquityMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOfForeignOperationsIncludingEffectsOfTranslationOfInvestmentsAccountedForUsingEquityMethod", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations including effects of translation of investments accounted for using equity method", "label": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations including effects of translation of investments accounted for using equity method", "terseLabel": "Currency translation differences" } } }, "auth_ref": [] }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss": { "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans", "terseLabel": "Remeasurement of defined benefit plans" } }, "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, related to gains (losses) on remeasurements of defined benefit plans, which comprise actuarial gains and losses; the return on plan assets, excluding amounts included in net interest on the net defined benefit liability (asset); and any change in the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability (asset). [Refer: Other comprehensive income; Defined benefit plans [member]; Plan assets [member]; Net defined benefit liability (asset)] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income]" } } }, "auth_ref": [ "r25", "r39", "r228" ] }, "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Other comprehensive income that will be reclassified to profit or loss, net of tax", "totalLabel": "Items that will be reclassified subsequently to profit or loss", "verboseLabel": "Items that will be reclassified subsequently to profit or loss" } }, "en": { "role": { "documentation": "The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r181", "r182" ] }, "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Other comprehensive income that will not be reclassified to profit or loss, net of tax", "totalLabel": "Items that will not be reclassified subsequently to profit or loss", "verboseLabel": "Items that will not be reclassified subsequently to profit or loss" } }, "en": { "role": { "documentation": "The amount of other comprehensive income that will not be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r181", "r182" ] }, "ifrs-full_OtherContingentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherContingentLiabilitiesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" ], "lang": { "en-us": { "role": { "label": "Other contingent liabilities [member]", "terseLabel": "Other" } }, "en": { "role": { "documentation": "This member stands for contingent liabilities that the entity does not separately disclose in the same statement or note. [Refer: Contingent liabilities [member]]" } } }, "auth_ref": [ "r186" ] }, "ifrs-full_OtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherCurrentAssets", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails": { "parentTag": "iva_OtherCurrentAssetsAndReceivables", "weight": 1.0, "order": 1.0 }, "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Other current assets", "terseLabel": "Other current assets", "totalLabel": "Other current assets" } }, "en": { "role": { "documentation": "The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]" } } }, "auth_ref": [ "r218" ] }, "iva_OtherCurrentAssetsAndReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "OtherCurrentAssetsAndReceivables", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of other current assets and receivables as of balance sheet date.", "label": "Other Current Assets And Receivables", "totalLabel": "Other current assets and receivables" } } }, "auth_ref": [] }, "ifrs-full_OtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherCurrentLiabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 3.0 }, "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesShortTermContractLiabilitiesAndOtherCurrentLiabilitiesDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Other current liabilities", "terseLabel": "Other current liabilities", "totalLabel": "Other current liabilities" } }, "en": { "role": { "documentation": "The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]" } } }, "auth_ref": [ "r218" ] }, "ifrs-full_OtherCurrentPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherCurrentPayables", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesDetails": { "parentTag": "ifrs-full_OtherCurrentLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Other current payables", "terseLabel": "Other miscellaneous payables" } }, "en": { "role": { "documentation": "The amount of current payables that the entity does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r218" ] }, "ifrs-full_OtherCurrentReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherCurrentReceivables", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails": { "parentTag": "ifrs-full_OtherCurrentAssets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Other current receivables", "terseLabel": "Other receivables" } }, "en": { "role": { "documentation": "The amount of current other receivables. [Refer: Other receivables]" } } }, "auth_ref": [ "r179" ] }, "iva_OtherCurrentTaxReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "OtherCurrentTaxReceivables", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails": { "parentTag": "ifrs-full_CurrentTaxAssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of other tax receivables, classified as current.", "label": "Other Current Tax Receivables", "terseLabel": "Other" } } }, "auth_ref": [] }, "ifrs-full_OtherFinanceCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherFinanceCost", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Other finance cost", "negatedLabel": "Other financial expenses" } }, "en": { "role": { "documentation": "The amount of finance costs that the entity does not separately disclose in the same statement or note. [Refer: Finance costs]" } } }, "auth_ref": [ "r215" ] }, "iva_OtherFinancialInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "OtherFinancialInformationAbstract", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Other financial information" } } }, "auth_ref": [] }, "iva_OtherIncomeFromOrdinaryActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "OtherIncomeFromOrdinaryActivities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss": { "parentTag": "ifrs-full_RevenueAndOperatingIncome", "weight": 1.0, "order": 1.0 }, "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossRevenuesAndOtherIncomeDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossRevenuesAndOtherIncomeDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "documentation": "The amount of other income from ordinary activities.", "label": "Other income from ordinary activities", "terseLabel": "Other income", "totalLabel": "Other income" } } }, "auth_ref": [] }, "iva_OtherIncomeReinvoicingOfSpecificCostsUnderServiceAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "OtherIncomeReinvoicingOfSpecificCostsUnderServiceAgreement", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount related to reinvoicing of specific costs incurred on services with customer research organization accrued liabilities included in other income.", "label": "Other Income, Reinvoicing Of Specific Costs Under Service Agreement", "terseLabel": "Reinvoicing of specific costs related to CRO accrued liabilities included in other income" } } }, "auth_ref": [] }, "iva_OtherIncomeRelatingToReinvoicingOfShareOfCostsUnderLicensingAndCollaborationAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "OtherIncomeRelatingToReinvoicingOfShareOfCostsUnderLicensingAndCollaborationAgreement", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount related to reinvoicing of share of costs incurred under the licensing and collaboration agreements included in other income.", "label": "Other Income, Relating To Reinvoicing Of Share Of Costs Under Licensing And Collaboration Agreement", "terseLabel": "Reinvoicing of share of costs incurred included in other income" } } }, "auth_ref": [] }, "ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Other inflows (outflows) of cash, classified as investing activities", "verboseLabel": "Increase / (Decrease) in other non-current financial assets" } }, "en": { "role": { "documentation": "Inflows (outflows) of cash, classified as investing activities, that the entity does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r83" ] }, "ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Other inflows (outflows) of cash, classified as operating activities", "verboseLabel": "Other" } }, "en": { "role": { "documentation": "Inflows (outflows) of cash, classified as operating activities, that the entity does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r81" ] }, "iva_OtherMiscellaneousPayablesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "OtherMiscellaneousPayablesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for other miscellaneous payables.", "label": "Other miscellaneous payables", "terseLabel": "Other miscellaneous payables" } } }, "auth_ref": [] }, "iva_OtherNonCurrentAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "OtherNonCurrentAssetsLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherNonCurrentAssetsLongTermDepositAccountsDetails" ], "lang": { "en-us": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.", "label": "Other Non Current Assets [Line Items]", "verboseLabel": "Other Non Current Assets" } } }, "auth_ref": [] }, "iva_OtherNonCurrentAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "OtherNonCurrentAssetsTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherNonCurrentAssetsLongTermDepositAccountsDetails" ], "lang": { "en-us": { "role": { "documentation": "Schedule disclosing information related to other non-current assets.", "label": "Other Non Current Assets [Table]" } } }, "auth_ref": [] }, "ifrs-full_OtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherNoncurrentAssets", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherNonCurrentAssetsDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Other non-current asset", "terseLabel": "Other non-current assets", "totalLabel": "Other noncurrent assets" } }, "en": { "role": { "documentation": "The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]" } } }, "auth_ref": [ "r218" ] }, "ifrs-full_OtherNoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherNoncurrentLiabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesAdditionalInformationDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Other non-current liabilities", "terseLabel": "Other non-current liabilities" } }, "en": { "role": { "documentation": "The amount of non-current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Non-current liabilities]" } } }, "auth_ref": [ "r218" ] }, "iva_OtherOperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "OtherOperatingExpenses", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to other operating expenses.", "label": "Other operating expenses", "negatedLabel": "Other operating expenses" } } }, "auth_ref": [] }, "ifrs-full_OtherOperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherOperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0, "order": 4.0 }, "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOtherOperatingIncomeAndExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOtherOperatingIncomeAndExpensesDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Other operating income (expense)", "terseLabel": "Other operating income (expenses)", "totalLabel": "Other operating income and expenses" } }, "en": { "role": { "documentation": "The amount of operating income (expense) that the entity does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r222" ] }, "ifrs-full_OtherProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherProvisions", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsForRetirementBenefitObligationsNetProvisionDetails" ], "lang": { "en-us": { "role": { "label": "Other provisions", "terseLabel": "Provisions" } }, "en": { "role": { "documentation": "The amount of provisions other than provisions for employee benefits. [Refer: Provisions]" } } }, "auth_ref": [ "r27", "r69" ] }, "iva_OtherReceivablesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "OtherReceivablesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for other receivables.", "label": "Other receivables", "terseLabel": "Other receivables" } } }, "auth_ref": [] }, "srt_OwnershipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "OwnershipAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "label": "Ownership [Axis]" } } }, "auth_ref": [] }, "srt_OwnershipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "OwnershipDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "label": "Ownership [Domain]" } } }, "auth_ref": [] }, "ifrs-full_ParValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ParValuePerShare", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityShareCapitalDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "label": "Par value per share", "terseLabel": "Par value of share", "verboseLabel": "Nominal value" } }, "en": { "role": { "documentation": "The nominal value per share." } } }, "auth_ref": [ "r29" ] }, "ifrs-full_PastServiceCostAndLossesGainsArisingFromSettlementsDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PastServiceCostAndLossesGainsArisingFromSettlementsDefinedBenefitPlans", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsForRetirementBenefitObligationsBreakdownOfExpenseRecognizedForYearDetails": { "parentTag": "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsForRetirementBenefitObligationsBreakdownOfExpenseRecognizedForYearDetails" ], "lang": { "en-us": { "role": { "label": "Past service cost and losses (gains) arising from settlements, defined benefit plans", "negatedLabel": "Benefits for the period" } }, "en": { "role": { "documentation": "The amount of expense (income) resulting from past service cost and losses (gains) arising from settlements. [Refer: Post-employment benefit expense in profit or loss, defined benefit plans; Past service cost, defined benefit plans] [Contrast: Increase (decrease) in net defined benefit liability (asset) resulting from past service cost and losses (gains) arising from settlements]" } } }, "auth_ref": [ "r228" ] }, "iva_Patents": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "Patents", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to patents.", "label": "Patents", "negatedLabel": "Patents" } } }, "auth_ref": [] }, "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments of lease liabilities, classified as financing activities", "negatedLabel": "Repayment of lease liabilities" } }, "en": { "role": { "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r191" ] }, "iva_PayrollTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "PayrollTaxes", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesPersonnelCostsAndHeadcountDetails": { "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "documentation": "A class of employee benefits expense that represents payroll taxes.", "label": "Payroll taxes", "negatedLabel": "Payroll taxes" } } }, "auth_ref": [] }, "iva_PercentageOfCompanySShareCapitalOutstandingIssuedAsWarrants": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "PercentageOfCompanySShareCapitalOutstandingIssuedAsWarrants", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of Company's share capital outstanding, issued as warrants by the entity.", "label": "Percentage Of Company's Share Capital Outstanding, Issued As Warrants", "terseLabel": "Percentage of company's share capital outstanding, issued as warrants" } } }, "auth_ref": [] }, "iva_PercentageOfLoanGuaranteedByFrenchState": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "PercentageOfLoanGuaranteedByFrenchState", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of loan guaranteed by French state.", "label": "Percentage of Loan Guaranteed by French State", "terseLabel": "Percentage of loan guaranteed by French state" } } }, "auth_ref": [] }, "iva_PercentageOfPatientsInTrialEnrolledInExploratoryCohort": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "PercentageOfPatientsInTrialEnrolledInExploratoryCohort", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "The percentage of patients in trail enrolled in exploratory cohort.", "label": "Percentage of Patients in Trial, Enrolled in Exploratory Cohort", "terseLabel": "Percentage of patients in trial, enrolled in exploratory cohort" } } }, "auth_ref": [] }, "iva_PercentageOfPatientsInTrialEnrolledInMainCohort": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "PercentageOfPatientsInTrialEnrolledInMainCohort", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "The percentage of patients in trail enrolled in main cohort.", "label": "Percentage of Patients in Trial, Enrolled in Main Cohort", "terseLabel": "Percentage of patients in trial, enrolled in main cohort" } } }, "auth_ref": [] }, "iva_PercentageOfPatientsRandomizedInMainCohort": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "PercentageOfPatientsRandomizedInMainCohort", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details" ], "lang": { "en-us": { "role": { "documentation": "Percentage of patients randomized in the main cohort", "label": "Percentage of patients randomized in the main cohort" } } }, "auth_ref": [] }, "iva_PercentageOfPatientsTreatedInTrial": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "PercentageOfPatientsTreatedInTrial", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "The percentage of patients treated in this trial.", "label": "Percentage of Patients Treated in The Trial", "terseLabel": "Percentage of patients treated in trial" } } }, "auth_ref": [] }, "iva_PercentageOfShareCapitalHeldByCounterpartyIfAllOutstandingWarrantsAreExercised": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "PercentageOfShareCapitalHeldByCounterpartyIfAllOutstandingWarrantsAreExercised", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details" ], "lang": { "en-us": { "role": { "documentation": "Percentage of share capital held by counterparty if all outstanding warrants are exercised", "label": "Percentage of share capital held by counterparty if all outstanding warrants are exercised" } } }, "auth_ref": [] }, "iva_PeriodWithinWhichPaymentIsReceivedFromSettlement": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "PeriodWithinWhichPaymentIsReceivedFromSettlement", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "The period within which the payment is made from settlement date.", "label": "Period Within Which Payment is Received From Settlement", "terseLabel": "Received from settlement" } } }, "auth_ref": [] }, "iva_PersonnelCostsAndHeadcount": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "PersonnelCostsAndHeadcount", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossTables" ], "lang": { "en-us": { "role": { "documentation": "Personnel costs and headcount", "label": "Personnel costs and headcount", "terseLabel": "Schedule of personnel costs and headcount" } } }, "auth_ref": [] }, "iva_PharmaceuticalResearchAssociatesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "PharmaceuticalResearchAssociatesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Pharmaceutical Research Associates.", "label": "Pharmaceutical Research Associates [Member]", "terseLabel": "Pharmaceutical Research Associates" } } }, "auth_ref": [] }, "iva_PhaseIiClinicalTrialEvaluatingLanifibranorInPatientsWithT2dAndNonalcoholicFattyLiverDiseaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "PhaseIiClinicalTrialEvaluatingLanifibranorInPatientsWithT2dAndNonalcoholicFattyLiverDiseaseMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the Phase II clinical trial evaluating lanifibranor in patients with T2D and nonalcoholic fatty liver disease", "label": "Phase II clinical trial evaluating lanifibranor in patients with T2D and nonalcoholic fatty liver disease [Member]", "terseLabel": "Phase II clinical trial evaluating lanifibranor in patients with T2D and nonalcoholic fatty liver disease" } } }, "auth_ref": [] }, "iva_PhaseIiClinicalTrialEvaluatingPlaceboInPatientsWithMashNashAndT2dMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "PhaseIiClinicalTrialEvaluatingPlaceboInPatientsWithMashNashAndT2dMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for phase II clinical trial evaluating placebo in patients with MASH/NASH and T2D.", "label": "Phase II Clinical Trial Evaluating Placebo In Patients With MASH/NASH And T2D [Member]", "terseLabel": "Phase II Clinical Trial Evaluating Placebo In Patients With MASH/NASH And T2D" } } }, "auth_ref": [] }, "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PostemploymentBenefitExpenseDefinedBenefitPlans", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsForRetirementBenefitObligationsBreakdownOfExpenseRecognizedForYearDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsForRetirementBenefitObligationsBreakdownOfExpenseRecognizedForYearDetails" ], "lang": { "en-us": { "role": { "label": "Post-employment benefit expense, defined benefit plans", "negatedTotalLabel": "Total" } }, "en": { "role": { "documentation": "The amount of post-employment benefit expense included in profit or loss relating to defined benefit plans. [Refer: Profit (loss); Defined benefit plans [member]] [Contrast: Increase (decrease) in net defined benefit liability (asset) resulting from expense (income) in profit or loss]" } } }, "auth_ref": [ "r228", "r230" ] }, "ifrs-full_PostemploymentBenefitExpenseInProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PostemploymentBenefitExpenseInProfitOrLoss", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesPersonnelCostsAndHeadcountDetails": { "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "label": "Post-employment benefit expense in profit or loss", "negatedLabel": "Provisions for retirement benefit obligations" } }, "en": { "role": { "documentation": "The amount of post-employment benefit expense included in profit or loss" } } }, "auth_ref": [ "r230" ] }, "iva_PresentationOfResultsFromStudyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "PresentationOfResultsFromStudyMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to the presentation of results from a study.", "label": "Presentation of results from study [Member]", "terseLabel": "Presentation of results from study" } } }, "auth_ref": [] }, "ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProceedsFromBorrowingsClassifiedAsFinancingActivities", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from borrowings, classified as financing activities", "terseLabel": "Subscription of borrowings and warrants net of transaction cost", "verboseLabel": "Loan obtained" } }, "en": { "role": { "documentation": "The cash inflow from borrowings obtained. [Refer: Borrowings]" } } }, "auth_ref": [ "r189" ] }, "iva_ProceedsFromFinancing": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "ProceedsFromFinancing", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of cash proceeds from financing.", "label": "Proceeds From Financing", "terseLabel": "Gross cash proceeds" } } }, "auth_ref": [] }, "ifrs-full_ProceedsFromIssuingShares": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProceedsFromIssuingShares", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from issuing shares", "terseLabel": "Capital increase" } }, "en": { "role": { "documentation": "The cash inflow from issuing shares." } } }, "auth_ref": [ "r188" ] }, "iva_ProceedsFromLicensingArrangements": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "ProceedsFromLicensingArrangements", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossNarrativesDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount paid on licensing arrangements.", "label": "Proceeds From Licensing Arrangements", "terseLabel": "Amount received on licensing arrangements" } } }, "auth_ref": [] }, "iva_ProceedsFromSalesOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "ProceedsFromSalesOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The cash inflow from the disposal of property, plant and equipment and intangible assets, classified as investing activities.", "label": "Proceeds From Sales Of Property Plant And Equipment And Intangible Assets Classified As Investing Activities", "terseLabel": "Disposals of property, plant and equipment and intangible assets" } } }, "auth_ref": [] }, "ifrs-full_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 2.0 }, "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 3.0 }, "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossBasicAndDilutedLossPerShareDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Profit (loss)", "terseLabel": "Net loss for the period", "totalLabel": "Net loss for the period", "verboseLabel": "Loss for the period" } }, "en": { "role": { "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r2", "r32", "r82", "r90", "r92", "r162", "r165", "r195", "r199" ] }, "ifrs-full_ProfitLossFromOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProfitLossFromOperatingActivities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Profit (loss) from operating activities", "totalLabel": "Net operating loss", "verboseLabel": "Net operating loss" } }, "en": { "role": { "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r184", "r222" ] }, "ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PropertyPlantAndEquipmentIncludingRightofuseAssets", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionPropertyPlantAndEquipmentDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Property, plant and equipment including right-of-use assets", "periodEndLabel": "Balance at the end", "periodStartLabel": "Balance at the beginning", "terseLabel": "Property, plant and equipment" } }, "en": { "role": { "documentation": "The amount of property, plant and equipment including right-of-use assets whose underlying assets would be presented as property, plant and equipment if they were owned. [Refer: Property, plant and equipment; Right-of-use assets]" } } }, "auth_ref": [ "r217", "r226" ] }, "ifrs-full_PropertyPlantAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PropertyPlantAndEquipmentMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionPropertyPlantAndEquipmentAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property, plant and equipment [member]" } }, "en": { "role": { "documentation": "This member stands for property, plant and equipment. It also represents the standard value for the 'Classes of property, plant and equipment' axis if no other member is used. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r48", "r185", "r198" ] }, "ifrs-full_ProportionOfOwnershipInterestInAssociate": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProportionOfOwnershipInterestInAssociate", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails" ], "lang": { "en-us": { "role": { "label": "Proportion of ownership interest in associate", "terseLabel": "Group's share in %", "verboseLabel": "Proportion of ownership interest" } }, "en": { "role": { "documentation": "The proportion of ownership interest in an associate attributable to the entity. [Refer: Associates [member]]" } } }, "auth_ref": [ "r59", "r61", "r97" ] }, "ifrs-full_ProportionOfOwnershipInterestInSubsidiary": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProportionOfOwnershipInterestInSubsidiary", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails" ], "lang": { "en-us": { "role": { "label": "Proportion of ownership interest in subsidiary", "terseLabel": "Percent of ownership interest" } }, "en": { "role": { "documentation": "The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]]" } } }, "auth_ref": [ "r59", "r61", "r95" ] }, "iva_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethodPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethodPricePerShare", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Purchase of interests in investments accounted for using equity method, price per share", "label": "Purchase of interests in investments accounted for using equity method, price per share", "terseLabel": "Purchase of interests in investments accounted for using equity method, price per share" } } }, "auth_ref": [] }, "iva_PurchaseOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "PurchaseOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Purchase Of Property Plant And Equipment And Intangible Assets Classified As Investing Activities", "label": "Purchase Of Property Plant And Equipment And Intangible Assets Classified As Investing Activities", "negatedLabel": "Purchases of property, plant and equipment and intangible assets" } } }, "auth_ref": [] }, "ifrs-full_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RangeAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" ], "lang": { "en-us": { "role": { "label": "Range [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r117", "r129", "r133", "r196", "r197", "r244" ] }, "ifrs-full_RangesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RangesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" ], "lang": { "en-us": { "role": { "label": "Ranges [member]" } }, "en": { "role": { "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used." } } }, "auth_ref": [ "r117", "r129", "r133", "r196", "r197", "r244" ] }, "ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Reconciliation of changes in intangible assets other than goodwill", "terseLabel": "Intangible assets" } } }, "auth_ref": [] }, "ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Reconciliation of changes in property, plant and equipment [abstract]" } } }, "auth_ref": [] }, "ifrs-full_RepairsAndMaintenanceExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RepairsAndMaintenanceExpense", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Repairs and maintenance expense", "negatedLabel": "Maintenance" } }, "en": { "role": { "documentation": "The amount of expenses incurred for the day-to-day servicing of assets, which may include the cost of labour, consumables or small parts." } } }, "auth_ref": [ "r222" ] }, "iva_RepaymentPeriodOfLoan": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "RepaymentPeriodOfLoan", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "documentation": "The period for repayment of loan.", "label": "Repayment Period of Loan", "terseLabel": "Repayment period for loan" } } }, "auth_ref": [] }, "ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RepaymentsOfBorrowingsClassifiedAsFinancingActivities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Repayments of borrowings, classified as financing activities", "negatedLabel": "Repayment of debt", "terseLabel": "Repayments of borrowings" } }, "en": { "role": { "documentation": "The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]" } } }, "auth_ref": [ "r190" ] }, "ifrs-full_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Research and development expense", "negatedLabel": "Research and development costs" } }, "en": { "role": { "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss." } } }, "auth_ref": [ "r74" ] }, "iva_ResearchAndDevelopmentMarketingTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "ResearchAndDevelopmentMarketingTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossTables" ], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of Research and Development, Marketing.", "label": "Research and Development, Marketing [Table Text Block]", "terseLabel": "Schedule of research and development, marketing" } } }, "auth_ref": [] }, "ifrs-full_ReserveOfExchangeDifferencesOnTranslation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ReserveOfExchangeDifferencesOnTranslation", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Reserve of exchange differences on translation", "terseLabel": "Translation reserve" } }, "en": { "role": { "documentation": "A component of equity representing exchange differences on translation of financial statements recognised in other comprehensive income and accumulated in equity. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r55" ] }, "ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ReserveOfExchangeDifferencesOnTranslationMember", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Reserve of exchange differences on translation [member]", "terseLabel": "Translation reserves" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing accumulated exchange differences on the translation of financial statements recognised in other comprehensive income. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r55", "r176" ] }, "ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriod": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RetainedEarningsExcludingProfitLossForReportingPeriod", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails" ], "lang": { "en-us": { "role": { "label": "Retained earnings, excluding profit (loss) for reporting period", "verboseLabel": "Earnings brought forward" } }, "en": { "role": { "documentation": "A component of equity representing the entity\u2019s cumulative undistributed earnings or deficit excluding the profit or loss for the reporting period. [Refer: Retained earnings]" } } }, "auth_ref": [ "r219" ] }, "iva_RetainedEarningsExcludingProfitLossForReportingPeriodAndTreasuryShares": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "RetainedEarningsExcludingProfitLossForReportingPeriodAndTreasuryShares", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "documentation": "A component of equity representing retained earnings excluding profit (loss) for the reporting period, and treasury shares", "label": "Retained earnings excluding profit (loss) for the reporting period and treasury shares", "terseLabel": "Reserves" } } }, "auth_ref": [] }, "iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "This member represent a component of equity consisting of retained earnings excluding the current reporting period, and treasury shares.", "label": "Retained earnings excluding profit (loss) from current reporting period and treasury shares [Member]", "terseLabel": "Reserves" } } }, "auth_ref": [] }, "ifrs-full_RetainedEarningsProfitLossForReportingPeriod": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RetainedEarningsProfitLossForReportingPeriod", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Retained earnings, profit (loss) for reporting period", "terseLabel": "Net loss for the period" } }, "en": { "role": { "documentation": "A component of equity representing the entity\u2019s undistributed profit or loss for the reporting period. [Refer: Retained earnings; Profit (loss)]" } } }, "auth_ref": [ "r219" ] }, "ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RetainedEarningsProfitLossForReportingPeriodMember", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Retained earnings, profit (loss) for reporting period [member]", "terseLabel": "Net profit (loss)" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing the entity\u2019s undistributed profit or loss for the reporting period. [Refer: Retained earnings [member]; Profit (loss)]" } } }, "auth_ref": [ "r214" ] }, "ifrs-full_Revenue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Revenue", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss": { "parentTag": "ifrs-full_RevenueAndOperatingIncome", "weight": 1.0, "order": 2.0 }, "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossRevenuesAndOtherIncomeDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossRevenuesAndOtherIncomeDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Revenue", "terseLabel": "Revenue", "totalLabel": "Total revenue" } }, "en": { "role": { "documentation": "The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims." } } }, "auth_ref": [ "r35", "r103", "r138", "r159", "r164", "r169", "r170", "r171", "r174", "r175", "r195" ] }, "ifrs-full_RevenueAndOperatingIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RevenueAndOperatingIncome", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossRevenuesAndOtherIncomeDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Revenue and other operating income", "totalLabel": "Total revenues and other income" } }, "en": { "role": { "documentation": "The aggregate amount of the entity's revenue and other operating income. [Refer: Revenue]" } } }, "auth_ref": [ "r222" ] }, "iva_RevenueAndOperatingIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "RevenueAndOperatingIncomeAbstract", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Revenue And Operating Income [Abstract]", "terseLabel": "Revenues and other income" } } }, "auth_ref": [] }, "iva_RevenueAndOtherIncomeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "RevenueAndOtherIncomeTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of revenue and other income.", "label": "Revenue and Other Income [Table Text Block]", "terseLabel": "Schedule of revenues and other income" } } }, "auth_ref": [] }, "ifrs-full_RevenueFromContractsWithCustomers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RevenueFromContractsWithCustomers", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossRevenuesAndOtherIncomeDetails": { "parentTag": "ifrs-full_Revenue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossRevenuesAndOtherIncomeDetails" ], "lang": { "en-us": { "role": { "label": "Revenue from contracts with customers", "terseLabel": "Revenue" } }, "en": { "role": { "documentation": "The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity\u2019s ordinary activities in exchange for consideration." } } }, "auth_ref": [ "r119", "r120" ] }, "ifrs-full_RightofuseAssetsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RightofuseAssetsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionPropertyPlantAndEquipmentAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Right of use" } }, "en": { "role": { "documentation": "This member stands for right-of-use assets. [Refer: Right-of-use assets]" } } }, "auth_ref": [ "r122" ] }, "iva_RoyaltyCertificateLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "RoyaltyCertificateLiabilitiesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtRoyaltyCertificatesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Royalty Certificate Liabilities.", "label": "Royalty Certificate Liabilities [Member]", "terseLabel": "Royalty Certificate" } } }, "auth_ref": [] }, "iva_RoyaltyCertificatesEffectiveInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "RoyaltyCertificatesEffectiveInterestRate", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtRoyaltyCertificatesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate on royalty certificates.", "label": "Royalty Certificates, Effective Interest Rate", "terseLabel": "Royalty certificates, effective interest rate" } } }, "auth_ref": [] }, "iva_RoyaltyCertificatesLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "RoyaltyCertificatesLiabilitiesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtRoyaltyCertificatesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for royalty certificates liabilities.", "label": "Royalty Certificates Liabilities [Member]", "terseLabel": "Royalty certificates liabilities" } } }, "auth_ref": [] }, "ifrs-full_SalesAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "SalesAndMarketingExpense", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Sales and marketing expense", "negatedLabel": "Marketing - Business development expenses" } }, "en": { "role": { "documentation": "The amount of expense relating to the marketing and selling of goods or services." } } }, "auth_ref": [ "r222" ] }, "iva_SalesTaxReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "SalesTaxReceivableCurrent", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails": { "parentTag": "ifrs-full_OtherCurrentAssets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of sales tax receivables, classified as current.", "label": "Sales Tax Receivable, Current", "terseLabel": "Sales tax receivable" } } }, "auth_ref": [] }, "iva_ScenarioOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "ScenarioOneMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for scenario one.", "label": "Scenario One [Member]", "terseLabel": "First tranche" } } }, "auth_ref": [] }, "iva_ScenarioThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "ScenarioThreeMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for scenario three.", "label": "Scenario Three [Member]", "terseLabel": "Third tranche upon publication of pivotal data" } } }, "auth_ref": [] }, "iva_ScenarioTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "ScenarioTwoMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for scenario two.", "label": "Scenario Two [Member]", "terseLabel": "Second tranche" } } }, "auth_ref": [] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "auth_ref": [] }, "iva_ScheduleOfInventoryDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "ScheduleOfInventoryDisclosureLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInventoriesDetails" ], "lang": { "en-us": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.", "label": "Schedule of Inventory Disclosure [Line Items]", "terseLabel": "Inventories" } } }, "auth_ref": [] }, "iva_ScheduleOfInventoryDisclosureTable": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "ScheduleOfInventoryDisclosureTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInventoriesDetails" ], "lang": { "en-us": { "role": { "documentation": "Schedule disclosing information related to inventories.", "label": "Schedule of Inventory Disclosure [Table]" } } }, "auth_ref": [] }, "iva_ServiceContractWithAvantSanteMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "ServiceContractWithAvantSanteMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for service contract with Avant Sante.", "label": "Service contract with Avant Sante [Member]", "terseLabel": "Service contract with Avant Sante" } } }, "auth_ref": [] }, "iva_ServiceProvidersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "ServiceProvidersMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityOptionsAndShareWarrantsBsaAndBspceDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to service providers.", "label": "Service Providers", "terseLabel": "Service providers" } } }, "auth_ref": [] }, "ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss": { "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Share of other comprehensive income of associates and joint ventures accounted for using equity method that will be reclassified to profit or loss, net of tax", "terseLabel": "Currency translation differences - equity method" } }, "en": { "role": { "documentation": "Share of the other comprehensive income of associates and joint ventures accounted for using the equity method that will be reclassified to profit or loss, net of tax." } } }, "auth_ref": [ "r38" ] }, "ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 4.0 }, "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Share of profit (loss) of associates accounted for using equity method", "totalLabel": "Share of net profit - Equity method", "verboseLabel": "Share of net loss - Equity method" } }, "en": { "role": { "documentation": "The entity's share of the profit (loss) of associates accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method; Profit (loss)]" } } }, "auth_ref": [ "r222" ] }, "iva_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethodBeforeEliminations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethodBeforeEliminations", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails": { "parentTag": "ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails" ], "lang": { "en-us": { "role": { "documentation": "Share of profit (loss) of associates accounted for using equity method before eliminations", "label": "Share of profit (loss) of associates accounted for using equity method before eliminations", "terseLabel": "Share of net profit" } } }, "auth_ref": [] }, "ifrs-full_SharePremium": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "SharePremium", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Share premium", "terseLabel": "Premiums related to share capital" } }, "en": { "role": { "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value." } } }, "auth_ref": [ "r180" ] }, "ifrs-full_SharePremiumMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "SharePremiumMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Premiums related to share capital" } }, "en": { "role": { "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value." } } }, "auth_ref": [ "r6" ] }, "ifrs-full_SharebasedPaymentArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "SharebasedPaymentArrangementsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFreeShareAwardsAndPerformanceUnitsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityOptionsAndShareWarrantsBsaAndBspceDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables" ], "lang": { "en-us": { "role": { "label": "Sharebased compensation expense" } }, "en": { "role": { "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used." } } }, "auth_ref": [ "r134" ] }, "iva_SharesIssuableUponExerciseOfWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "SharesIssuableUponExerciseOfWarrants", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details" ], "lang": { "en-us": { "role": { "documentation": "Shares issuable upon exercise of warrants.", "label": "Shares Issuable Upon Exercise of Warrants", "terseLabel": "Shares issuable upon exercise of warrants" } } }, "auth_ref": [] }, "iva_ShortTermDepositAccountsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "ShortTermDepositAccountsCurrent", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails": { "parentTag": "ifrs-full_OtherCurrentAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of short term deposits accounts, classified as current.", "label": "Short-Term Deposit Accounts, Current", "terseLabel": "Short-term deposit accounts" } } }, "auth_ref": [] }, "iva_ShortTermDepositAccountsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "ShortTermDepositAccountsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for short-term deposit accounts.", "label": "Shortterm deposit accounts", "terseLabel": "Short-term deposit accounts" } } }, "auth_ref": [] }, "ifrs-full_ShorttermBorrowingsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ShorttermBorrowingsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Short-term debt", "terseLabel": "Short-term debt" } }, "en": { "role": { "documentation": "This member stands for short-term borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r192", "r194" ] }, "ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ShorttermDepositsClassifiedAsCashEquivalents", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionCashAndCashEquivalentsDetails": { "parentTag": "ifrs-full_CashAndCashEquivalents", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionCashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "label": "Short-term deposits, classified as cash equivalents", "verboseLabel": "Other cash equivalents" } }, "en": { "role": { "documentation": "A classification of cash equivalents representing short-term deposits. [Refer: Cash equivalents]" } } }, "auth_ref": [ "r240" ] }, "ifrs-full_SignificantInvestmentsInAssociatesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "SignificantInvestmentsInAssociatesAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" ], "lang": { "en-us": { "role": { "label": "Associates [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r60", "r62", "r111" ] }, "ifrs-full_SignificantInvestmentsInSubsidiariesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "SignificantInvestmentsInSubsidiariesAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails" ], "lang": { "en-us": { "role": { "label": "Subsidiaries [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r60", "r62", "r110" ] }, "ifrs-full_SignificantUnobservableInputLiabilities": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "SignificantUnobservableInputLiabilities", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtRoyaltyCertificatesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Significant Unobservable Input Liabilities", "terseLabel": "Significant unobservable input, liabilities" } }, "en": { "role": { "documentation": "The value of significant unobservable input used in the measurement of the fair value of liabilities." } } }, "auth_ref": [ "r114" ] }, "ifrs-full_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Unaudited interim condensed consolidated statement of cash flows" } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "StatementOfChangesInEquityAbstract", "lang": { "en-us": { "role": { "label": "Unaudited interim condensed consolidated statement of changes in shareholders' equity" } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "StatementOfChangesInEquityLineItems", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement of changes in equity [line items]", "terseLabel": "CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "StatementOfChangesInEquityTable", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement of changes in equity [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to changes in equity." } } }, "auth_ref": [ "r6" ] }, "iva_StatementOfComplianceAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "StatementOfComplianceAbstract", "lang": { "en-us": { "role": { "documentation": "N/A", "label": "Basis of preparation and statement of compliance" } } }, "auth_ref": [] }, "ifrs-full_StatementOfComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "StatementOfComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "label": "Unaudited interim condensed consolidated statement of comprehensive (income) loss" } } }, "auth_ref": [] }, "ifrs-full_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Unaudited interim condensed consolidated statement of financial position" } } }, "auth_ref": [] }, "ifrs-full_StatementOfIFRSCompliance": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "StatementOfIFRSCompliance", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfCompliance" ], "lang": { "en-us": { "role": { "label": "Statement of IFRS compliance [text block]", "terseLabel": "Basis of preparation and statement of compliance" } }, "en": { "role": { "documentation": "An explicit and unreserved statement of compliance with all the requirements of IFRSs." } } }, "auth_ref": [ "r8" ] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementScenarioAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "auth_ref": [] }, "iva_StockIssuedDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "StockIssuedDuringPeriodShares", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued during the period.", "label": "Stock Issued During Period, Shares", "terseLabel": "Number of shares issued during the period" } } }, "auth_ref": [] }, "iva_StockIssuedDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "StockIssuedDuringPeriodValue", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value", "terseLabel": "Stock issued during period" } } }, "auth_ref": [] }, "iva_Studies": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "Studies", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to studies.", "label": "Studies", "negatedLabel": "Studies" } } }, "auth_ref": [] }, "iva_SubscriptionOfLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "SubscriptionOfLeaseLiabilities", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtMovementsInPeriodBreakDownDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of subscription of lease liabilities.", "label": "Subscription Of Lease Liabilities", "terseLabel": "Subscription of lease liabilities" } } }, "auth_ref": [] }, "iva_SubscriptionPremiumPricePerShareOfOtherEquityInstrumentsGranted": { "xbrltype": "perShareItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "SubscriptionPremiumPricePerShareOfOtherEquityInstrumentsGranted", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Subscription premium price per share of other equity instruments granted in share-based payment arrangement.", "label": "Subscription Premium Price Per Share Of Other Equity Instruments Granted", "terseLabel": "Subscription premium price per share (\u20ac)" } } }, "auth_ref": [] }, "iva_SubsidiesIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "SubsidiesIncome", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossRevenuesAndOtherIncomeDetails": { "parentTag": "iva_OtherIncomeFromOrdinaryActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossRevenuesAndOtherIncomeDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of income from subsidies.", "label": "Subsidies income", "terseLabel": "Subsidies" } } }, "auth_ref": [] }, "iva_SupportCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "SupportCosts", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to support costs.", "label": "Support costs", "negatedLabel": "Support costs (including taxes)" } } }, "auth_ref": [] }, "ifrs-full_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Tax rate effect of adjustments for current tax of prior periods", "terseLabel": "Projected tax rate" } }, "en": { "role": { "documentation": "Tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from adjustments for the current tax of prior periods. [Refer: Average effective tax rate; Applicable tax rate; Adjustments for current tax of prior periods]" } } }, "auth_ref": [ "r224" ] }, "iva_TermOverWhichVolumeWeightedAveragePricePerShareToDetermineNumberOfWarrantsToBeIssued": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "TermOverWhichVolumeWeightedAveragePricePerShareToDetermineNumberOfWarrantsToBeIssued", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the term over which volume weighted average price per share to determine number of warrants to be issued.", "label": "Term Over Which Volume Weighted Average Price Per Share To Determine Number Of Warrants To Be Issued", "terseLabel": "Term over which volume weighted average price per share to determine number of warrants to be issued" } } }, "auth_ref": [] }, "ifrs-full_TopOfRangeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TopOfRangeMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" ], "lang": { "en-us": { "role": { "label": "Maximum", "terseLabel": "Maximum" } }, "en": { "role": { "documentation": "This member stands for top of a range." } } }, "auth_ref": [ "r117", "r129", "r133", "r196", "r197", "r244" ] }, "ifrs-full_TradeAndOtherCurrentPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TradeAndOtherCurrentPayables", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesBreakDownDetails" ], "lang": { "en-us": { "role": { "label": "Trade and other current payables", "terseLabel": "Trade payable" } }, "en": { "role": { "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]" } } }, "auth_ref": [ "r15" ] }, "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 1.0 }, "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesShortTermContractLiabilitiesAndOtherCurrentLiabilitiesDetails": { "parentTag": "iva_TradePayablesAndOtherCurrentLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesShortTermContractLiabilitiesAndOtherCurrentLiabilitiesDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current trade payables", "terseLabel": "Trade payables" } }, "en": { "role": { "documentation": "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]" } } }, "auth_ref": [ "r178", "r220" ] }, "ifrs-full_TradeAndOtherCurrentReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TradeAndOtherCurrentReceivables", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsTradeReceivablesDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Trade and other current receivables", "terseLabel": "Trade receivables" } }, "en": { "role": { "documentation": "The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]" } } }, "auth_ref": [ "r13", "r26" ] }, "iva_TradePayableAndOtherCurrentLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "TradePayableAndOtherCurrentLiabilitiesLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesBreakDownDetails" ], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Trade Payable And Other Current Liabilities [Line Items]" } } }, "auth_ref": [] }, "iva_TradePayableAndOtherCurrentLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "TradePayableAndOtherCurrentLiabilitiesTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesBreakDownDetails" ], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Trade Payable And Other Current Liabilities [Table]" } } }, "auth_ref": [] }, "iva_TradePayablesAndOtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "TradePayablesAndOtherCurrentLiabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesShortTermContractLiabilitiesAndOtherCurrentLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesShortTermContractLiabilitiesAndOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of trade payables and other current liabilities.", "label": "Trade Payables And Other Current Liabilities.", "totalLabel": "Trade payables and other current liabilities" } } }, "auth_ref": [] }, "iva_TradePayablesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "TradePayablesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for trade payables.", "label": "Trade payables", "terseLabel": "Trade payables" } } }, "auth_ref": [] }, "iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.", "label": "Trade Receivables and Other Current Assets and Receivables [Line Items]", "terseLabel": "Trade receivables, tax receivables and other current assets" } } }, "auth_ref": [] }, "iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "TradeReceivablesAndOtherCurrentAssetsAndReceivablesTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Schedule disclosing information related to trade receivables and other current assets and receivables.", "label": "Trade Receivables and Other Current Assets and Receivables [Table]" } } }, "auth_ref": [] }, "ifrs-full_TradeReceivablesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TradeReceivablesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Trade receivables", "terseLabel": "Trade receivables" } }, "en": { "role": { "documentation": "This member stands for trade receivables. [Refer: Trade receivables]" } } }, "auth_ref": [ "r142", "r146", "r200", "r215" ] }, "iva_TransactionCostsOnIssueOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "TransactionCostsOnIssueOfWarrants", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Transaction costs on issue of warrants", "label": "Transaction costs on issue of warrants" } } }, "auth_ref": [] }, "ifrs-full_TreasuryShares": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TreasuryShares", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails" ], "lang": { "en-us": { "role": { "label": "Treasury shares", "negatedLabel": "Treasury Shares" } }, "en": { "role": { "documentation": "An entity\u2019s own equity instruments, held by the entity or other members of the consolidated group." } } }, "auth_ref": [ "r63", "r180" ] }, "iva_TreatmentPeriodUnderStudy": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "TreatmentPeriodUnderStudy", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details" ], "lang": { "en-us": { "role": { "documentation": "Treatment period under study", "label": "Treatment period under study" } } }, "auth_ref": [] }, "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TypesOfSharebasedPaymentArrangementsAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFreeShareAwardsAndPerformanceUnitsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityOptionsAndShareWarrantsBsaAndBspceDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables" ], "lang": { "en-us": { "role": { "label": "Types of share-based payment arrangements [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r134" ] }, "ifrs-full_UnobservableInputsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "UnobservableInputsAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtRoyaltyCertificatesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Unobservable inputs [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r114", "r242" ] }, "ifrs-full_UnobservableInputsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "UnobservableInputsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtRoyaltyCertificatesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Unobservable inputs [member]" } }, "en": { "role": { "documentation": "This member stands for all the unobservable inputs. It also represents the standard value for the 'Unobservable inputs' axis if no other member is used." } } }, "auth_ref": [ "r114", "r242" ] }, "ifrs-full_WagesAndSalaries": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WagesAndSalaries", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesPersonnelCostsAndHeadcountDetails": { "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "label": "Wages and salaries", "negatedLabel": "Wages, salaries and similar costs" } }, "en": { "role": { "documentation": "A class of employee benefits expense that represents wages and salaries. [Refer: Employee benefits expense]" } } }, "auth_ref": [ "r232" ] }, "iva_WarrantAgreementWithEuropeanInvestmentBankMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "WarrantAgreementWithEuropeanInvestmentBankMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Warrant agreement with the European Investment Bank.", "label": "Warrant Agreement With The European Investment Bank [Member]", "terseLabel": "Warrant agreement with the European Investment Bank" } } }, "auth_ref": [] }, "iva_WarrantAverageLife": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "WarrantAverageLife", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Average life used to calculate fair value of warrant.", "label": "Warrant Average Life", "verboseLabel": "Maturity (years)" } } }, "auth_ref": [] }, "iva_WarrantsCapOfPutOption": { "xbrltype": "decimalItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "WarrantsCapOfPutOption", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Cap of the put option used to calculate fair value of warrants.", "label": "Warrants, Cap of Put Option", "terseLabel": "Cap of the put option (m\u20ac)" } } }, "auth_ref": [] }, "iva_WarrantsStockPrice": { "xbrltype": "decimalItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "WarrantsStockPrice", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Stock price used to calculate fair value of warrants.", "label": "Warrants, Stock Price", "terseLabel": "Stock price (\u20ac)" } } }, "auth_ref": [] }, "iva_WarrantsSubscriptionPrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "WarrantsSubscriptionPrice", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityOptionsAndShareWarrantsBsaAndBspceDetails" ], "lang": { "en-us": { "role": { "documentation": "The subscription price per warrant.", "label": "Warrants, Subscription Price", "verboseLabel": "Subscription price per share" } } }, "auth_ref": [] }, "iva_WarrantsTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "WarrantsTerm", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details" ], "lang": { "en-us": { "role": { "documentation": "Term of warrants.", "label": "Warrants Term", "terseLabel": "Term of warrants" } } }, "auth_ref": [] }, "iva_WarrantsThresholdTradingDays": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "WarrantsThresholdTradingDays", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Threshold number of specified trading days that common stock price to conversion price of warrants must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.", "label": "Warrants, Threshold Trading Days", "terseLabel": "Threshold trading days of warrants" } } }, "auth_ref": [] }, "iva_WarrantsUnitFairValue": { "xbrltype": "decimalItemType", "nsuri": "http://www.inventivapharma.com/20240630", "localname": "WarrantsUnitFairValue", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "The fair value per warranty unit outstanding", "label": "Warrants, Unit Fair Value", "verboseLabel": "Unit fair value" } } }, "auth_ref": [] }, "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityOptionsAndShareWarrantsBsaAndBspceDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price of other equity instruments granted in share-based payment arrangement", "verboseLabel": "Exercise price" } }, "en": { "role": { "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) granted in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r243" ] }, "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFreeShareAwardsAndPerformanceUnitsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement", "terseLabel": "Exercise price (in euros)" } }, "en": { "role": { "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r243" ] }, "ifrs-full_WeightedAverageSharePrice2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WeightedAverageSharePrice2019", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFreeShareAwardsAndPerformanceUnitsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average share price", "verboseLabel": "Stock price at grant date (in euros)" } }, "en": { "role": { "documentation": "The weighted average share price. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r132" ] }, "ifrs-full_WeightedAverageShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WeightedAverageShares", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossBasicAndDilutedLossPerShareDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Weighted average number of ordinary shares used in calculating basic earnings per share", "terseLabel": "Weighted average number of shares outstanding used to calculate basic loss per share" } }, "en": { "role": { "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor." } } }, "auth_ref": [ "r66" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "104", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_104&doctype=Standard", "URIDate": "2023-03-23" }, "r1": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "106", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_a&doctype=Standard", "URIDate": "2023-03-23" }, "r2": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_i&doctype=Standard", "URIDate": "2023-03-23" }, "r3": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_iii&doctype=Standard", "URIDate": "2023-03-23" }, "r5": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d&doctype=Standard", "URIDate": "2023-03-23" }, "r6": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "106", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106&doctype=Standard", "URIDate": "2023-03-23" }, "r7": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "117", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_117&doctype=Standard", "URIDate": "2023-03-23" }, "r8": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "16", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_16&doctype=Standard", "URIDate": "2023-03-23" }, "r9": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_35&doctype=Standard", "URIDate": "2023-03-23" }, "r10": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_c&doctype=Standard", "URIDate": "2023-03-23" }, "r11": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_e&doctype=Standard", "URIDate": "2023-03-23" }, "r12": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_g&doctype=Standard", "URIDate": "2023-03-23" }, "r13": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_h&doctype=Standard", "URIDate": "2023-03-23" }, "r14": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_i&doctype=Standard", "URIDate": "2023-03-23" }, "r15": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "k", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_k&doctype=Standard", "URIDate": "2023-03-23" }, "r16": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "n", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_n&doctype=Standard", "URIDate": "2023-03-23" }, "r17": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "o", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_o&doctype=Standard", "URIDate": "2023-03-23" }, "r18": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "q", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_q&doctype=Standard", "URIDate": "2023-03-23" }, "r19": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_55&doctype=Standard", "URIDate": "2023-03-23" }, "r20": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "56", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_56&doctype=Standard", "URIDate": "2023-03-23" }, "r21": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "61", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_61_a&doctype=Standard", "URIDate": "2023-03-23" }, "r22": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "61", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_61&doctype=Standard", "URIDate": "2023-03-23" }, "r23": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_66&doctype=Standard", "URIDate": "2023-03-23" }, "r24": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "69", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_69&doctype=Standard", "URIDate": "2023-03-23" }, "r25": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard", "URIDate": "2023-03-23" }, "r26": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_b&doctype=Standard", "URIDate": "2023-03-23" }, "r27": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "78", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_d&doctype=Standard", "URIDate": "2023-03-23" }, "r28": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2023-03-23" }, "r29": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_iii&doctype=Standard", "URIDate": "2023-03-23" }, "r30": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_iv&doctype=Standard", "URIDate": "2023-03-23" }, "r31": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a&doctype=Standard", "URIDate": "2023-03-23" }, "r32": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "81A", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_a&doctype=Standard", "URIDate": "2023-03-23" }, "r33": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "81A", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_b&doctype=Standard", "URIDate": "2023-03-23" }, "r34": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "81A", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_c&doctype=Standard", "URIDate": "2023-03-23" }, "r35": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "82", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_a&doctype=Standard", "URIDate": "2023-03-23" }, "r36": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "82", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_b&doctype=Standard", "URIDate": "2023-03-23" }, "r37": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "82", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_d&doctype=Standard", "URIDate": "2023-03-23" }, "r38": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "82A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82A&doctype=Standard", "URIDate": "2023-03-23" }, "r39": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "91", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_91_a&doctype=Standard", "URIDate": "2023-03-23" }, "r40": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "99", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_99&doctype=Standard", "URIDate": "2023-03-23" }, "r41": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "10", "IssueDate": "2023-01-01", "Paragraph": "21", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2023-en-r&anchor=para_21&doctype=Standard", "URIDate": "2023-03-23" }, "r42": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_79&doctype=Standard", "URIDate": "2023-03-23" }, "r43": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "81", "Subparagraph": "c", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_c_i&doctype=Standard", "URIDate": "2023-03-23" }, "r44": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "81", "Subparagraph": "c", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_c_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r45": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "81", "Subparagraph": "g", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_g_i&doctype=Standard", "URIDate": "2023-03-23" }, "r46": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_d&doctype=Standard", "URIDate": "2023-03-23" }, "r47": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e&doctype=Standard", "URIDate": "2023-03-23" }, "r48": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73&doctype=Standard", "URIDate": "2023-03-23" }, "r49": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "75", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_75_b&doctype=Standard", "URIDate": "2023-03-23" }, "r50": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "140", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_140_a&doctype=Standard", "URIDate": "2023-03-23" }, "r51": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "141", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_141_c&doctype=Standard", "URIDate": "2023-03-23" }, "r52": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "142", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_142&doctype=Standard", "URIDate": "2023-03-23" }, "r53": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "36", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2023-en-r&anchor=para_36_b&doctype=Standard", "URIDate": "2023-03-23" }, "r54": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2023-01-01", "Paragraph": "52", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2023-en-r&anchor=para_52_a&doctype=Standard", "URIDate": "2023-03-23" }, "r55": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2023-01-01", "Paragraph": "52", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2023-en-r&anchor=para_52_b&doctype=Standard", "URIDate": "2023-03-23" }, "r56": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2023-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS21_g51-57_TI", "URIDate": "2023-03-23" }, "r57": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2023-01-01", "Paragraph": "19", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_19&doctype=Standard", "URIDate": "2023-03-23" }, "r58": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "26", "IssueDate": "2023-01-01", "Paragraph": "35", "Subparagraph": "b", "Clause": "viii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2023-en-r&anchor=para_35_b_viii&doctype=Standard", "URIDate": "2023-03-23" }, "r59": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2023-01-01", "Paragraph": "16", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_16_b_iii&doctype=Standard", "URIDate": "2023-03-23" }, "r60": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2023-01-01", "Paragraph": "16", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_16_b&doctype=Standard", "URIDate": "2023-03-23" }, "r61": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2023-01-01", "Paragraph": "17", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_17_b_iii&doctype=Standard", "URIDate": "2023-03-23" }, "r62": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2023-01-01", "Paragraph": "17", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_17_b&doctype=Standard", "URIDate": "2023-03-23" }, "r63": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "32", "IssueDate": "2023-01-01", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2023-en-r&anchor=para_34&doctype=Standard", "URIDate": "2023-03-23" }, "r64": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2023-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_66&doctype=Standard", "URIDate": "2023-03-23" }, "r65": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2023-01-01", "Paragraph": "67", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_67&doctype=Standard", "URIDate": "2023-03-23" }, "r66": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2023-01-01", "Paragraph": "70", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_70_b&doctype=Standard", "URIDate": "2023-03-23" }, "r67": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2023-01-01", "Paragraph": "134", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_134_a&doctype=Standard", "URIDate": "2023-03-23" }, "r68": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2023-01-01", "Paragraph": "135", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_135_a&doctype=Standard", "URIDate": "2023-03-23" }, "r69": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2023-01-01", "Paragraph": "84", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_84_a&doctype=Standard", "URIDate": "2023-03-23" }, "r70": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2023-01-01", "Paragraph": "86", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_86&doctype=Standard", "URIDate": "2023-03-23" }, "r71": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "118", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_c&doctype=Standard", "URIDate": "2023-03-23" }, "r72": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "118", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e&doctype=Standard", "URIDate": "2023-03-23" }, "r73": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "118", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118&doctype=Standard", "URIDate": "2023-03-23" }, "r74": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "126", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_126&doctype=Standard", "URIDate": "2023-03-23" }, "r75": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2023-01-01", "Paragraph": "76", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_76&doctype=Standard", "URIDate": "2023-03-23" }, "r76": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_79_c&doctype=Standard", "URIDate": "2023-03-23" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_79_d&doctype=Standard", "URIDate": "2023-03-23" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "41", "IssueDate": "2023-01-01", "Paragraph": "50", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2023-en-r&anchor=para_50&doctype=Standard", "URIDate": "2023-03-23" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "41", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2023-en-r&anchor=para_54_f&doctype=Standard", "URIDate": "2023-03-23" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "10", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_10&doctype=Standard", "URIDate": "2023-03-23" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "14", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_14&doctype=Standard", "URIDate": "2023-03-23" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "18", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_18_b&doctype=Standard", "URIDate": "2023-03-23" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "21", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_21&doctype=Standard", "URIDate": "2023-03-23" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_25&doctype=Standard", "URIDate": "2023-03-23" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "28", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_28&doctype=Standard", "URIDate": "2023-03-23" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35&doctype=Standard", "URIDate": "2023-03-23" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard", "URIDate": "2023-03-23" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "50", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_50_d&doctype=Standard", "URIDate": "2023-03-23" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2023-03-23" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "24", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2023-03-23" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "32", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_32_a_i&doctype=Standard", "URIDate": "2023-03-23" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "32", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_32_a_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "10", "IssueDate": "2023-01-01", "Paragraph": "22", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=10&code=ifrs-tx-2023-en-r&anchor=para_22&doctype=Standard", "URIDate": "2023-03-23" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "12", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_12_f&doctype=Standard", "URIDate": "2023-03-23" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "19B", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_19B_c&doctype=Standard", "URIDate": "2023-03-23" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "2", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_2_b_i&doctype=Standard", "URIDate": "2023-03-23" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "21", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_21_a_iv&doctype=Standard", "URIDate": "2023-03-23" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "ix", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "v", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "viii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B13", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B13", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_f&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B13", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B14", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B14_b&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B16", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B16&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B4", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B4_a&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B4", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B4_d&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "93", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_a&doctype=Standard", "URIDate": "2023-03-23" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "93", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_b&doctype=Standard", "URIDate": "2023-03-23" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "93", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_d&doctype=Standard", "URIDate": "2023-03-23" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "93", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_e&doctype=Standard", "URIDate": "2023-03-23" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "93", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93&doctype=Standard", "URIDate": "2023-03-23" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "14", "IssueDate": "2023-01-01", "Paragraph": "33", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2023-en-r&anchor=para_33_b&doctype=Standard", "URIDate": "2023-03-23" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2023-01-01", "Paragraph": "105", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_105&doctype=Standard", "URIDate": "2023-03-23" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2023-01-01", "Paragraph": "113", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_113_a&doctype=Standard", "URIDate": "2023-03-23" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2023-01-01", "Paragraph": "114", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_114&doctype=Standard", "URIDate": "2023-03-23" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2023-01-01", "Paragraph": "120", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_120_b_i&doctype=Standard", "URIDate": "2023-03-23" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_33&doctype=Standard", "URIDate": "2023-03-23" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2023-03-23" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "53", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_h&doctype=Standard", "URIDate": "2023-03-23" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "94", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_94&doctype=Standard", "URIDate": "2023-03-23" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "97", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_97&doctype=Standard", "URIDate": "2023-03-23" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "109", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_109&doctype=Standard", "URIDate": "2023-03-23" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "109A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_109A&doctype=Standard", "URIDate": "2023-03-23" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "120", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_120&doctype=Standard", "URIDate": "2023-03-23" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "132", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_132_b&doctype=Standard", "URIDate": "2023-03-23" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "C32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_C32&doctype=Appendix&subtype=C", "URIDate": "2023-03-23" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_c&doctype=Standard", "URIDate": "2023-03-23" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_d&doctype=Standard", "URIDate": "2023-03-23" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard", "URIDate": "2023-03-23" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2023-03-23" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "51", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_51_a&doctype=Standard", "URIDate": "2023-03-23" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2023-01-01", "Paragraph": "B67", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "5", "IssueDate": "2023-01-01", "Paragraph": "33", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2023-en-r&anchor=para_33_b_i&doctype=Standard", "URIDate": "2023-03-23" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "23B", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_23B_a&doctype=Standard", "URIDate": "2023-03-23" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_25&doctype=Standard", "URIDate": "2023-03-23" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_31&doctype=Standard", "URIDate": "2023-03-23" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35H", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35H_b_iii&doctype=Standard", "URIDate": "2023-03-23" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35H", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35H&doctype=Standard", "URIDate": "2023-03-23" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35I", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35I&doctype=Standard", "URIDate": "2023-03-23" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35K", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35K&doctype=Standard", "URIDate": "2023-03-23" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35M", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35M_b_iii&doctype=Standard", "URIDate": "2023-03-23" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35M", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35M&doctype=Standard", "URIDate": "2023-03-23" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "39", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_39_a&doctype=Standard", "URIDate": "2023-03-23" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "42E", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_42E_e&doctype=Standard", "URIDate": "2023-03-23" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "42I", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_42I&doctype=Standard", "URIDate": "2023-03-23" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_6&doctype=Standard", "URIDate": "2023-03-23" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard", "URIDate": "2023-03-23" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "8", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_8_a&doctype=Standard", "URIDate": "2023-03-23" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "8", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_8_e&doctype=Standard", "URIDate": "2023-03-23" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "8", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_8_f&doctype=Standard", "URIDate": "2023-03-23" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "8", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_8_g&doctype=Standard", "URIDate": "2023-03-23" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "8", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_8&doctype=Standard", "URIDate": "2023-03-23" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "B2", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B2_a&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "23", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_a&doctype=Standard", "URIDate": "2023-03-23" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "23", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_d&doctype=Standard", "URIDate": "2023-03-23" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "23", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_h&doctype=Standard", "URIDate": "2023-03-23" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23&doctype=Standard", "URIDate": "2023-03-23" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2023-03-23" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "28", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_a&doctype=Standard", "URIDate": "2023-03-23" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2023-03-23" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "28", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_c&doctype=Standard", "URIDate": "2023-03-23" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "28", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_d&doctype=Standard", "URIDate": "2023-03-23" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "28", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_e&doctype=Standard", "URIDate": "2023-03-23" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_32&doctype=Standard", "URIDate": "2023-03-23" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "33", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_33_a&doctype=Standard", "URIDate": "2023-03-23" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_34&doctype=Standard", "URIDate": "2023-03-23" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "9", "IssueDate": "2023-01-01", "Paragraph": "7.2.34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2023-en-r&anchor=para_7.2.34&doctype=Standard", "URIDate": "2023-03-23" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "9", "IssueDate": "2023-01-01", "Paragraph": "7.2.42", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2023-en-r&anchor=para_7.2.42&doctype=Standard", "URIDate": "2023-03-23" }, "r174": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "102", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_102&doctype=Standard", "URIDate": "2023-03-23" }, "r175": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_103&doctype=Standard", "URIDate": "2023-03-23" }, "r176": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_108&doctype=Standard", "URIDate": "2023-03-23" }, "r177": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "68", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_68&doctype=Standard", "URIDate": "2023-03-23" }, "r178": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "70", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_70&doctype=Standard", "URIDate": "2023-03-23" }, "r179": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_b&doctype=Standard", "URIDate": "2023-03-23" }, "r180": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2023-03-23" }, "r181": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "82A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82A&doctype=Standard", "URIDate": "2023-03-23" }, "r182": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "IG6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_IG6&doctype=Implementation%20Guidance", "URIDate": "2023-03-23" }, "r183": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "147", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_147_c&doctype=Standard", "URIDate": "2023-03-23" }, "r184": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "32", "IssueDate": "2023-01-01", "Paragraph": "IE33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2023-en-r&anchor=para_IE33&doctype=Illustrative%20Examples", "URIDate": "2023-03-23" }, "r185": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "36", "IssueDate": "2023-01-01", "Paragraph": "127", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_127&doctype=Standard", "URIDate": "2023-03-23" }, "r186": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "37", "IssueDate": "2023-01-01", "Paragraph": "88", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_88&doctype=Standard", "URIDate": "2023-03-23" }, "r187": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "14", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_14_f&doctype=Standard", "URIDate": "2023-03-23" }, "r188": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "17", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2023-03-23" }, "r189": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "17", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17_c&doctype=Standard", "URIDate": "2023-03-23" }, "r190": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "17", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17_d&doctype=Standard", "URIDate": "2023-03-23" }, "r191": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "17", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2023-03-23" }, "r192": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "44C", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_44C&doctype=Standard", "URIDate": "2023-03-23" }, "r193": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Section": "A Statement of cash flows for an entity other than a financial institution", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A_TI", "URIDate": "2023-03-23" }, "r194": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Section": "C Reconciliation of liabilities arising from financing activities", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_C_TI", "URIDate": "2023-03-23" }, "r195": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B10", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r196": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "B6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_B6&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r197": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "IE63", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_IE63&doctype=Illustrative%20Examples", "URIDate": "2023-03-23" }, "r198": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "53", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53&doctype=Standard", "URIDate": "2023-03-23" }, "r199": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "113", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_113_b&doctype=Standard", "URIDate": "2023-03-23" }, "r200": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35N", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35N&doctype=Standard", "URIDate": "2023-03-23" }, "r201": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "B11", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B11_a&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r202": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "B11", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B11&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r203": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "B35", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B35_a&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r204": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "B35", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B35_e&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r205": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "B35", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B35_f&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r206": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "B35", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B35_g&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r207": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "B35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B35&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r208": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "IG20D", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_IG20D&doctype=Implementation%20Guidance", "URIDate": "2023-03-23" }, "r209": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "IG31A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance", "URIDate": "2023-03-23" }, "r210": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r211": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "10", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_10_e&doctype=Standard", "URIDate": "2023-03-23" }, "r212": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "104", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_104&doctype=Standard", "URIDate": "2023-03-23" }, "r213": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d&doctype=Standard", "URIDate": "2023-03-23" }, "r214": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_108&doctype=Standard", "URIDate": "2023-03-23" }, "r215": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "112", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_112_c&doctype=Standard", "URIDate": "2023-03-23" }, "r216": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "117", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_117&doctype=Standard", "URIDate": "2023-03-23" }, "r217": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_a&doctype=Standard", "URIDate": "2023-03-23" }, "r218": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_55&doctype=Standard", "URIDate": "2023-03-23" }, "r219": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2023-03-23" }, "r220": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "78", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78&doctype=Standard", "URIDate": "2023-03-23" }, "r221": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a&doctype=Standard", "URIDate": "2023-03-23" }, "r222": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "85", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_85&doctype=Standard", "URIDate": "2023-03-23" }, "r223": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "80", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_80&doctype=Standard", "URIDate": "2023-03-23" }, "r224": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "81", "Subparagraph": "c", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_c_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r225": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "37", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_37&doctype=Standard", "URIDate": "2023-03-23" }, "r226": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_a&doctype=Standard", "URIDate": "2023-03-23" }, "r227": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_d&doctype=Standard", "URIDate": "2023-03-23" }, "r228": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "135", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_135_b&doctype=Standard", "URIDate": "2023-03-23" }, "r229": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "141", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_141&doctype=Standard", "URIDate": "2023-03-23" }, "r230": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "5", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_5&doctype=Standard", "URIDate": "2023-03-23" }, "r231": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "57", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_57_a&doctype=Standard", "URIDate": "2023-03-23" }, "r232": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "9", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_9&doctype=Standard", "URIDate": "2023-03-23" }, "r233": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "118", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_c&doctype=Standard", "URIDate": "2023-03-23" }, "r234": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "40", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_79_c&doctype=Standard", "URIDate": "2023-03-23" }, "r235": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "41", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2023-en-r&anchor=para_54_f&doctype=Standard", "URIDate": "2023-03-23" }, "r236": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "16", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_16&doctype=Standard", "URIDate": "2023-03-23" }, "r237": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "20", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20_a&doctype=Standard", "URIDate": "2023-03-23" }, "r238": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "20", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20_b&doctype=Standard", "URIDate": "2023-03-23" }, "r239": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20&doctype=Standard", "URIDate": "2023-03-23" }, "r240": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard", "URIDate": "2023-03-23" }, "r241": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "93", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_d&doctype=Standard", "URIDate": "2023-03-23" }, "r242": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "93", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_h&doctype=Standard", "URIDate": "2023-03-23" }, "r243": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard", "URIDate": "2023-03-23" }, "r244": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard", "URIDate": "2023-03-23" } } }